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ABSTRACT 
 The experience of chronic stress plays an important role in the pathogenesis of major depressive 
disorder. Prolonged stress induces a state of chronically elevated glucocorticoid exposure in the 
brain, which is neurotoxic and can lead to the dysfunction of glutamatergic signaling. Since 
memory is highly dependent upon glutamatergic neurotransmission, patients with depression 
commonly display alterations in memory processing that bias the recollection of past events 
towards negative emotional information. Negative cognitive biases are believed to support the 
development and maintenance of depression, emphasizing the need for antidepressant treatments 
that can effectively combat these insidious symptoms. Memory for negative emotional events 
can be studied in animals using fear conditioning and extinction paradigms. Fear conditioning 
trains an animal to associate a neutral cue with an emotionally aversive experience, while 
extinction learning challenges this association by forming a new memory that identifies the cue 
as harmless. The aim of this dissertation was to investigate the antidepressant-like effects of 
ketamine on auditory fear conditioning and extinction in both healthy rats and those with chronic 
glucocorticoid exposure. The first experiment sought to dissociate the effects of ketamine on 
distinct stages of auditory fear conditioning and extinction by administering a subanesthetic dose 
of ketamine at one of three unique time points: before fear conditioning training, immediately 
after fear conditioning training, or before fear extinction training. Post-conditioning and pre-
extinction ketamine attenuated the long-term expression of cue-elicited freezing, suggesting that 
the consolidation and recall of conditioned fear were impaired, respectively. Pre-conditioning 
ketamine did not disrupt the acquisition of fear conditioning, and none of the treatments 
examined affected the long-term expression of fear extinction. The second experiment aimed to 
build upon these findings by examining the effect of pre-extinction ketamine on conditioned fear 
and extinction behavior in a repeated exogenous corticosterone (CORT) animal model of 
depression. Repeated CORT treatment provoked a spontaneous recovery of conditioned freezing 
between extinction sessions and induced a reinstatement of freezing following a sub-
conditioning retraining procedure. Ketamine prevented CORT-induced failures in long-term 
extinction expression, and also greatly reduced freezing during early phase extinction training. 
Collectively, the findings of this dissertation help establish ketamine as a powerful modulator of 
negatively-valenced memory and emotionally-driven behavior, and contribute to our 
understanding of its antidepressant-like qualities.  
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CHAPTER 1 
General Introduction 
1. Thesis Outline 
 Depression is a serious and debilitating psychiatric disorder that is estimated to affect 350 
million people worldwide. The World Health Organization has identified depression as the 
leading cause of global disability, making this disorder a source of substantial social, clinical, 
and economic burden (World Health Organization, 2012). The most salient symptoms of 
depression are chronically depressed mood and a profound loss of interest in once-pleasurable 
activities (anhedonia). However, depression may also present with disturbances in sleep or 
appetite, cognitive difficulties, feelings of guilt or worthlessness, and suicidal ideation (American 
Psychiatric Association, 2013). Supporting the development and maintenance of depression are 
symptoms referred to as cognitive biases: pathological modifications in attention, processing, 
interpretation, and memory that bias individuals towards focus on negative emotional content 
(Elliott, Zahn, Deakin, & Anderson, 2011; Harmer, Goodwin, & Cowen, 2009a; Robinson & 
Sahakian, 2008). These negative cognitive biases alter the way in which depressed individuals 
view their world, causing them to think and behave in an abnormally pessimistic manner that is 
detrimental to their wellbeing. If not successfully treated, depression can ultimately result in 
suicide (Lesage et al., 1994), a tragedy that claims the lives of over 842,000 people every year 
(GBD 2013 Mortality and Causes of Death Collaborators, 2015). 
  There is a clear need for fast-acting and effective antidepressant treatments, but many of 
today’s commonly-prescribed antidepressant drugs leave considerable room for improvement in 
both of these regards. In a large open-label study of antidepressant efficacy, less than one-third 
of patients with depression achieved remission following up to four months of standard 
antidepressant drug treatment, and only 50% of patients remitted after six months of treatment 
and two unique drug therapies (Judd et al., 2002; Thase et al., 2005; Trivedi et al., 2006). 
Furthermore, a third of depressed patients remain resistant to treatment even after four 
antidepressant trials (Gaynes et al., 2009). The therapeutic delays and poor remission rates 
associated with standard antidepressant drugs illustrate significant limitations in current 
treatment strategies that must be addressed. Furthermore, both human and animal research has 
suggested that acute treatment with some antidepressants may actually worsen elements of 
negative cognitive biases (Browning, Reid, Cowen, Goodwin, & Harmer, 2007; Burghardt et al., 
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2004; Burghardt, Sullivan, McEwen, Gorman, & LeDoux, 2013; Burhans, Smith-Bell, & 
Schreurs, 2013; Cassaday & Thur, 2015; Godsil et al., 2015; Lebrón-Milad, Tsareva, Ahmed, & 
Milad, 2013; Montezinho et al., 2010; Mørk et al., 2013; Ravinder, Burghardt, Brodsky, Bauer, 
& Chattarji, 2013), raising concerns that these drugs might have counter-productive effects in 
early stages of treatment. 
 Antidepressant drug development has largely been predicated upon the belief that 
symptoms of depression are primarily caused by disturbances in monoamine levels in the brain, 
but the considerable delay between antidepressant regulation of monoamine availability and 
therapeutic improvement casts doubt upon this hypothesis (Maeng & Zarate, 2007; Sanacora, 
Treccani, & Popoli, 2012). A wealth of evidence collected over the past two decades has lead 
researchers to identify pathological alterations in the excitatory glutamatergic system of the brain 
(and its downstream impairments of neuroplasticity) as a core factor in the neurobiology of 
depression, offering new targets for pharmacological intervention (Deutschenbaur et al., 2015; 
Krystal, Sanacora, & Duman, 2013; Pittenger, Sanacora, & Krystal, 2007; Pittenger & Duman, 
2008; Sanacora et al., 2008; Sanacora et al., 2012). Furthermore, research has identified the 
experience of chronic stress as a significant mediating factor of both glutamatergic dysfunction 
and the onset of depression (Deutschenbaur et al., 2015; Pittenger & Duman, 2008; Sanacora et 
al., 2012; Willner, Scheel-Krüger, & Belzung, 2013). Amongst several novel antidepressants 
sought to address glutamatergic dysfunction in depression, the most promising thus far is 
ketamine, a glutamate receptor antagonist that is commonly used in anesthesia. Treatments with 
acute, subanesthetic doses of ketamine reliably produce rapid and long-lasting antidepressant 
effects in depressed patients, even those who are classified as treatment-resistant (Berman et al., 
2000; Diazgranados et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013; Phelps et al., 2009; 
Price, Nock, Charney, & Mathew, 2009; Rasmussen et al., 2013; Zarate et al., 2006). Instead of 
taking weeks or months to experience a therapeutic effect, depressed patients treated with a 
single dose of ketamine can achieve remission in as little as one day, and the effects of one 
treatment can last more than a week (Zarate et al., 2006). The antidepressant qualities of 
ketamine have been replicated in animal models of depression (Garcia et al., 2009; Jett et al., 
2015; Koike, Iijima, & Chaki, 2013; Li et al., 2011; Perrine et al., 2014), but research on the 
efficacy of ketamine in relieving depression-associated negative cognitive biases remains 
limited. 
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 This dissertation includes two studies that explore ketamine’s ability to modulate the 
expression of negative emotional memory. The first study sought to dissociate the effects of 
ketamine on the acquisition, consolidation, and recall of auditory fear conditioning in rats. 
Furthermore, it addressed prior uncertainty regarding the influence of ketamine on the induction 
and recall of fear extinction. The second study aimed to expand upon these findings by 
examining the efficacy of ketamine in preventing long-term extinction retention failure induced 
by chronic exposure to the stress hormone corticosterone (CORT). Together, these studies help 
elucidate the relationship between chronic stress, glutamatergic neurotransmission, and memory 
for negative emotional information. 
 The remainder of this chapter is dedicated to a review of the etiology of human 
depression, the study of depression-like behaviors in chronic stress animal models, and the utility 
of ketamine as an antidepressant treatment. The discussion begins with an introduction to the 
role that chronic stress plays in the development of depressive symptomatology, and the 
neurophysiological and functional consequences of prolonged stress exposure. Following this is 
an overview of human and animal research supporting the stress-induced dysregulation of 
glutamatergic neurotransmission in the pathophysiology of depression. Next, the validity of 
chronic exogenous CORT administration as an animal model of depression is discussed. Fear 
conditioning and fear extinction are then explored as measures of negative emotional memory, 
and the effects of stress and antidepressant drugs on fear-motivated behavior are reviewed. The 
use of ketamine as a rapid-acting antidepressant is then discussed, along with the 
pharmacokinetic mechanisms which may underlie its antidepressant qualities. Concluding the 
chapter is an overview of the specific research questions that each experiment in this dissertation 
sought to address, and their respective hypotheses. 
 
2. Diathesis, Stress, and the Role of HPA Axis Dysfunction in Depression 
2.1. The Diathesis-Stress Model of Depression 
 There is no singular cause of depression; rather, the manifestation of a major depressive 
episode involves a complex interplay between genetics, personal history, and stress. Genetic 
diatheses are believed to account for 31-42% of variability in the development of depression, 
making it a highly heritable disorder (Sullivan, Neale, & Kendler, 2000). However, there remains 
a large contribution of individual-specific environmental effects (Sullivan et al., 2000), which 
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may include historical risk factors for depression such as childhood abuse (Kendler, Gardner, & 
Prescott, 2002; Kendler, Gardner, & Prescott, 2006) and early parental loss or separation 
(Slavich, Monroe, & Gotlib, 2011). The most salient and immediate factor preceding the onset of 
depression, however, is the recent experience of a stressful life event. Individuals who have 
recently experienced divorce, interpersonal loss (Farmer & McGuffin, 2003; Kessing, Agerbo, & 
Mortensen, 2003), severe humiliation (Farmer & McGuffin, 2003), or social rejection (Slavich, 
O’Donovan, Epel, & Kemeny, 2010) are at considerably greater risk for the development of a 
depressive episode. It is in part for this reason that stress is now widely believed to be a 
fundamental precipitating factor in the etiology of depression (Deutschenbaur et al., 2015; 
Monroe & Simons, 1991; Pittenger & Duman, 2008; Willner et al., 2013). 
 The severity of stress that precedes a depressive episode does not appear to be the same 
for all individuals (Dienes, Hammen, Henry, Cohen, & Daley 2006; Kendler et al., 2001). While 
some might interpret this as evidence against the contribution of stressful life events to the 
development of depression, this observation can be readily explained by the diathesis-stress 
model (Monroe & Simmons, 1991). Variation in one’s genetic and historical (i.e., early-life risk 
factors) diatheses will likewise produce variation in the amount of stress required to elicit 
depression. Theoretically, a minor stressor could be sufficient to lead to a depressive episode in 
an individual with a strong diathesis, whereas an individual with a weak diathesis would 
necessitate a severe stressor for the same result. In support of this theory, a large twin study 
found that women at a low genetic risk for depression were far more likely to experience a 
severely stressful life event prior to the onset of depression than women at a high genetic risk 
(Kendler, Thornton, & Gardner, 2001). Similarly, lower levels of stress preceded bipolar 
depression in at-risk adults with early experience of adversity compared to adults without early 
experience of adversity (Dienes et al., 2006). The reason for why diatheses appear to lower the 
threshold of stress needed to develop depression is unsurprisingly complicated (see Willner et 
al., 2013 for review), but one essential element is that both genetic risk factors for depression 
(Gotlib, Joormann, Minor, & Hallmayer, 2008) and the experience of early life stressors (Essex 
et al., 2011; Heim, Newport, Mletzko, Miller, & Nemeroff, 2008; Wilkinson & Goodyer, 2011) 
impair the brain’s ability to regulate concentrations of potentially harmful stress hormones. 
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2.2. The Role of the HPA Axis in the Regulation of Stress 
 When an organism encounters an environmental stressor, a neuroendocrine system 
known as the hypothalamic-pituitary-adrenal (HPA) axis is activated in order to effectively adapt 
the body to these challenges towards homeostasis. The process is initiated by activation of the 
paraventricular nucleus of the hypothalamus through amygdalar inputs, which stimulates the 
release of corticotropin-releasing factor (CRF). The pituitary gland reacts to the presence of CRF 
by producing adrenocorticotropin hormone (ACTH), which then prompts the adrenal cortex to 
secrete glucocorticoids (cortisol in humans; CORT in rodents) into the bloodstream (Herman & 
Cullinan, 1997). Acute glucocorticoid release has beneficial effects on cognition that help an 
organism adapt to stressful events, but prolonged glucocorticoid exposure can have serious 
maladaptive physiological and behavioral consequences (de Kloet, Oitzl, & Joēls, 1999). 
 In the healthy brain, regulation of the HPA axis is accomplished through a number of 
internal excitatory and inhibitory feedback mechanisms that maintain homeostasis (de Kloet, 
Vreugdenhil, Oitzl, & Joēls, 1998; Willner et al., 2013). Relative levels of glucocorticoids are 
evaluated by the brain through the binding of these hormones to mineralocorticoid receptors and 
glucocorticoid receptors. Mineralocorticoid receptors are widely activated during basal levels of 
stress due to their high affinity for cortisol and CORT, and play an important role in maintaining 
stable neuronal firing through small calcium (Ca2+) currents (de Kloet et al., 1998; Reul & de 
Kloet, 1985). Conversely, glucocorticoid receptors have a tenth the binding affinity of 
mineralocorticoid receptors, and as a result are only widely activated when cortisol or CORT 
levels are high (e.g., during times of stress; de Kloet et al., 1998). Glucocorticoid receptor 
activation in the hippocampus initiates negative feedback control over the HPA axis to inhibit 
further stress hormone release and protect the brain from excessive levels of stress (de Kloet et 
al., 1998; Herman & Cullinan, 1997; Jacobson & Sapolsky, 1991; Nestler et al., 2002; Willner et 
al., 2013). In addition to the hippocampus, the dorsomedial prefrontal cortex and the prelimbic 
cortex also serve a vital role in the inhibition of HPA axis activity (Jankord & Herman, 2008; 
Ulrich-Lai & Herman, 2009). The amygdala, however, has an excitatory effect on the HPA axis 
in response to glucocorticoid receptor activation, and stimulates further cortisol release in a 
positive feedback loop (Duvarci & Paré, 2007). The integrity of the hippocampus and other 
inhibitory structures is thus imperative in counteracting the amygdala and maintaining healthy 
HPA axis function, as damage to any of these structures could upset the fine balance of 
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homeostasis (Herman, Prewitt, & Cullinan, 1996; Jacobson & Sapolsky, 1991; Magariños, 
Somoza, & de Nicola, 1987; Nestler et al., 2002). For example, hippocampal lesioning has been 
shown to upregulate CRF mRNA and increase glucocorticoid release in rats and primates, 
presumably due to decreased inhibitory HPA axis control (Herman & Cullinan, 1997; Jacobson 
& Sapolsky, 1991). 
 
2.3. HPA Axis Dysfunction in Depression 
 There is a large body of evidence supporting a strong relationship between HPA axis 
dysfunction and depression. Patients with depression exhibit elevated mean levels of plasma and 
urinary cortisol, and circadian cortisol secretion rhythmicity is likewise disturbed (Carroll, 
Curtis, & Mendels, 1976; Sachar, 1975). Contributing to this effect, the adrenal cortex of 
depressed individuals is hyperresponsive to ACTH, resulting in greater secretion of cortisol in 
response to this hormone than normal (Amsterdam, Maislin, Abelman, Berwish, & Winokur, 
1986; Amsterdam, Maislin, Droba, & Winokur, 1987). The importance of elevated cortisol in the 
etiology of depression is underscored by the fact that Cushing’s disease, a disorder caused by 
chronic excessive cortisol secretion, is highly comorbid with depression (Sonino & Fava, 2002). 
It is noteworthy that depressive symptomatology is ameliorated by correction of 
hypercortisolemia in the course of treatment for Cushing’s disease (Starkman, Schteingart, & 
Schork, 1986). 
 A widely used tool in the study of depression’s relationship with stress is the 
dexamethasone suppression test, which assesses the integrity of HPA axis inhibitory feedback 
control in response to glucocorticoid receptor activation. When dexamethasone binds to 
glucocorticoid receptors in healthy individuals, the potent steroid initiates inhibition of ACTH 
secretion, and in turn, downstream suppression of cortisol release (Holsboer, 2001). Studies have 
reliably demonstrated that depressed patients lack this dexamethasone-induced suppression of 
plasma cortisol levels, suggesting an impairment of HPA axis inhibition mechanisms 
(Amsterdam et al., 1986; Amsterdam et al., 1987; Carrol et al., 1976; Heuser et al., 1996; 
Holsboer, Lauer, Schreiber, & Krieg, 1995; Holsboer-Trachsler et al., 1994; Zobel, Yassouridis, 
Frieboes, & Holsboer, 1999; Zobel et al., 2000). Dexamethasone-induced cortisol suppression is 
normalized in depressed patients following successful antidepressant treatment (Heuser et al., 
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1996; Holsboer-Trachsler et al., 1994), but remains impaired in treatment-resistant patients and 
those who relapse within a 6 month period (Zobel et al., 1999; Zobel et al., 2000).  
 Abnormal HPA axis functioning is also noted in individuals possessing significant risk 
factors for depression. Nondepressed individuals who have first-degree relatives with depression 
(high familial risk) exhibit impaired dexamethasone-CRH suppression of cortisol, though not to 
the same degree as those currently experiencing a major depressive episode (Holsboer et al., 
1995). The experience of early life stressors is also associated with HPA axis hyperreactivity and 
an impaired ability to regulate stress in both children and adults (Essex et al., 2011; Francis & 
Meaney, 1999; Heim et al., 2008; Heim & Nemeroff, 2001; Wilkinson & Goodyer, 2011), an 
effect that is linked to the epigenetic modification of glucocorticoid receptors (Wilkinson & 
Goodyer, 2011). Experimental research has revealed similar HPA axis dysfunction in adult rats 
that have experienced maternal separation early in life (Rentesi et al., 2010). In line with the 
diathesis-stress model of depression, these genetic and early-life risk factors increase the odds of 
developing depression by impairing one’s ability to cope with stress, exposing individuals to 
chronically elevated levels of cortisol, thereby reducing the threshold of stress required to trigger 
a depressive episode (Willner et al., 2013). 
 
2.4. The Neurophysiological and Functional Consequences of Prolonged Stress Exposure 
 Although acute challenges of stress can normally be readily managed through HPA axis 
inhibition mechanisms, prolonged exposure to glucocorticoids is neurotoxic, and has profound 
negative effects on the morphology and functioning of the brain. Chronically elevated levels of 
glucocorticoids can arise from stressful life experiences, genetic and/or historical risk factors for 
depression, or a combination of both. Neurons in the hippocampus, prefrontal cortex (PFC), and 
amygdala are abundant in glucocorticoid receptors, making these structures highly vulnerable to 
the deleterious effects of chronic stress on morphological neuroplasticity (Feldman & 
Weidenfeld, 1999; Herman et al., 2003; Herman, Ostrander, Mueller, & Figueiredo, 2005; Mitra 
& Sapolsky, 2008; Morimoto et al., 1996). 
 In studies investigating the physiological and behavioral effects of chronic glucocorticoid 
exposure in rodents, elevated basal CORT levels can be achieved through long-term restraint 
stress or unpredictable stress paradigms (Ayensu et al., 1995; Bachis, Cruz, Nosheny, & 
Mochetti, 2008; Bielajew, Konkle, & Merali, 2002; Kitayama et al., 1989; Konkle et al., 2003; 
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Pitman, Ottenweller, & Natelson, 1988; Rodríguez Echandia, Gonzalez, Cabrera, & Fraccia, 
1988; Song, Che, Min-Wei, Murakami, & Matsumoto, 2006; Ushijima, Morikawa, Higuchi, & 
Ohdo, 2006; Vogel & Jensh, 1988). Alternatively, behavioral stress manipulations can be 
circumvented entirely by systemically injecting exogenous CORT solutions into test subjects 
over a period of weeks. Prolonged exposure to unpredictable stress is associated with reduced 
hippocampal volume in rats (Delgado et al., 2011), which is believed to result from pathological 
alterations in neuronal morphology (Czéh & Lucassen, 2007; Tata & Anderson, 2010). Dendritic 
atrophy of CA3 and CA1 hippocampal pyramidal neurons occurs following chronic restraint 
stress (Magariños & McEwen, 1995a; Magariños & McEwen, 1995b; Watanabe, Gould, Daniels, 
Cameron, & McEwen, 1992a; Watanabe, Gould, & McEwen, 1992b), chronic unpredictable 
stress (Magariños & McEwen, 1995a; Magariños, McEwen, Flügge, & Fuchs, 1996; Sousa, 
Lukoyanov, Madeira, Almeida, & Paula-Barbosa, 2000), or chronic exogenous CORT 
administration (Magariños, Orchinik, & McEwen, 1998; Morales-Medina, Sanchez, Flores, 
Dumont, & Quirion, 2009; Sousa et al., 2000; Watanabe et al., 1992a; Woolley, Gould, & 
McEwen, 1990). Treatment with a steroid synthesis blocker prevents dendritic atrophy in 
chronically stressed rats, suggesting that CORT secretion is an essential driving factor behind the 
neuronal damage (Magariños & McEwen, 1995b). Chronic stress also causes a profound loss of 
mossy fiber CA3 synapses, an observation that occurs independently of hippocampal volume 
reductions (Sousa et al., 2000; Tata, Marciano, & Anderson, 2006). This finding demonstrates 
that stress-induced damage to the hippocampus extends far beyond what is merely suggested by 
loss in structural volume (Tata et al., 2006). Impaired morphological plasticity, as evidenced by 
dendritic atrophy and reduced dendritic spine density, has likewise been found in the medial 
prefrontal cortex (mPFC) in response to chronic restraint stress (Cook & Wellman, 2004; Liston 
et al., 2006; Liu & Aghajanian, 2008; Radley et al., 2004), chronic unpredictable stress (Dias-
Ferreira et al., 2009; Izquierdo, Wellman, & Holmes, 2006; Li et al., 2011; Liu & Aghajanian, 
2008; Shansky & Morrison, 2009), and chronic exogenous CORT exposure (Liu & Aghajanian, 
2008; Wellman, 2001). 
 Not all structures of the brain are affected in the same way by prolonged exposure to 
glucocorticoids, however. Some regions remain apparently unchanged in the face of chronic 
stress (Liston et al., 2006), but the amygdala undergoes alterations in morphological plasticity 
that pathologically intensifies its function (Drevets, 2003). Chronic daily restraint stress and 
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CORT treatment lead to long-lasting dendritic hypertrophy and increased dendritic spine density 
in the amygdala of rats (Mitra, Jadhay, McEwen, Vyas, & Chattarji 2005; Mitra & Sapolsky, 
2008; Vyas, Bernal, & Chattarji, 2003; Vyas, Jadhav, & Chattarji, 2006; Vyas, Mitra, 
Shankaranarayana Rao, & Chattarji, 2002; Vyas, Pillai, & Chattarji, 2004). 
 The brains of human patients with depression exhibit similar alterations in morphology to 
those observed in chronically stressed rats. Magnetic resonance imaging reveals reductions of 
hippocampal volume in depressed individuals (Campbell, Marriott, Nahmias, & Macqueen, 
2004; Cole et al., 2010; Colla et al., 2007; Lange & Irle, 2004; Sheline, Gado, & Kraemer, 2003; 
Sheline, Sanghavi, Mintun, & Gado, 1999; Videbech & Ravnkilde, 2004), with specific 
deformations in CA1, CA2, and CA3 subregions (Cole et al., 2010). Longer durations of 
untreated depression are correlated with greater hippocampal volume loss, as is the number of 
past depressive episodes (Cole et al., 2010; Colla et al., 2007; Sheline et al., 1999; Sheline et al., 
2003). Antidepressant treatment reverses volume loss (Frodl et al., 2008; Sheline et al., 2003), 
but smaller hippocampal volumes and a history of depression predict poorer clinical outcomes 
(Frodl et al., 2008). The PFC has not been studied in humans as intensively as the hippocampus, 
but volume loss has been detected in the anterior cingulate cortex (Phillips, Drevets, Rauch, & 
Lane, 2003; Savitz & Drevets, 2009; van Tol et al., 2010). Similar to rats treated with chronic 
exogenous CORT, hypertrophy is also present in the amygdala of depressed humans (Bremner et 
al., 2000; Frodl et al., 2002; Lange & Irle, 2004), which is associated with greater levels of 
activity as measured by positron emission tomography (Drevets et al., 1992). Although these 
depression-associated alterations in brain morphology cannot be causally tied to chronic 
glucocorticoid exposure, it should be noted that patients with hypercortisolemia resulting from 
Cushing’s Disease exhibit similar hippocampal atrophy, which is reversed following successful 
treatment and reduction of cortisol levels (Bourdeau et al., 2002; Heinz, Martinez, & Haengeli, 
1977; Starkman et al., 1999).  
 The dendritic remodeling initiated by chronic stress presents a serious threat to HPA axis 
homeostasis. As previously discussed, the hippocampus and PFC serve a critical function in 
inhibiting HPA axis activity and glucocorticoid release (de Kloet et al., 1998; Willner et al., 
2013). It is therefore likely that stress-induced dendritic atrophy and loss of synapses in these 
structures could lead to further impairment of negative feedback control (Nestler et al., 2002). 
Prolonged stress also leads to a loss of hippocampal glucocorticoid receptors, compromising the 
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means by which excessive glucocorticoid levels are detected by the brain in the first place 
(Raison & Miller, 2003). Meanwhile, neurons in the amygdala, which function to promote stress 
hormone secretion, are strengthened by chronic stress and become hyperreactive (Duvarci & 
Paré, 2007; Pittenger & Duman, 2008), biasing the HPA axis towards a system of positive 
feedback. A vicious cycle is thereby created in which the brain becomes increasingly incapable 
of managing stress and preventing continued neuronal damage caused by excessive 
glucocorticoid exposure (Willner et al., 2013). Since depression is consistently accompanied by 
increased cortisol levels and impaired stress response, it is believed that this process of stress-
induced dendritic modification and HPA axis dysfunction plays a role in the development of the 
disorder (Holsboer, 2001; Nestler et al., 2002; Parker, Schatzberg, & Lyons, 2003; Sachar, 1976; 
Sachar & Baron, 1979; Sterner & Kalynchuk, 2010). 
 Some of the functional implications of chronic stress exposure can be seen through its 
effects on long-term potentiation (LTP) and long-term depression (LTD). LTP is a component of 
neuroplasticity that is characterized by a strengthening of synaptic efficacy between presynaptic 
and postsynaptic neurons that experience temporally coincident depolarization (Bliss & 
Collingridge, 1993). This activity-dependent potentiation of synaptic transmission is believed to 
play a fundamental role in learning and memory by forming new associative pathways in the 
brain (Malenka & Bear, 2004). Conversely, LTD is an opposing process that weakens synaptic 
efficacy, making it less likely for a presynaptic neuron to stimulate depolarization in a 
postsynaptic neuron (Bear & Malenka, 1994). Stress has the potential to modulate synaptic 
efficacy because the induction of LTP and LTD is regulated by extracellular stress hormone 
concentrations. Whereas LTP is favored when cortisol binding to glucocorticoid receptors is low, 
high levels of cortisol binding induce LTD instead (Coussens, Kerr, & Abraham, 1997; 
Diamond, Bennett, Fleshner, & Rose, 1992; Pavlides, Ogawa, Kimura, & McEwen, 1996; Rey, 
Carlier, Talmi, & Soumireu-Mourat, 1994). Accordingly, chronic behavioral stress has been 
found to impair hippocampal LTP in rodents while facilitating LTD (Foy, Stanton, Levine, & 
Thompson, 1987; Garcia, Vouimba, & Jaffard, 1997; Kim, Foy, & Thompson, 1996; Pavlides, 
Nivón, & McEwen, 2002; Shors, Seib, Levine, & Thompson, 1989; Xu, Anwyl, & Rowan, 
1997). In addition, chronic stress impairs LTP in the hippocampal-PFC pathway, a neural system 
that is integral in suppressing amygdalar activity (Cerqueira, Mailliet, Almeida, Jay, & Sousa, 
2007). Considering LTP’s importance in learning and memory, it is not surprising that chronic 
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CORT exposure and depression is associated with an array of pathological alterations in 
cognition, particularly in processes that depend upon function of the hippocampus, PFC, and 
amygdala (Sterner & Kalynchuk, 2010). 
 
3. Glutamatergic System Dysregulation in the Pathophysiology of Depression 
3.1. Introduction to the Glutamate Hypothesis of Depression 
 While it is apparent that chronic excessive glucocorticoid exposure impairs the 
morphological plasticity of prefrontal and hippocampal neurons, the mechanisms through which 
this damage takes place have not yet been discussed. It is now widely believed that 
glucocorticoid-induced dysregulation of glutamatergic neurotransmission underlies the neuronal 
damage and impaired synaptic plasticity observed in depressed patients, a theory that is referred 
to as the glutamate hypothesis of depression (Deutschenbaur et al., 2015; Maeng & Zarate, 2007; 
Pittenger & Duman, 2008; Pittenger et al., 2007; Sanacora et al., 2012; Willner et al., 2013).  
 Glutamate is the most commonly utilized excitatory neurotransmitter in the brain, and 
plays a fundamental role in learning and memory by regulating mechanisms of neuroplasticity 
(Sanacora, Zarate, Krystal, & Manji, 2008). Glutamatergic neurotransmission occurs both 
through fast-acting ionotropic receptors, as well as slower-acting metabotropic receptors. 
Ionotropic glutamate receptors include the α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate 
(AMPA) receptor, which functions as the primary mechanism of excitatory synaptic transmission 
at resting membrane potentials, and the N-methyl-D-asparate (NMDA) receptor, which initiates 
LTP through voltage-dependent activation and increased AMPA receptor subunit membrane 
insertion (Deutschenbaur et al., 2015; Johansen, Cain, Ostroff, & LeDoux, 2011; Maeng & 
Zarate, 2007; Nowak, Bregestovski, Ascher, Herbet, & Prochiantz, 1984; Pape & Paré, 2010; 
Sah, Westbrook, & Lüthi, 2008). 
 In order to maintain homeostasis and normal neuronal functioning, synaptic glutamate is 
constantly and rapidly cleared by glutamate transporters located in astrocyte glial cells, thus 
preventing extracellular neurotransmitter accumulation (Pittenger et al., 2007). Successful and 
sustained glutamate clearance is imperative to neuronal survival, as high levels of extracellular 
glutamate can lead to excitotoxicity through stimulation of extrasynaptic NMDA receptors. 
Unlike synaptic NMDA receptors, which serve a critical function in healthy neurotransmission 
and promote mechanisms of neuroplasticity (Deutschenbaur et al., 2015; Pittenger et al., 2007), 
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extrasynaptic NMDA receptors initiate intracellular processes that impair neuroplasticity 
(Hardingham, Fukunaga, & Bading, 2002; Ivanov et al., 2006) and even promote cell death 
(Ankarcrona et al., 1995; Manev, Favaron, Guidotti, & Costa, 1989). Accordingly, glutamate-
induced neurotoxicity and cell death is prevented by administration of NMDA receptor 
antagonists (Manev et al., 1989), which block extrasynaptic NMDA receptors from permitting 
Ca2+ influx and triggering anti-plasticity cascades (Hardingham et al., 2002). Extrasynaptic 
NMDA receptor activation impairs neuroplasticity by decreasing activation of the cyclic 
adenosine monophosphate (cAMP) response element-binding protein (CREB) transcription 
factor (Hardingham et al., 2002; Ivanov et al., 2006), which in turn downregulates the production 
of brain-derived neurotrophic factor (BDNF; Conti, Cryan, Dalvi, Lucki, & Blendy, 2002; 
Hardingham et al., 2002; Tao, Finkbeiner, Arnold, Shaywitz, & Grennberg, 1998). The BDNF 
protein plays an important role in promoting mechanisms of synaptic plasticity (Horch, Krüttgen, 
Portbury, & Katz, 1999; Yoshii & Constantine-Paton, 2007; Yoshii & Constantine-Paton, 2010) 
and is necessary for the induction of LTP (Kang, Welcher, Shelton, & Schuman, 1997; Korte, 
Staiger, Griesbeck, Thoenen, & Bonhoeffer, 1996; Patterson et al., 1996), so the loss of BDNF 
resulting from excessive glutamate exposure poses a significant threat to normal learning, 
memory, and processing in the brain (Heldt, Stanek, Chhatwal, & Ressler, 2007).  
 The glutamate hypothesis of depression postulates that the experience of chronic stress 
causes a sustained and excessive accumulation of glucocorticoids in the brain, which then bind to 
neurons expressing glucocorticoid receptors (especially those in the PFC and hippocampus) and 
initiate an enhanced presynaptic release of glutamate (Sanacora et al., 2012; Stein-Behrens et al., 
1992; Stein-Behrens, Lin, & Sapolsky, 1994; Venero & Borrell, 1999). This increase in synaptic 
glutamate release, coupled with a stress-induced impairment of astrocyte-mediated synaptic 
glutamate clearance, may then lead to an accumulation of extracellular glutamate and the 
activation of extrasynaptic NMDA receptors. The resulting downregulation of CREB expression 
would in turn downregulate BDNF, and thus lead to an impairment of synaptic plasticity and 
mechanisms of cell survival (Pittenger & Duman, 2008; Pittenger et al., 2007). It is believed that 
the neuronal damage caused by excessive glutamate exposure in regions such as the PFC and 
hippocampus may underlie some of the cognitive and behavioral pathologies typically observed 
in depression (Deutschenbaur et al., 2015; Pittenger & Duman, 2008; Pittenger et al., 2007; 
Sanacora et al., 2012).  
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 Paradoxically, high levels of extracellular glutamate might ultimately lead to an 
impairment of overall glutamatergic neurotransmission by damaging dendrites and synapses 
containing AMPA and NMDA receptors (Deutschenbaur et al., 2015; Pittenger et al., 2007). The 
functional and neurobiological effects of this damage would be compounded by the fact that a 
loss of synaptic NMDA receptor activation would also decrease the postsynaptic membrane 
insertion of AMPA receptors (Pittenger et al., 2007). Since both synaptic NMDA and AMPA 
receptor activation induces BDNF (Hardingham et al., 2002; Jourdi et al., 2009), impaired 
ionotropic glutamate receptor activity would exacerbate the downregulation of this important 
neurotrophin. 
 
3.2. Evidence from Animal Research 
 The glutamate hypothesis of depression is supported by considerable evidence from 
animal research demonstrating a mediatory relationship between stress, a major precipitating 
factor of depression that causes neuronal damage, and extracellular glutamate accumulation, an 
inducer of depression-like neuronal damage. Acute and chronic behavioral stress increases 
extracellular glutamate levels in the PFC and hippocampus (Bagley & Moghaddam, 1997; de 
Vasconcellos-Bittencourt et al., 2011; Fontella et al., 2004; Lowy, Gault, & Yamamoto, 1993; 
Moghaddam, 1993; Moghaddam, Bolinao, Stein-Behrens, & Sapolsky, 1994; Musazzi et al., 
2010; Reznikov et al., 2007; Satoh & Shimeki, 2010; Wang & Wang, 2009), two brain regions 
which also exhibit neuronal damage in chronic stress paradigms and human depression, as 
previously discussed. Glucocorticoid release underlies stress-induced increases of extracellular 
glutamate, as prior removal of the CORT-releasing adrenal gland abolishes the majority of 
excess glutamate accumulation in stressed animals (Lowy et al., 1993; Moghaddam et al., 1994). 
Furthermore, direct administration of CORT through injection or pellet implantation causes a 
dose-dependent increase of extracellular glutamate in the hippocampus (Stein-Behrens et al., 
1992; Stein-Behrens et al., 1994; Venero & Borrell, 1999), with levels reaching as high as 4x 
above baseline at doses equivalent to behavioral stress (Stein-Behrens et al., 1994).  
 The extrasynaptic accumulation of glutamate following chronic stress suggests that 
astrocytes and excitatory amino acid transporters are unable to adequately clear the extracellular 
space of this neurotransmitter relative to the rate of presynaptic release. This effect might be the 
result of stress-induced increases in presynaptic glutamate release (Pittenger et al., 2007; Satoh 
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& Shimeki, 2010; Wang & Wang, 2009), but could also be exacerbated by the fact that chronic 
stress and CORT exposure impairs hippocampal glutamate uptake (Almeida et al., 2010; Banasr 
et al., 2010; de Vasconcellos-Bittencourt et al., 2011; Yang, Huang, & Hsu, 2005; Virgin et al., 
1991). Hippocampal and cortical expression of glutamate transporters is reduced in a learned 
helplessness rodent model of depression, suggesting one means by which impaired glutamate 
uptake might occur (Zink, Vollmayr, Gebicke-Haerter, & Henn, 2010). In addition, chronic 
behavioral stress reduces the number and proliferation of astrocytes in the PFC (Banasr & 
Duman, 2008; Banasr et al., 2007; Czéh et al., 2007; Leventopoulos et al., 2007), as well as the 
number of astrocytes in the hippocampus (Liu et al., 2011). Supporting a role for disrupted 
glutamate clearance in the etiology of depression’s behavioral symptomatology, blocking 
glutamate uptake in PFC glial cells produces anhedonia in rats (John et al., 2012). Conversely, 
reversal of stress-induced glial dysfunction with the antiglutamatergic drug riluzole is 
accompanied by a similar reversal of anhedonic behavior (Banasr et al., 2010). Treatment with 
riluzole also demonstrates antidepressant qualities in the forced swim and incentive 
disengagement tests of depression-like behavior (Gourley, Espita, Sanacora, & Taylor, 2012). 
Further illustrating a modulatory role for glutamate clearance in depression-like behavior, 
stimulation of glutamate uptake with ceftriaxone produces antidepressant-like behavioral effects 
in the tail suspension and forced swim tests (Mineur, Picciotto, & Sanacora, 2007). 
 Evidence suggests that stress-induced extracellular glutamate accumulation likely leads 
to the activation of extrasynaptic NMDA receptors, which in turn inhibits intracellular 
mechanisms of neuroplasticity and alters behavior. First, the hippocampal neuronal damage 
caused by chronic stress is prevented by NMDA receptor antagonism, implicating glutamatergic 
neurotransmission as a downstream mediating factor of the neurophysiological effects of 
glucocorticoid exposure (Duman, Li, Liu, Duric, & Aghajanian, 2012; Magariños & McEwen, 
1995b). Additionally, stress-induced impairments in LTP and enhancements in LTD are 
dependent upon extrasynaptic NMDA receptor function, linking extracellular glutamate 
accumulation to functional modification of the brain (Kim et al., 1996; Yang et al., 2005). 
Finally, NMDA antagonists produce a variety of antidepressant-like behavioral effects in 
rodents, including reductions of depression-like behavior in tests for anhedonia (Carrier & 
Kabbaj, 2013; Garcia et al., 2009; Li et al., 2011; Papp & Moryl, 1993; Papp & Moryl, 1994; 
Papp & Moryl, 1996), behavioral despair (Autry et al., 2011; Carrier & Kabbaj, 2013; 
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Chaturvedi, Chandra, & Bapna, 1999; Gigliucci et al., 2013; Koike et al., 2013; Koike, Iijima, & 
Chaki, 2011; Li et al., 2010; Maeng et al., 2008; Moryl, Danysz, & Quack, 1993; Popik, Kos, 
Sowa-Kućma, & Nowak, 2008; Perrine et al., 2014; Przegaliński, Tatarczyńska, Dereń-Wesołek, 
& Chojnacka-Wojcik, 1997; Trullas & Skolnick, 1990; Yilmaz, Schulz, Aksoy, & Canbeyli, 
2002), negative cognitive bias (Amann et al., 2009; Pietersen et al., 2006), and cognitive 
flexibility (Jett et al., 2015). The antidepressant-like properties of NMDA antagonists extend to 
the abolishment of depression-like behaviors induced by chronic stress paradigms (Chaturvedi et 
al, 1999; Garcia et al., 2009; Gigliucci et al., 2013; Jett et al., 2015; Koike et al., 2011; Koike et 
al., 2013; Li et al., 2011; Papp & Moryl, 1993; Papp & Moryl, 1994; Papp & Moryl, 1996; 
Perrine et al., 2014; Trullas & Skolnick, 1990), and are accompanied by the normalization of 
circulating CORT (Garcia et al., 2009), promotion of synaptic plasticity (Li et al., 2010), and 
reversal of stress-induced neuronal atrophy (Li et al., 2011). Although NMDA antagonists can 
bind to both synaptic and extrasynaptic glutamate receptors, they are more likely to bind 
extrasynaptically due to the greater presence of high affinity Grin2b NMDA receptor subunits in 
this area and the reduced binding competition with endogenous glutamate in extracellular space 
(Pittenger & Duman, 2008). Combined with the fact that synaptic NMDA receptors promote 
neuroplasticity while extrasynaptic NMDA receptors oppose it, it is likely that the antidepressant 
morphological and behavioral effects of NMDA antagonists occur primarily through blocking 
extrasynaptic NMDA receptors (Krystal et al., 2013; Pittenger & Duman, 2008). It is thus clear 
from the reviewed research that NMDA receptor activation is a significant mediating factor of 
stress-induced neuronal damage and behavioral disorder, positioning the glutamate system as a 
valuable target for antidepressant action. 
 In addition to morphological and functional neuronal deficits, chronic stress is associated 
with intracellular neurobiological changes that are consistent with extrasynaptic NMDA receptor 
activation. Exposure to chronic stress reduces hippocampal CREB transcriptional activity in 
rodents alongside increases in anhedonic behavior (Gourley, Kiraly, Howell, Olausson, & 
Taylor, 2008a; Grønli et al., 2006). Chronic stress also decreases CREB protein expression and 
CREB phosphorylation in the PFC (Liu et al., 2014; Zhu et al., 2016). Levels of CREB have 
been demonstrated to mediate depression-like behavior. For example, viral vector-enhanced 
hippocampal CREB expression produces an antidepressant response in tests for behavioral 
despair and learned helplessness (Chen, Shirayama, Shin, Neve, & Duman, 2001a). One study 
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has also demonstrated that chronic activation of glucocorticoid receptors with CORT inhibits 
CREB transcriptional activity in clonal neurons (Föcking, Hölker, & Trapp, 2003), which would 
directly impair CREB’s downstream effects. Since CREB regulates transcription of the BDNF 
gene, it is unsurprising that chronic stress and CORT exposure decrease BDNF mRNA and 
protein expression in the hippocampus of rodents (Chen, Li, Zhao, & Yang, 2008; Dwivedi, 
Rizavi, & Pandey, 2006; Filho et al., 2015; Fu et al., 2014; Gourley et al., 2008a; Grønli et al., 
2006; Hamani et al., 2012; Jacobsen & Mørk, 2006; Jin, Yu, Tian-Lan, & Quan, 2015; Li et al., 
2012; Liang et al., 2012a; Liang et al., 2012b; Liu et al., 2014; Liu et al., 2015; Luoni, Macchi, 
Papp, Molteni, & Riya, 2014; Monsey et al., 2014; Nibuya, Takahashi, Russell, & Duman, 1999; 
Nitta, Fukumitsu, Kataoka, Nomoto, & Furukawa, 1997; Smith, Makino, Kvetnansky, & Post, 
1995; Yan et al., 2015; Zhang et al., 2015a). BDNF expression within the PFC is likewise 
impaired as a result of chronic stress paradigms (Aboul-Fotouh, 2015; Chen et al., 2008; Filho et 
al., 2015; Fu et al., 2014; Guo et al., 2014; Jin et al., 2015; Liang, Lu, Cui, Wang, & Tu, 2012a; 
Liu et al., 2014; Liu et al., 2015; Ray et al., 2011; Yan et al., 2015; Zhang et al., 2015a; Zhu et 
al., 2016). While CREB mediates the transcription of a number of genes, its effects on BDNF are 
likely of the greatest relevance to depression, as mice with forebrain (Monteggia et al., 2007) or 
hippocampal (Adachi, Barrot, Autry, Theobald, & Monteggia, 2008; Taliaz, Stall, Dar, & 
Zangen, 2010) BDNF gene deletions exhibit a variety of depression-like behaviors. Conversely, 
central (Hoshaw, Malberg, & Lucki, 2005; Siuciak, Lewis, Wiegand, & Lindsay, 1997) or 
hippocampal (Gourley et al., 2008a; Shirayama, Chen, Nakagawa, Russell, & Duman, 2002;) 
BDNF infusions have antidepressant-like effects in rodent models of depression, even following 
chronic stress (Schmidt & Duman, 2010).  
 
3.3. Evidence from Human Research 
 Although the majority of research investigating the glutamate hypothesis of depression 
has utilized rodent subjects, human patient research has replicated many of these findings and 
supports an association between depression and glutamatergic dysfunction. Blood serum 
glutamate content is increased in depressed patients compared to healthy controls (Altamura et 
al., 1993; Almatura, Maes, Dai, & Meltzer, 1995; Kim, Schmid-Burgk, Claus, & Kornhuber, 
1970; Küçükibrahimoğlu et al., 2009; Mauri et al., 1998; Mitani et al., 2006), and is positively 
correlated with depressive symptomatology (Mitani et al., 2006). Additionally, postmortem 
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analysis of brain tissue from individuals with depression has revealed increases in PFC glutamate 
levels (Hashimoto, Sawa, & Iyo, 2007), and both prefrontal (Jun et al., 2014; Lan et al., 2009) 
and hippocampal (Jun et al., 2014) glutamate levels are enhanced in patients with bipolar 
depression. Glial pathology has also been noted in depressed patients, including reductions in 
both the density and size of glial cells in various regions of the PFC (Miguel-Hidalgo et al., 
2002; Ongür, Drevets, & Price, 1998; Rajkowska et al., 1999; Rajkowska, Halaris, & Selemon, 
2001); reduced numbers of glial fibrillary acidic protein (GFAP)-immunoreactive astrocytes in 
the PFC (Miguel-Hidalgo et al., 2010; Si, Miguel-Hidalgo, O’Dwyer, Stockmeier, & Rajkowska, 
2004; Toro, Hallak, Dunham, & Deakin, 2006), hippocampus (Müller et al., 2001; Toro et al., 
2006), and cerebellum (Fatemi et al., 2004); and reduced immunoreactivity of glutamate 
transporters (Choudary et al., 2005; Miguel-Hidalgo et al., 2010). Together, these disruptions of 
normal glial function could lead to a harmful accumulation of extracellular glutamate, triggering 
anti-neuroplasticity processes (Sanacora et al., 2012). In line with this theory, depressed 
individuals exhibit downstream pathological alterations in neurobiology that are consistent with 
extracellular glutamate accumulation and extrasynaptic NMDA receptor activation. Postmortem 
analyses have demonstrated reduced CREB in the PFC of depressed individuals (Dowlatshahi, 
MacQueen, Wang, & Young, 1998; Yamada, Yamamoto, Ozawa, Reiderer, & Saito, 2003), as 
well as reduced BDNF mRNA in the hippocampus and PFC of suicide victims (Dwivedi et al., 
2003). Serum BDNF levels are also lower in patients with depression compared to healthy 
controls (Aydemir, Deveci, & Taneli, 2005; Gervasoni et al., 2005; Karege et al., 2002; Karege 
et al., 2005; Lee, Kim, Park, & Kim, 2007; Sen, Duman, & Sanacora, 2008; Shimizu et al., 
2003), and are negatively correlated with the severity of depressive symptoms (Brunoni, Lopes, 
& Fregni, 2008; Deuschle, et al., 2013; Gervasoni et al., 2005; Karege et al., 2002; Kim et al., 
2007b; Ricken et al., 2013; Shimizu et al., 2003). Although further human research is needed in 
this area, there is ample evidence to suggest that many of the same systems that are disordered in 
chronic stress animal models of depression are likewise disturbed in human depression. 
 If the glutamate hypothesis of depression is correct, then it would be expected that 
pharmacological intervention with any of the pathological processes described above would have 
antidepressant behavioral effects. Interestingly, virtually all classes of antidepressant treatments 
modulate the glutamatergic system and initiate neurobiological processes which oppose the 
effects of glutamate excitotoxicity. First, a variety of antidepressant drugs, including those from 
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the selective serotonin reuptake inhibitor (SSRI), monoamine oxidase inhibitor (MAOI), 
norepinephrine reuptake inhibitor (NERI), serotonin and norepinephrine reuptake inhibitor 
(SNRI), tricyclic, and melatonergic classes, have been shown to reduce depolarization-evoked 
presynaptic release of glutamate (Bonanno et al., 2005; Michael-Titus, Bains, Jeetle, & 
Whelpton, 2000; Musazzi et al., 2010; Reznikov et al., 2007), thus preventing stress-induced 
enhancements in extracellular glutamate accumulation (Musazzi et al., 2010; Reznikov et al., 
2007). Second, the binding characteristics of the NMDA receptor are altered by imipramine, 
citalopram, and electroconvulsive therapy (ECT; Nowak, Trullas, Layer, Skolnick, & Paul, 1993; 
Paul, Nowak, Layer, Popik, & Skolnick, 1994; Skolnick, 1999), and NMDA receptor antagonists 
have powerful antidepressant effects in humans (Berman et al., 2000; Cusin, Hilton, Nierenberg, 
& Fava, 2012; Diazgranados et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013; Phelps et 
al., 2009; Price et al., 2009; Rasmussen et al., 2013; Zarate et al., 2006). Third, postmortem 
analysis of brain tissue from depressed patients has revealed that antemortem antidepressant 
treatment abolishes the reduced temporal cortex concentration of CREB that is otherwise present 
in untreated depressed individuals (Dowlatshahi et al., 1998). Furthermore, chronic 
administration of a wide variety of antidepressant drugs increases CREB mRNA and CREB 
protein in the hippocampus of rats (Nibuya, Nestler, & Duman, 1996), as well as CREB 
phosphorylation (Thome et al., 2000; Tiraboschi et al., 2004), CREB binding activity (Frechilla, 
Otano, & Del Rio, 1998), and CREB transcription (Thome et al., 2000) in the PFC and 
hippocampus. Finally, hippocampal (Chen et al., 2001b) and serum (Aydemir et al., 2005; 
Brunoni et al., 2008; Deuschle et al., 2013; Gervasoni et al., 2005; Ricken et al., 2013; Sen et al., 
2008) BDNF concentrations are likewise increased in patients that have received antidepressant 
treatment compared to untreated patients with depression. Rodent research has also revealed 
increases in prefrontal and hippocampal BDNF mRNA resulting from several classes of 
antidepressant drugs and ECT (Coppell, Pei, & Zetterström, 2003; Dwivedi et al., 2006; Molteni 
et al., 2006; Nibuya, Morinobu, & Duman, 1995; Russo-Neustadt, Beard, & Cotman, 1999; 
Zetterström, Pei, & Grahame-Smith, 1998). It has also been found that the therapeutic actions of 
SSRI and tricyclic antidepressants are blocked by either whole-brain (Ibarguen-Vargas et al., 
2009; Saarelainen et al., 2003), forebrain- (Monteggia et al., 2007), or hippocampal-specific 
(Adachi et al., 2008) BDNF gene knockouts in mice. It is noteworthy that antidepressant-induced 
upregulation of CREB and BDNF only occurs following chronic, but not acute, antidepressant 
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treatment, thus mirroring the time course of antidepressant behavioral effects (Coppell et al., 
2003; Thome et al., 2000; Tiraboschi et al., 2004). 
 Although it is common for current antidepressant treatments to address glutamatergic 
dysfunction in one way or another, most do not target the brain’s glutamatergic system directly, 
leading to a considerable delay in therapeutic effect. As a result, there is substantial room for 
improvement in antidepressant therapies, and drugs with a more targeted influence on the 
glutamatergic system may hold the future for faster-acting and more effective antidepressant 
treatments. 
 
4. The Use of Animal Models in the Study of Depression-Like Behaviors 
 Human patient research has established a clear relationship between stress, HPA axis 
dysregulation, and depression, but the conclusions one can draw from these correlational studies 
alone are limited. Precise experimental manipulation of stress induction is required in order for 
causal inferences between glucocorticoid exposure and the development of depression to be 
made. Studies using animal models of depression thus fill an important void left by human 
patient research, and give researchers an opportunity to experimentally explore questions that 
could not be ethically addressed in humans. Some of these studies were discussed above in 
regards to the effects of prolonged stress on the brain, but animal models are also used to 
examine the stress-induced development of pathological depression-associated behaviors. 
 
4.1. Considerations of Validity 
 The use of animal models in the study of a human psychiatric disorder such as depression 
introduces a number of inherent challenges. If the results from these studies are to produce 
meaningful insights into the etiology of depression and guide the development of novel 
therapeutics, then the animal models being used must bear remarkable resemblance to the human 
disorder on a number of levels. However, it is unlikely that any one animal model can 
successfully reconstruct every possible facet of a psychiatric illness, nor would it necessarily be 
realistic if it could. Depression is characterized by a significant degree of heterogeneity in 
symptoms among patients, some of which are contradictory (e.g., insomnia or hypersomnia), and 
others which are impossible to measure in non-human animals (e.g., suicidal ideation, feelings of 
worthlessness). Nevertheless, valuable animal models of depression can be developed within 
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these limits, provided they take into consideration a number of factors defining the validity of the 
experimental model. Belzung and Lemoine (2011) have developed a comprehensive set of 
criteria to evaluate the validity of psychiatric disorder animal models, the most important of 
which will be summarized below in specific reference to rodent studies of depression. 
 First, it is important that behavioral animal models have pathogenic validity: the 
processes leading to disease in rodents should be semantically similar to those believed to lead to 
depression in humans (i.e., recent or early life stress). These etiological factors must then in turn 
produce a physiological and behavioral pathology similar to the human disorder of interest, a 
criterion known as induction validity. There should also be a shared neurobiological mechanism 
underlying the disorder (mechanistic validity), such as the neurodegeneration observed in both 
humans and rodents following stress, in addition to similarity of biomarkers indicative of 
depression (biomarker validity; e.g., elevated glucocorticoid levels). Since pathological 
behavioral alterations are the primary feature of psychiatric disorders, face validity requires that 
animal models must feature behavioral symptoms that are analogous to those seen in humans 
with depression. Symptoms like anhedonia or cognitive impairment will manifest differently 
between humans and rodents, so it must be noted that the material similarity of these behaviors is 
less important to validity than equivalency in what they mean to the animals producing them. 
Finally, of prime importance to the development and testing of antidepressant treatments is the 
concept of predictive validity. Drugs and therapies that are effective in treating depression in 
humans should likewise be effective in reversing the symptoms of pathology produced in the 
animal model. Excellent predictive validity, in conjunction with the fulfillment of the 
accompanying validity criteria discussed above, can allow animal models to produce meaningful 
results in the evaluation, refinement, and development of antidepressant treatments (Belzung & 
Lemoine, 2011). 
 
4.2. Animal Models of Depression 
 There are several different animal models available to researchers in the study of 
depression. Each model possesses a unique set of strengths and weaknesses in validity, and the 
choice of which model a researcher should use depends on the specific aims of the proposed 
study. Since the experience of prolonged stress appears to be a significant precipitating factor in 
the development of human depression, a number of models have utilized exposure to various 
 21 
forms of chronic stress as a pathogenically valid method of producing depression-like 
physiological and behavioral pathology in animals. The induction of chronic stress in a study can 
take one of two general forms: experimenter-applied behavioral stress, or exogenous CORT 
administration. In the former category, the most commonly used paradigms include repeated 
restraint stress and chronic unpredictable stress. Repeated restraint stress involves daily 
immobilization of the rodent in a restraint apparatus for several hours, and is typically performed 
over period of 21 days. This method of applying chronic stress is successful at inducing the 
neuronal atrophy that is characteristic of depression (Beck & Luine, 2002; Conrad, Magariños, 
LeDoux, & McEwen, 1999; Cook & Wellman, 2004; Liston et al., 2006; Liu & Aghajanian, 
2008; Magariños & McEwen, 1995a; Magariños & McEwen, 1995b; Radley et al., 2004; 
Watanabe et al., 1992a; Vyas et al., 2002; Vyas et al., 2003; Vyas et al., 2006), but produces 
inconsistent and sometimes contradictory alterations in depression-like behaviors (Dunn & 
Swiergiel, 2008; Platt & Stone, 1982), or fails to produce depressive symptomatology at all 
(Gregus, Wintink, Davis, & Kalynchuk, 2005; Lussier, Caruncho, & Kalynchuk, 2009; Perrot-
Sinal, Gregus, Boudreau, & Kalynchuk, 2004). One explanation for these inconsistent behavioral 
effects is that is that rats can eventually habituate to the restraint procedure, causing a decrease in 
CORT release over subsequent sessions (Galea et al., 1997; Gregus et al., 2005; Grissom et al., 
2007).  
 The chronic unpredictable stress model avoids the issue of procedure habituation by 
exposing rats to a variety of mild stressors, twice or several times a day, over a prolonged period 
of time (often 21 days). The stressors used in this protocol can include overnight food and water 
deprivation, alterations in colony room lighting (e.g., on during night, off during day, 
stroboscope during night), isolation, crowding, or abnormal home cage manipulations (e.g., tilt, 
rotation, bedding, odor), and are designed to be analogous to the daily life stressors that might 
precede the onset of depression. The chronic unpredictable stress model has excellent pathogenic 
and face validity and produces robust increases in depression-like behaviors (Willner, 1997; 
Willner, 2005), but its exceptional time and space requirements may exceed the available 
resources of many labs. One issue that is common amongst all experimenter-applied stress 
models is that the effects of chronic stress on behavior are liable to be influenced by individual 
variations in an animal's stress susceptibility and HPA axis response. While this variability is 
also present in random human populations, and may prove useful in the study of the differences 
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between at-risk and depression-resistant individuals, it is problematic if the researcher desires to 
study a homogenous sample of highly stressed animals with uniform depression-like behavior. 
 More precise control over stress exposure is made possible through chronic exogenous 
CORT administration models. Animals can be exposed to CORT daily through drinking water, 
pellet implantation, or subcutaneous injections over the course of 21 days. By exposing animals 
directly to CORT, these models bypass the subjective interpretation of a stressor, avoiding the 
possibility of stressor habituation and individual variability in stressor response. A daily injection 
paradigm was used in the present studies to ensure that every rat received the exact same dose of 
CORT by weight. As previously discussed, chronic CORT administration produces hippocampal 
(Magariños et al., 1998; Magariños et al., 1999; Morales-Medina et al., 2009; Sousa et al., 2000; 
Tata et al., 2006; Watanabe et al., 1992a; Woolley et al., 1990), prefrontal (Liu & Aghajanian, 
2008; Morales-Medina et al., 2009; Seib & Wellman, 2003; Wellman, 2001), and amygdalar 
(Mitra & Sapolsky, 2008) alterations in neuronal morphology in rodents similar to that observed 
in human depression (Bremner et al., 2000; Campbell et al., 2004; Cole et al., 2010; Colla et al., 
2007; Frodl et al., 2002; Lange & Irle, 2004; Sheline et al., 1999; Sheline et al., 2003; Videbech 
& Ravnkilde, 2004). These pathological changes in neuroplasticity are believed to contribute to 
cognitive and behavioral symptoms of depression (Duman et al., 2012; Nestler et al., 2002; 
Pittenger & Duman, 2008; Sterner & Kalynchuk, 2010; Willner et al., 2013), providing the 
repeated exogenous CORT model with sound mechanistic validity.  
 
4.3. Measuring the Effect of Chronic CORT Exposure on Depression-Like Behaviors 
 Depression is associated with a number of possible maladaptive alterations in cognition 
and behavior, which have become well-established through human research. However, practical 
and ethical constraints have restricted the extent of information one can glean regarding the 
etiology and treatment of these symptoms when using human patients. As a result, researchers 
have turned to the animal models described above in order to more extensively investigate 
cognitive and behavioral symptoms associated with depression. Numerous test protocols have 
been developed in order to study depression-like symptoms in animals through experimentally-
induced changes in overt behavior. In the interest of face validity, the changes in animal behavior 
being measured should bear semantic similarity to the corresponding symptoms of human 
depression that the researchers are attempting to replicate. Through the use of the CORT 
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injection animal model of depression, in conjunction with behavioral test protocols, a wealth of 
evidence has been uncovered linking chronic stress to the development of depression-like 
behavior. The effects of chronic CORT on depression-like behaviors, the various tests used to 
assess behavioral pathology, and the face validity of these protocols will be discussed in detail 
below. 
 
4.3.1. Anhedonia 
 Anhedonia, an inability to derive pleasure from normally enjoyable activities, is inferred 
in animal models of depression through an abnormally dampened response to natural rewards. 
The sucrose preference test takes advantage of the fact that rats possess an innate affinity for 
sweet substances. It measures a rat’s consumption of a sucrose solution compared to plain water 
when both solutions are available ad libitum in identical bottles in the animal’s home cage. 
Chronic CORT exposure decreases sucrose consumption (David et al., 2009; Gorzalka, Hanson, 
Harrington, Killam, & Campbell-Meiklejohn, 2003; Gourley et al., 2008a; Gupta, 
Radhakrishnan, & Kurhe, 2015; Wu et al., 2013; Yau et al., 2014), suggesting that the hedonic 
impact of this reward has been diminished. In addition to modified sucrose preference, rats 
undergoing chronic CORT exposure demonstrate anhedonia through decreased sexual activity 
(Gorzalka, Brotto, & Hong, 1999; Gorzalka & Hanson, 1998; Gorzalka, Hanson, & Hong, 2001), 
and an impaired value of food rewards (Gourley et al., 2008a; Gourley et al., 2008b). The stress-
induced suppression of hedonic indulgence supports both the face validity of these anhedonia 
measures, as well the induction validity of the chronic exogenous CORT model.  
 
4.3.2. Learned Helplessness 
 The forced swim test is a popular tool in the study of depression, and is believed to 
measure despair, resignation, and helplessness by presenting animals with the imminent threat of 
drowning (Porsolt, Anton, Blavet, & Jalfre, 1978; Porsolt, Le, & Jalfre, 1977). Animals are 
placed in a cylindrical tank of water from which escape is impossible, and their swimming 
behavior is recorded. Typically, rats will actively attempt to escape the tank for as long as 
possible, but premature passivity (i.e. immobility) is inferred to represent a cognitive state of 
learned helplessness. Chronic exposure to CORT reduces active coping and increases passive 
immobility in the forced swim test (Brummelte, Pawluski, & Galea, 2006; David et al., 2009; 
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Fenton et al., 2015; Gourley et al., 2008a; Gregus et al., 2005; Hill, Brotto, Lee, & Gorzalka, 
2003; Kalynchuk, Gregus, Boudreau, & Perrot-Sinal, 2004; Koike et al., 2013; Marks, Fournier, 
& Kalynchuk, 2009; Murray, Smith, & Hutson, 2008; Wu et al., 2013) in a dose-dependent 
manner (Johnson, Fournier, & Kalynchuk, 2006; Zhao et al., 2008a; Zhao et al., 2008b). 
Consistent with the theory that prolonged stress is required for the development of depression, 
acute treatment of CORT is ineffective at increasing depression-like behavior in the forced swim 
test (Johnson et al., 2006; Stone & Lin, 2008; Zhao et al., 2008b). 
 Although the behavioral inferences made by the forced swim test have been questioned 
by some researchers (Borsini & Meli, 1988), the measure’s greatest strength lies in its value as a 
predictive tool for effective antidepressant treatments. A wide array of known antidepressant 
therapies ameliorate depression-like behavior in the forced swim test (Porsolt et al., 1977; 
Porsolt et al., 1978), including imipramine (Fenton et al., 2015), ketamine (Koike et al., 2013), 
BDNF (Gourley et al., 2008a), spironolactone (mineralocorticoid receptor antagonist; Wu et al., 
2013), metabotropic glutamate 2/3 receptor antagonists (Ago et al., 2013), sertraline (Ulloa et al., 
2010), melatonin (Crupi et al., 2010), ECT (O’Donovan, Dalton, Harkin, & McLoughlin, 2014), 
piperine (Mao, Huang, Zhong, Xian, & Ip, 2014), peony glycosides (Mao, Huang, Ip, Xian, & 
Che, 2012), ginseng total saponins (Chen et al., 2014), and curcumin (Huang et al., 2011) in 
animals chronically injected with CORT. This excellent predictive validity makes the exogenous 
CORT model and forced swim test extremely valuable in the study and pursuit of novel 
therapeutics. 
 
4.3.3. Negative Cognitive Biases in Attention, Processing, and Interpretation 
 The psychological effects of depression are not merely limited to subjective feelings of 
depressed mood, but extend to serious maladaptive alterations in cognition that cause individuals 
to perceive information and interact with their environment in an abnormally pessimistic manner. 
Depression is associated with pathological modifications in attention, processing, interpretation, 
and memory that bias individuals towards focus on exogenous and endogenous negative 
emotional content. Collectively referred to as a negative cognitive bias, these abnormalities in 
perception and memory are believed to support the development and maintenance of depression 
(Elliott et al., 2011; Harmer et al., 2009a; Robinson & Sahakian, 2008), emphasizing the need to 
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address these symptoms through psychological and pharmacological intervention (Clark, 
Chamberlain, & Sahkian, 2009; Elliott et al., 2011; Roiser, Elliott, & Sahakian, 2012).  
 The ways in which negative cognitive biases can manifest in depression are varied and 
numerous. Several affective biases are quantitatively measurable through cognitive testing, 
which has allowed researchers to identify many of the mental processes impaired by depression. 
Attention, the cognitive process responsible for selecting and maintaining focus on specific 
environmental stimuli, is pathologically altered in association with depression, causing profound 
changes in the way depressed individuals view their world. Compared to healthy controls, 
depressed individuals spend less time gazing at faces with happy expressions (Isaac, Vrijsen, 
Rinck, Speckens, & Becker, 2014) and instead exhibit an attentional bias for faces expressing 
sadness (Gotlib, Krasnoperova, Yue, & Joormann, 2004), an effect which extends to individuals 
with a high genetic predisposition to depression (Joorman, Talbot, & Gotlib, 2007). Additionally, 
depression is associated with decreased attention towards pictures depicting positive emotional 
scenes and increased attention towards negative emotional scenes, with an impaired ability to 
disengage from negative stimuli (Caseras, Garner, Bradley, & Mogg, 2007; Sears, Thomas, 
LeHuquet, & Johnson, 2010). An attentional bias for negative emotional words is likewise 
present alongside depression (Broomfield, Davies, MacMahon, Ali, & Cross, 2007; Gupta & 
Kar, 2012), which appears to remain even following successful treatment (Gupta & Kar, 2012). 
Attentional biases for negative emotional stimuli are pernicious, as they could help contribute to 
the development and reinforcement of unrealistically pessimistic perceptions of the world (Balut, 
Paulewicz, Szastok, Prochwicz, & Koster, 2013).  
 Electrophysiology and neuroimaging research have revealed depression-related 
alterations in the underlying neural processing of emotional stimuli, which could be responsible 
for affective attentional biases. Mood-congruent attentional biases for faces are accompanied by 
changes in event-related potentials (ERP), with depressed individuals exhibiting higher intensity 
scores, as well as greater P1 and P2 amplitudes in response to sad expressions compared to 
healthy controls (Dai & Feng, 2012). Amplitude and latency of the N170 component, an ERP 
indicator of facial emotion processing, is disturbed in patients with a first episode of major 
depression, and even more greatly disordered in patients with recurrent major depression (Chen 
et al., 2014). Functional magnetic resonance imaging (fMRI) of blood oxygen level-dependent 
activity has aided in the identification of several brain regions implicated in the depression-
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associated abnormal processing of emotional stimuli (Stuhrmann, Suslow, & Dannlowski, 2011). 
Of particular interest is the amygdala (due to its hypertrophy in the depressed brain), which in 
depressed patients exhibits increased activity in response to negative facial emotional 
expressions, including both sad (Fu et al., 2004; Fu et al., 2008; Surguladze et al., 2005; Suslow 
et al., 2010; Victor, Furey, Fromm, Ohman, & Drevets, 2010) and fearful faces (Matthews, 
Strigo, Simmons, Yang, & Paulus, 2008; Peluso et al., 2009; Sheline et al., 2001; Zhong et al., 
2011). Conversely, depression is accompanied by decreased amygdalar activation in response to 
faces expressing happiness (Suslow et al., 2010; Victor et al., 2010). Additional brain regions in 
depressed patients that display abnormal neural reactivity to facial emotional expressions include 
the PFC, parahippocampal gyrus, insula, putamen, and fusiform face area (Stuhrmann et al., 
2011). Supporting the relationship between stress and depressive symptomatology, the recent 
experience of negative life stressors is significantly correlated with neural activation in regions 
of the orbitofrontal cortex, ventrolateral PFC, subgenual cingulate cortex, and nucleus 
accumbens of depressed individuals (but not healthy controls) when viewing negative emotional 
words (Hsu, Langenecker, Kennedy, Zubieta, & Heitzberg, 2010). It is thus well established that 
depressed individuals process exogenous sources of information differently than healthy 
individuals, with a general bias of hyperactivation in response to negative emotional stimuli and 
hypoactivation in response to positive emotional stimuli. 
 Antidepressant treatment has been found to normalize pathological neural responses to 
negative emotional stimuli in depressed individuals (Davidson, Irwin, Anderle, & Kalin, 2003; 
Fu et al., 2004; Sheline et al., 2001), affecting regions including the amygdala as well as several 
others (for review, see Harmer & Cowen, 2013). In addition, antidepressants increase previously-
suppressed neural responses to positive emotional stimuli in several brain regions (Fu et al., 
2007; Schaefer, Putnam, Benca, & Davidson, 2006). Interestingly, acute antidepressant 
treatments can positively bias cognitive emotional processing while simultaneously being 
insufficient to induce congruent changes in mood, which requires longer-term administration 
(Harmer, 2013; Harmer & Cowen, 2013). This suggests that affective states do not play a causal 
role in the pharmacological correction of negative cognitive biases (and perhaps the opposite is 
instead true). Therefore, identifying drugs that are particularly efficacious at addressing the 
underlying neuropathologies of cognitive affective biases is an endeavor of great value to the 
treatment of depression. 
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 Not only is the perceptual experience of depressed individuals biased towards negativity 
through disordered attention, but also through a propensity to interpret ambiguous information in 
a pessimistic manner. When orally presented words containing both emotionally neutral and 
negative homophones (e.g., gilt/guilt, teas/tease), depressed individuals demonstrate negative 
interpretations of the ambiguous words more frequently than healthy controls (Mogg, Bradbury, 
& Bradley, 2006). Additionally, currently depressed individuals are more likely to interpret 
ambiguous facial expressions as exhibiting negative emotions, and this perceptual bias is 
associated with an increased likelihood of relapse (Bouhuys, Geerts, & Gordijn, 1999). Negative 
interpretational biases have also been found to extend to girls at genetic risk for depression 
following the presentation of both emotionally ambiguous words and narratives (Dearing & 
Gotlib, 2009). 
 Another form of negative cognitive bias is evident in the way that depressed individuals 
perceive their future. When asked to make predictions about the likelihood of various desirable 
and undesirable life events occurring in the next 30 days, individuals with high levels of 
depressive symptoms are strongly pessimistic in their judgements (Strunk & Adler, 2009; 
Strunk, Lopez, & DeRubeis, 2006). In addition, the pessimistic predictions made by depressed 
individuals are unrealistic and largely inaccurate, as they do not coincide with the actual life 
experiences reported 30 days later by the same participants (Strunk et al., 2006). It seems 
possible that the unrealistically pessimistic expectations observed in depression could in part 
develop from attentional, interpretational, and memory biases that cause individuals to perceive 
their world in an exaggeratedly negative light. If cognition is constantly biased towards negative 
emotional information, then one might have little reason to expect positive outcomes in the 
future when they have paid little attention to them in the past. 
 Although largely unexplored until relatively recently, the study of negative cognitive 
biases in animals and the development of respective evaluative measures has offered researchers 
the opportunity to explore yet another facet of depression through animal models. Supporting the 
translational value of such research, the neural circuits implicated in the processing of negative 
cognitive biases in humans are also present in rodents (Cryan & Holmes, 2005). In order to 
detect cognitive affective biases in animals, researchers have developed a modified ambiguous 
cue interpretation (ACI) protocol inspired by similar tests used with human patients. In ACI 
tests, rats are trained to press a lever to receive a food reward when prompted by a tone of a 
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specific frequency. In addition, the same rats are also trained to press a separate lever to avoid an 
aversive electric footshock when prompted by another tone of a different frequency. The 
dependent variable is the choice of lever press an animal makes when presented with a new, 
ambiguous tone of intermediate kHz frequency that is halfway between reward and punishment 
tone. Pressing the reward lever in response to the ambiguous tone cue is inferred to reflect an 
animal’s positive interpretation of the stimulus and optimistic expectation of future outcome. 
Conversely, pressing the punishment avoidance lever is inferred to be indicative of a negative 
cognitive bias, as the animal has interpreted the intermediate tone cue to be predictive of an 
emotionally negative outcome. 
 As with other forms of depression-like behavior, a negative cognitive bias can be induced 
in animals through the experience of stress. Rats that have been exposed to repeated restraint 
stress (Rygula, Papciak, & Popik, 2013), chronic unpredictable stress (Harding, Paul, & Mendl, 
2004), and psychosocial stress (Papciak, Popik, Fuchs, & Rygula, 2013) exhibit pessimistic 
behavior in ACI testing compared to nonstressed animals. Using a genetic animal model of 
depression, rats selectively bred for helpless behavior in the forced swim test also respond 
negatively towards an ambiguous tone cue (Enkel et al., 2010). Supporting the diathesis-stress 
theory of depression, a natural variance exists in the degree of pessimistic responding in the ACI 
test, and inherently pessimistic rats are more vulnerable to stress-induced anhedonia than 
inherently optimistic rats (Rygula et al., 2013). One week of treatment with the antidepressant 
fluoxetine is capable of mitigating negative ACI responding in rats (Anderson, Munafò, & 
Robinson, 2013), providing the measure with some early potential for predictive validity. Since 
animal research investigating this measure is still in its infancy, only one study to date has 
examined the effect of CORT injection on ACI behavior. However, CORT injection prior to ACI 
testing in rats has yielded results consistent with studies using multiple forms of exogenous stress 
exposure, causing a bias towards pessimistic lever pressing (Enkel et al., 2010). Although the 
ACI measure of negative cognitive bias has generated reliable stress-induced effects on behavior, 
and possesses strong face validity, further research is needed in order to establish good predictive 
validity and replicate findings in the CORT animal model of depression. 
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4.4. Summary: Using Repeated CORT Injection as a Model of Depression 
 The repeated CORT injection model of depression offers an excellent platform from 
which one can study depression-like behaviors as well as the efficacy and underlying 
neurobiology of antidepressant treatments. By exposing animals to an elevated level of 
circulating glucocorticoids, a state believed to strongly contribute to the development of human 
depression, this model is capable of producing depression-like alterations in neuronal 
morphology and behavior in rodents, thus fulfilling the requirements of pathogenic, induction, 
and mechanistic validity. The various depression-like behaviors produced by chronic CORT 
exposure have been evaluated through valid testing protocols including the sucrose preference 
test, forced swim test, and ambiguous cue interpretation test. In addition, these behaviors are 
preventable through antidepressant treatment, supporting the model with valuable predictive 
validity. In addition to fulfilling the major criteria of animal model validity outlined by Belzung 
and Lemoine (2011), exogenous CORT administration offers advantages over other models of 
depression through precise manipulation of stress exposure, avoiding the undesired effects of 
stressor habituation or individual variance in stressor response. It is for these reasons that a 
repeated CORT injection paradigm was selected as a model of depression in the experiments 
performed in my thesis research. 
 
5. Modeling Depression-Associated Memory Bias Through Fear Conditioning 
5.1. Depression-Associated Negative Cognitive Bias in Memory 
 In addition to the cognitive affective biases of attention, processing, and interpretation 
described above, individuals with depression also experience maladaptive alterations in memory 
that skew the recollection of past events towards negative emotional information. One facet of 
depression-associated memory bias is evident in the process of rumination, which includes a 
pathological fixation on mentally rehearsing distressing memories. Rumination is a significant 
mediating factor on the development, severity, and chronicity of depression (Nolen-Hoeksema, 
2000). Not only do depressed individuals selectively attend to negative memories, but their 
ability to recall specific positive memories appears to be compromised, while the ability to recall 
negative memories is strengthened. When prompted to recall autobiographical memories related 
to positive, negative, or neutral cue words, depressed individuals recall positive events with 
limited detail and an increased response delay, but recall negative events with enhanced ability 
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compared to healthy controls (Gupta & Kar, 2012). A negative autobiographical memory bias is 
also present in individuals with currently remitted depression, but not those who have never been 
depressed (Gupta & Kar, 2012). 
 Affective memory bias in humans has been most heavily studied through tests assessing 
the explicit recall of incidentally encoded emotionally valenced trait adjectives. Similar to 
findings with autobiographical memory, depressed individuals demonstrate impaired recall of 
positively valenced words (Harmer et al., 2009a), instead exhibiting a memory bias for 
negatively valenced information in both adults (Balut et al., 2013; Gerritsen et al., 2012; Hsu et 
al., 2010; Liu et al., 2012; Mogg et al., 2006; Taylor & John, 2004), as well as children and 
adolescents (Neschat-Doost, Taghavi, Moradi, Yule, & Dalgeish, 1998). The emotional context 
of information also affects memory, as recall for neutral words is enhanced in depressed 
individuals when the words are incidentally encoded while reading emotionally negative 
narratives, compared to positive or neutral narratives (Nitschke, Heller, Etienne, & Miller, 2004). 
Although a negative memory bias for words has been demonstrated to be reversible through a 
single dose of the antidepressant reboxetine (Harmer et al., 2009b), individuals with remitted 
depression generally continue to experience maladaptive recall of negatively valenced stimuli 
(Romero, Sanchez, & Vasquez, 2014). The potential harm of negative cognitive biases is 
amplified in older patients, as these biases mediate global memory performance, which worsens 
in correlation with increased depressive symptom severity (Crane, Bogner, Bron, & Gallo, 
2007). 
 The various forms of negative cognitive bias do not operate in isolation, but rather 
possess the ability to influence the expression of one other. Attentional biases for negative 
stimuli not only coexist among memory biases in depression (Gupta & Kar, 2012), but also 
mediate the pathological enhancements in negative emotional memory described above (Balut et 
al., 2013). When trained to overcome the tendency to attend to negative stimuli, individuals with 
depression no longer exhibit a memory bias for negatively valenced words (Balut et al., 2013). 
Pessimistic stimulus interpretation also influences memory bias, as depressed individuals display 
enhanced memory for orally presented ambiguous homophones (e.g., dye/die; Mogg et al., 
2006). However, there are several other psychological and neurological factors that appear to 
underlie and contribute to the development of depression-associated memory bias. First, the 
degree to which memory is biased towards negative information increases in conjunction with 
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the severity of depression and symptoms of anhedonia (Liu et al., 2012). Negative memory bias 
is also associated with pathological neural activity and morphology in regions of the brain that 
are well-known to be susceptible to the effects of stress and depression. Electroencephalography 
of depressed individuals has revealed abnormal right PFC activity in association with emotional 
context word memory bias, a region heavily implicated in the production of negative emotions 
(Nitschke et al., 2004). Hippocampal atrophy and amygdalar hypertrophy are distinctive features 
of the depressed brain, and both the relative and absolute size of these structures are related to 
the expression of negative memory bias. Small hippocampal volume, large amygdalar volume, 
and a high ratio of amygdalar to hippocampal volume, are all associated with negatively biased 
memory (Gerritsen et al., 2012). The recent experience of stressful life events, a significant risk 
factor for depression (Farmer & McGuffin, 2003; Kessing et al., 2003; Slavich et al., 2010), is 
also positively associated with negative memory bias in depressed patients (Hsu et al., 2010). 
Furthermore, administration of cortisol in healthy individuals causes an enhancement in memory 
for negatively valenced words (Tops et al., 2003), illustrating a clear relationship between stress 
and negatively biased memory. 
 
5.2. Fear Conditioning 
5.2.1. Behavior and cognition 
 Although the prevalence of negative emotional memory biases in depressed individuals 
has been well-established through human patient research, the use of animal models in this field 
of study offers valuable opportunities to further evaluate the causative role of stress in memory 
bias, as well as the efficacy of antidepressants in alleviating these harmful symptoms. To study 
the effects of stress and antidepressant treatment on memory for emotionally valenced stimuli in 
animals, researchers have utilized various forms of Pavlovian fear conditioning. Fear is an 
adaptive emotional response that is triggered by the perception of an environmental threat, which 
initiates a cascade of changes in neurotransmission, behavior, and bodily function in order to 
prepare an organism for avoiding danger and minimizing physical harm. Some stimuli naturally 
evoke fear responses in rodents, such as the smell of a predator or physical pain, but the 
remarkable plasticity of the brain allows new stimuli-fear response associations to be formed, 
supporting dynamic adaptation to similarly dynamic environments (Kim & Jung, 2006; Pape & 
Paré, 2010). 
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 Fear conditioning takes advantage of this flexible learning process by repeatedly pairing 
an emotionally neutral conditioned stimulus (CS; e.g., tone cue, visual contextual cues) with an 
innately aversive and negatively valenced unconditioned stimulus (US; e.g., footshock), causing 
the formation of a predictive association between the two events (Johansen et al., 2011; Kim & 
Jung, 2006; Rodrigues, LeDoux, & Sapolsky, 2009; VanElzakker, Dahlgren, Davis, Dubois, & 
Shin, 2013). Following successful fear conditioning, presentation of the CS alone will elicit 
defensive fear responses, also known as conditioned responses (CRs), which are then measured 
to evaluate the degree of fear learning. Measures of CRs in rats can include ultrasonic distress 
vocalization, heart rate, respiration rate, blood pressure, potentiated startle, and pain sensitivity, 
but by far the most commonly utilized CR in fear conditioning research is freezing behavior 
(Kim & Jung, 2006). Freezing, defined as the absence of all non-respiratory movement, is an 
inborn rodent defense mechanism used to avoid predatory detection, and is automatically 
triggered in response to perceived threats (Blanchard & Blanchard, 1969; VanElzakker et al., 
2013). The percentage of time spent freezing during CS presentation is thus frequently used as a 
measure of fear conditioning, with greater percentages of freezing suggesting stronger CS-US 
association learning. 
 Researchers utilize a variety of different fear conditioning protocols depending on their 
specific needs, and often the most important distinction between testing procedures involves the 
nature of the conditioned stimuli. In contextual fear conditioning, a rat simply receives a series of 
footshocks while inside an operant chamber, which causes a fearful association to be formed 
between the aversive shock and the various ambient visual, auditory, and olfactory cues of the 
training environment. The animal will then exhibit freezing behavior if it is later placed within 
the same context that fear conditioning was acquired in, but not if it is exposed to a novel context 
with different persistent environmental cues. Auditory fear conditioning differs by repeatedly 
pairing a footshock with the termination of a discrete tone cue, thus effectively forming a 
predictive association between the onset of the tone and an emotionally unpleasant experience. 
Following auditory fear conditioning, the rat will freeze, even in a novel context, if presented 
with the same tone cue used during training. However, since conditioning to operant chamber 
contextual cues will unavoidably take place in tandem with conditioning to tone cues during 
auditory fear training, the rat will also freeze if placed again within the training environment. For 
this reason, tests of freezing to tone cues typically occur in a modified operant chamber with 
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novel ambient visual, auditory, and olfactory cues so that only auditory fear conditioning is being 
measured. Delay fear conditioning allows researchers to assess both contextual and auditory fear 
conditioning by following training with two distinct freezing tests that dissociate each form of 
learning (i.e., freezing to tone in novel context, and freezing without tone in training context). 
Both contextual and auditory fear conditioning paradigms are of value to researchers, as they 
recruit distinct neural circuits and can be differentially affected by treatments like chronic stress. 
Although successful contextual and auditory fear learning share a necessity for intact amygdala 
functioning, only contextual fear conditioning requires intact function of the hippocampus 
(LeDoux, 2000). 
 Although the induction of fear conditioning is relatively simple from a procedural 
standpoint, the cognitive systems underlying this phenomenon are complex, requiring the 
recruitment of a series of unique memory processes that must operate without error in order for 
CU-US associations to have long-lasting effects on behavior. The first stage of fear conditioning 
is acquisition, which begins immediately following the first CS-US pairing and consists of the 
automatically learned association between these two stimuli (Abel & Lattal, 2001; Johansen et 
al., 2011; Rodrigues et al., 2009). Memories of the CS-US pairing are extremely labile and 
sensitive to interference (e.g., drugs) during the period shortly following acquisition, and thus the 
long-term survival of these memories is contingent upon their ability to be converted into stable 
engrams (Abel & Lattal, 2001; Dudai, 2004; Rodrigues et al., 2009). Consolidation is the process 
responsible for the post-acquisition formation of long-term memories, which are largely resistant 
to pharmacological and behavioral disruption, and begins within minutes of fear conditioning 
(Duncan, 1949; McGaugh, 1966). Evaluation of the learned fear association typically takes place 
on a later date through presentation of the CS in the absence of US reinforcement, which initiates 
the process of long-term memory retrieval (Rodrigues et al., 2009). Expression, a related but 
distinct process, is responsible for the behavioral output (i.e., freezing, other CRs) resulting from 
the retrieval of fear memories. 
 All four of these memory processes are critical to successful fear conditioning, and 
interference at any stage through pharmacological treatment, brain lesions, or transient neuronal 
inactivation can dramatically alter the expression of CRs, both temporarily or permanently. This 
intrinsic feature of fear learning is highly exploitable by researchers, as precise manipulation of 
the time course of interference procedures can help uncover the structures and neurobiological 
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processes underpinning each stage of fear learning, as well as reveal which stages of memory a 
particular drug might affect. For example, if a drug administered immediately following fear 
conditioning training is later associated with lower levels of freezing during retrieval testing, it 
has likely impaired memory consolidation. Alternatively, if a drug reduces freezing when 
administered immediately prior to retrieval testing, but is ineffective when administered at earlier 
stages of fear conditioning, it likely interferes with the retrieval or expression of fear memory. 
However, it can sometimes be difficult to pinpoint the specific process of memory a drug might 
influence if the pharmacological treatment has long-lasting effects, as processing at multiple 
stages could potentially be altered. 
 
5.2.2. Neurobiology 
 An immense wealth of experimental research has culminated in the identification of the 
primary structures, nuclei, neural pathways, and neurobiological processes recruited during each 
stage of fear conditioning. Central to the induction of fear learning and the expression of fear-
motivated behavior is the amygdala, which integrates CS and US input, and initiates CR output. 
Early research revealed that large pre- and post-training amygdaloid lesions not only impaired 
fear conditioning (Blanchard & Blanchard, 1972; Kim, Rison, & Fanselow, 1993), but also 
prevented the expression of unconditioned fear-motivated behavior (Blanchard & Blanchard, 
1972; Hitchcock, Sananes, & Davis, 1989; Kim & Davis, 1993), suggesting a convergence of 
both conditioned and unconditioned stimuli processing in this structure (Kim & Jung, 2006). 
However, in order to fully comprehend the nuanced functioning of the amygdala in fear 
conditioning, it is necessary to distinguish between the dissociable amygdalar subsystem nuclei 
responsible for distinct stages of fear learning and behavioral response. Namely, the lateral (LA) 
and central (CE) amygdalar nuclei are of particular importance to the processing of fear 
associations and fear-motivated behavior.  
 The LA functions as the primary site of synaptic convergence for thalamic and cortical 
projections carrying a wide array of sensory information, including auditory, visual, and 
olfactory conditioned stimuli, as well as somatosensory (i.e. electrical shock) unconditioned 
stimuli (Dityatev & Bolshakov, 2005; Johansen et al., 2011; Kim & Jung, 2006; Maren, 1999a; 
Pape & Paré, 2010; Rodrigues et al., 2009; Sah et al., 2008). The LA also receives synaptic input 
from the hippocampus, which transmits information regarding diffuse ambient stimuli essential 
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for contextual fear learning (Ji & Maren, 2007; LeDoux, 2000; Maren, 1999a; Phillips & 
LeDoux, 1992; Pitkänen, Pikkarainen, Nurminen, & Ylinen, 2000). Since the LA is the primary 
sensory gateway for incoming fear-relevant stimuli, lesioning of this nucleus or its afferent 
sensory projections prevents both the induction of fear learning and the expression of fear-
motivated behavior, as observed in a wide variety of experimental protocols using several 
distinct forms of conditioned stimuli (Campeau & Davis, 1995; Cousens & Otto, 1998; Kim et 
al., 1993; Kim & Fanselow, 1992; LeDoux, Cicchetti, Xagoraris, & Romanski, 1990; Lee, 
Walker, & Davis, 1996; Maren, 1998; Maren, Aharonov, & Fanselow, 1996a; Maren, Aharonov, 
& Fanselow, 1997; Phillips & LeDoux, 1992; Romanski & LeDoux, 1992; Rosen et al., 1992; 
Sananes & Davis, 1992). Even if the amygdala is intact when recall testing occurs, transient 
neurotransmitter receptor inactivation of the LA during training results in impaired contextual 
and auditory fear learning, presumably because the CU-US association was initially unable to be 
formed in the LA (Bauer, Schafe, & LeDoux, 2002; Campeau, Miserendino, & Davis, 1992; 
Fanselow & Kim, 1994; Fendt, 2001; Gewirtz & Davis, 1997; Helmstetter & Bellgowan, 1994; 
Lee & Kim, 1998; Maren et al., 1996b; Miserendino, Sananes, Melia, & Davis, 1990; Muller, 
Corodimas, Fridel, & LeDoux, 1997; Rodrigues, Schafe, & LeDoux, 2001; Walker & Davis, 
2000). Further demonstrating the LA’s role in associative processing, rats with LA lesions are 
still capable of freezing in a unique conditioning paradigm that recruits amygdala-independent 
circuits (Maren, 1999b), suggesting that damage to the LA does not impair the ability to 
physically express fear-motivated behavior, but rather interferes with the upstream transmission 
of CS information in most auditory and contextual conditioning procedures. After being 
processed in the LA, signals initiated by unconditioned and/or conditioned stimuli are forwarded 
to the CE, which forms a common divergent output of hypothalamic, mesencephalic, and brain 
stem efferent projections that mediate defensive fear responses (i.e. CRs in fear conditioning; 
Johansen et al., 2011; Kim & Jung, 2006; LeDoux, 2000; Maren, 1999a; Pape & Paré, 2010; 
Rodrigues et al., 2009; Sah et al., 2008). Accordingly, lesioning of the CE abolishes the 
expression of conditioned fear (Hitchcock & Davis, 1986; Kim & Davis, 1993), while electrical 
stimulation initiates a CR-like physiological response in rats (Iwata, Chida, & LeDoux, 1987; 
Kapp, Gallagher, Underwood, McNall, & Whitehorn, 1982). The CE’s role in fear conditioning 
is limited to fear expression, as temporary inactivation of the CE during training has no effect on 
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freezing during subsequent recall testing, and thus the encoding and consolidation of fear 
memory (Fanselow & Kim, 1994).  
 Although the amygdala is the common locus of associative processing for a wide range of 
fear conditioning paradigms, there are other structures in the brain that play a significant role in 
various aspects of fear conditioning. As briefly mentioned above, the hippocampus projects 
contextual information to the LA, and thus the integrity of this structure is essential to the 
induction and expression of contextual fear conditioning (Anagnostaras, Maren, & Fanselow, 
1999; Kim & Fanselow, 1992; Maren et al., 1997; Phillips & LeDoux, 1992). However, auditory 
fear conditioning is hippocampus-independent, as cue-induced freezing is unaffected by 
hippocampal lesioning (Maren et al., 1997; Phillips & LeDoux, 1992). The mPFC is an 
important structure in the mediation of conditioned responding, as it possesses the ability to 
inhibit amygdalar output through efferent projections to the LA. Further discussion of the 
mPFC’s inhibitory influence on freezing can be found in the later section on fear extinction. 
Lastly, of particular relevance to the expression of fear conditioning is the periaqueductal gray, 
which serves a critical function in the freezing response (LeDoux et al., 1988).  
 Lesion studies have helped identify the LA as the point of synaptic convergence for US 
and CS signal input, but the research discussed thus far offers little insight into how associative 
fear learning occurs on a neurobiological level. Underlying the induction of conditioned fear is a 
form of synaptic plasticity referred to as Hebbian LTP, an activity-dependent strengthening of 
synaptic signaling that is initiated when presynaptic glutamate release coincides with 
postsynaptic depolarization (Johansen et al., 2011; Pape & Paré, 2010). One implication of 
Hebbian plasticity is that if a neuron receives a strong presynaptic input from one afferent 
connection, and at the same time receives a weak presynaptic input from a second afferent 
connection, membrane depolarization caused by the strong input is sufficient to enhance synaptic 
efficacy at both synapses (Johansen et al., 2011). Applying this model to fear conditioning 
training, a single LA pyramidal neuron may receive excitatory input from a cell transmitting 
shock information, as well as from a second cell transmitting auditory cue information 
(Romanski, Clugnet, Bordi, & LeDoux, 1993), but only the shock signal input is strong enough 
to cause postsynaptic depolarization and ultimately initiate a freezing response. However, the 
temporal pairing of the auditory presynaptic input and the shock-induced postsynaptic 
depolarization causes the auditory-LA synapse to strengthen, allowing presentation of the 
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auditory cue alone to initiate freezing (Johansen et al., 2010; Johansen et al., 2011; LeDoux, 
2000; Pape & Paré, 2010; Sah et al., 2008). Experimentally replicating this associative learning 
mechanism, optically-activated LA pyramidal neuron depolarization, when temporally paired 
with auditory cue presentation, causes rats to develop cue-elicited freezing in the absence of 
aversive conditioning (Johansen et al., 2010). The Hebbian model of associative learning is 
further supported by a wealth of in vivo and in vitro research demonstrating the enhanced 
efficacy of LA pyramidal neuron synapses following fear conditioning (Clem & Huganir, 2010; 
Hong et al., 2009; Hong et al., 2011; Kim et al., 2007a; McKernan & Shinnick-Gallagher, 1997; 
Rumpel, LeDoux, Zador, & Malinow, 2005; Schroeder & Shinnick-Gallagher, 2005). 
 Neurotransmission between afferent sensory projections (e.g., cortical and thalamic 
auditory inputs) and LA pyramidal neurons occurs through the presynaptic release of glutamate, 
which then binds to two types of coexpressed ionotropic glutamate receptors in the postsynaptic 
membrane (Mahanty & Sah, 1999). The AMPA receptor allows sodium and potassium ions to 
pass through the postsynaptic membrane when bound by glutamate, and functions as the primary 
mechanism of excitatory synaptic transmission in glutamatergic neurons at resting membrane 
potential (Deutschenbaur et al., 2015; Johansen et al., 2011; Maeng & Zarate, 2007; Sah et al., 
2008). Conversely, the NMDA receptor demonstrates voltage-dependent glutamate activation, as 
extracellular binding of magnesium (Mg2+) at resting membrane potential precludes the passage 
of ions through the channel pore. Cell membrane depolarization, induced by sufficient AMPA 
receptor ion transmission, frees the NMDA receptor of its Mg2+ block, allowing Ca2+ to flow into 
the cell (Deutschenbaur et al., 2015; Johansen et al., 2011; Maeng & Zarate, 2007; Nowak et al., 
1984; Pape & Paré, 2010; Sah et al., 2008). This increase of intracellular Ca2+ plays an important 
role in LTP, initiating a signaling cascade that upregulates postsynaptic membrane insertion of 
AMPA subunit Gria1, thereby enhancing synaptic efficacy and the ease with which presynaptic 
glutamate release may stimulate the pyramidal neuron (Johansen et al., 2011; Malinow & 
Malenka, 2002; Pape & Paré, 2010; Sah et al., 2008).  
 The unique circumstances by which NMDA receptors are activated causes them to act as 
coincidence detectors of pre- and postsynaptic activity, which combined with their ability to 
mediate LTP (and thus strengthen synapses between CS inputs and LA pyramidal neurons), 
makes NMDA receptors a critical component of associative fear learning (Johansen et al., 2011; 
Pape & Paré, 2010). Accordingly, infusion of the NMDA receptor antagonist DL-2-amino-5-
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phosphonovaleric acid (APV) into the LA (but not the CE; Fanselow & Kim, 1994) during 
training prevents the acquisition of fear conditioning (Bauer et al., 2002; Campeau et al., 1992; 
Fanselow & Kim, 1994; Fendt, 2001; Gewirtz & Davis, 1997; Lee, Choi, Brown, & Kim, 2001; 
Lee & Kim, 1998; Maren, Aharonov, Stote, & Fanselow, 1996b; Miserendino et al., 1990; 
Walker & Davis, 2000). A number of studies have demonstrated that LA infusion of APV prior 
to recall testing also impairs the expression of conditioned fear in successfully trained rats 
(Fendt, 2001; Lee et al., 2001; Lee & Kim, 1998; Maren et al., 1996b), but the evidence 
supporting the necessity of NMDA functioning during fear recall has been equivocal (Bauer et 
al., 2002; Campeau et al., 1992; Gewirtz & Davis, 1997; Miserendino et al., 1990; Walker & 
Davis, 2000). Likewise, the role of NMDA receptors in memory consolidation is unclear, as 
immediate post-training infusion of APV does not impair subsequent recall test freezing (Kim, 
DeCola, Landeira-Fernandez, & Fanselow, 1991; Maren et al., 1996b), whereas reversible post-
training genetic suppression of hippocampal NMDA receptor function has proved effective in 
interfering with contextual fear conditioning (Shimizu, Tang, Rampon, & Tsien, 2000). 
Additionally, human patient research suggests that emotional memory consolidation may be 
impaired by peritraumatic administration of the NMDA receptor antagonist ketamine (McGhee, 
Maani, Garza, Gaylord, & Black, 2008). Further investigation into the function of NMDA 
receptor activity during fear memory consolidation and recall is needed in order to help reconcile 
these seemingly conflicting results.  
 Since NMDA receptors cannot be activated without prior AMPA-facilitated membrane 
depolarization, and ultimately exert their influence on LTP in part through enhanced Gria1 
subunit membrane insertion, AMPA receptors share an essential role in the induction and 
expression of Pavlovian fear conditioning. Fear conditioning training reliably enhances the 
surface expression of AMPA receptor subunits in LA pyramidal neuron synapses (Kim et al., 
2007a; Nedelescu et al., 2010; Rumpel et al., 2005; Yeh, Mao, Lin, & Gean, 2006). Furthermore, 
not only is AMPA receptor synaptic incorporation dependent upon NMDA receptor activation 
(Yeh et al., 2006), but interference with this cell membrane insertion process also impairs fear 
conditioning (Rumpel et al., 2005). Additionally, intra-amygdalar infusion of the AMPA 
antagonist 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) blocks the expression of conditioned 
fear (Kim et al., 1993), while the AMPA receptor agonist 1-(quinoxolin-6-ylcarbonyl)piperidine 
(BDP-12) facilitates fear acquisition (Rogan, Stäubli, & LeDoux, 1997). 
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5.3. The Effects of Stress and Antidepressants on Fear Conditioning 
5.3.1. Stress and fear conditioning 
 The experience of chronic stress causes a number of morphological and functional 
alterations in the brain that have the potential to profoundly influence the neural processes 
underlying conditioned fear. Chronic behavioral stress or exogenous CORT exposure induces 
long-lasting dendritic hypertrophy and increased dendritic spine density in the LA of rats (Mitra 
et al., 2005; Mitra & Sapolsky, 2008; Vyas et al., 2002; Vyas et al., 2003; Vyas et al., 2004; 
Vyas et al., 2006). In addition to these morphological changes, stress and CORT attenuates 
GABAergic inhibition of LA neurons (Duvarci & Paré, 2007; Rodríguez Manzanares, Isoardi, 
Carrer, & Molina, 2005), and enhances LA neuron excitability (Duvarci & Paré, 2007; Garcia, 
Paquereau, Vouimba, & Jaffard, 1998; Kavushansky & Richter-Levin, 2006; Kavushansky, 
Vouimba, Cohen, & Richter-Levin, 2006; Rodríguez Manzanares et al., 2005). By enabling the 
induction of LTP at thalamic-LA synapses, stress enhances the ability for amygdalar neurons to 
form the associative connections that are pivotal to fear conditioning (Roozendaal, McEwen, & 
Chattarji, 2009; Tully, Li, Tsvetkov, & Bolshakov, 2007). 
 Glucocorticoids play an essential role in associative fear learning, as a variety of 
experimental manipulations that inhibit glucocorticoid receptor activation (i.e., adrenalectomy, 
amygdalar glucocorticoid receptor antagonism, and viral vector genes) likewise impair the 
consolidation of both auditory and contextual fear conditioning (Conrad, Mauldin-Jourdain, & 
Hobbs, 2001; Cordero, Kruyt, Merino, & Sandi, 2002; Donley, Schulkin, & Rosen, 2005; Jin, 
Lu, Yang, Ma, & Li, 2007; Kolber et al., 2008; Pugh, Fleshner, & Rudy, 1997a; Pugh, Tremblay, 
Fleshner, & Rudy, 1997b; Rodrigues & Sapolsky, 2009; Roozendaal & McGaugh, 1997). Not 
only are glucocorticoids necessary for fear conditioning, but their physiological concentrations 
also mediate how strongly fear is learned. Post-training levels of CORT and cortisol are 
correlated with the degree of conditioned responding in rodents (Cordero, Merino, & Sandi, 
1998; Cordero, Venero, Kruyt, & Sandi, 2003b) and humans (Zorawski, Blanding, Kuhn, & 
LaBar, 2006; Zorawski, Cook, Kuhn, & LaBar, 2005), respectively. By experimentally 
increasing glucocorticoid levels through either behavioral stress or CORT injection, further 
mediating effects on fear conditioning have been observed. Acute stress treatments have the 
ability to enhance both the consolidation and long-term recall of conditioned fear (Cordero et al., 
2003b; Corodimas, LeDoux, Gold, & Schulkin, 1994; Hui et al., 2004; Hui, Hui, Roozendaal, 
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McGaugh, & Weinberger, 2006; Izquierdo, Barros, Medina, & Izquierdo, 2002; Kohda et al., 
2007; Rau & Fanselow, 2009; Zorawski & Killcross, 2002), the effects of which are blocked by 
glucocorticoid receptor antagonists (Kohda et al., 2007). However, the most profound effects of 
glucocorticoids on fear-motivated behavior are seen in chronic stress animal models of 
depression. Chronic behavioral stress or chronic CORT injection prior to training reliably 
increases long-term conditioned freezing to contextual cues (Conrad et al., 1999; Conrad et al., 
2004; Cordero, Kruyt, & Sandi, 2003a; Marks, Fenton, Guskjolen, & Kalynchuk, 2015; Sandi, 
Merino, Cordero, Touyarot, & Venero, 2001; Skórzewska et al., 2006; Thompson, Erickson, 
Schulkin, & Rosen, 2004), and enhancements in auditory fear conditioning have also been 
demonstrated in these paradigms (Bisaz & Sandi, 2010; Conrad et al., 1999; Farrell, Sayed, 
Underwood, & Wellman, 2010; Marks et al., 2015; Monsey et al., 2014; Zhang & Rozencranz, 
2013). Prolonged glucocorticoid exposure increases conditioned responding in a dose-dependent 
manner (Marks et al., 2015), demonstrating a clear mediatory relationship between stress and 
memory for negatively-valenced stimuli. 
 
5.3.2. Antidepressants and fear conditioning 
 A wide array of antidepressants have been evaluated for their efficacy in suppressing the 
encoding and recall of negative emotional memories induced through fear conditioning. Studies 
on rodents have revealed that acute antidepressant treatment prior to fear memory recall can 
reduce context-elicited freezing, including the drugs citalopram (Hashimoto, Inoue, Muraki, & 
Koyama, 2009; Inoue et al., 2004; Kitaichi et al., 2014), desipramine (Santos, Martinez, & 
Brandão, 2006), diazepam (Miyamoto, Tsuji, Takeda, Nawa, & Matsumiya, 2000), escitalopram 
(Montezinho et al., 2010), flesinoxan (Li, Inoue, Hashimoto, & Koyama, 2001), fluoxetine 
(Santos et al., 2006), fluvoxamine (Li et al., 2001; Miyamoto et al., 2000; Miyamoto et al., 
2004), milnacipran (Miyamoto et al., 2004), mirtazapine (An et al., 2013; An et al., 2015), 
risperidone (Miyamoto et al., 2004), and venlafaxine (Slipczuk et al., 2013). Fewer studies have 
examined chronic antidepressant treatment regimens, but chronic citalopram (Burghardt et al., 
2004; Hashimoto et al., 2009) and tianeptine (Burghardt et al., 2004) treatment has been shown 
to impair contextual fear acquisition, while chronic flesinoxan, and fluvoxamine treatment has 
demonstrated efficacy in reducing auditory fear memory recall (Li et al., 2001). Very little 
research has investigated the effects of antidepressants on negative emotional memory in 
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chronically stressed animals, but recent research suggests that fluoxetine is effective in reducing 
tone cue-elicited freezing in rats that have received chronic daily CORT injection (Marks, 2014, 
unpublished results). Finally, in a single prolonged stress animal model of post-traumatic stress 
disorder (PTSD), chronic paroxetine treatment has proved efficacious in suppressing stress-
induced enhancements in contextual freezing (Takahashi, Morinobu, Iwamoto, & Yamawaki, 
2006). 
 However, not all antidepressants that have been investigated are effective at reducing 
conditioned fear, and some carry significant limitations as well. Acute treatments of paroxetine 
and tianeptine fail to reduce conditioned responding in stressed and nonstressed rats, 
respectively, exhibiting a delayed therapeutic effect (Burghardt et al., 2004; Takahashi et al., 
2006). Chronic tianeptine treatment has also failed to prevent a chronic stress-induced 
enhancement of auditory and contextual fear conditioning (Conrad et al., 1999). Additionally, the 
antidepressant effects of acute mirtazapine on contextual fear conditioning are short-lived, 
lasting less than a week (An et al., 2015). Surprisingly, a number of antidepressants actually 
enhance fear conditioning under certain conditions. When administered prior to training, acute 
escitalopram (Montezinho et al., 2010), fluvoxamine (Cassaday & Thur, 2015), sertraline 
(Cassaday & Thur, 2015), and vortioxetine (Mørk et al., 2013) enhance the acquisition of 
contextual fear conditioning, and acute citalopram (Burghardt et al., 2004) and fluoxetine 
(Burhans et al., 2013; Ravinder et al., 2013) enhance the acquisition of auditory fear 
conditioning. Although further investigation into this matter is needed, these results suggest that 
it might be possible for someone who is in the early stages of antidepressant treatment to 
experience an enhancement in memory for negative emotional information: an obviously 
undesirable and counter-productive effect. Based on the animal research conducted thus far, 
there appears to be considerable room for improvement in the efficacy of antidepressant drugs on 
suppressing measures of fear conditioning. An ideal antidepressant drug should produce an 
immediate and long-lasting reduction of conditioned responding, with no drug-induced 
enhancements of fear memory at any point during treatment.  
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5.4. Fear Extinction 
5.4.1. Behavior and cognition 
 Associative fear conditioning is rapidly induced through the pairing of a neutral stimulus 
with an inherently aversive emotional experience, but these fearful associations and their 
respective behavioral responses can later be challenged through a form of novel learning known 
as extinction. Extinction takes place by repeatedly presenting the CS in the absence of US 
reinforcement, which causes the organism to learn that the CS is no longer predictive of an 
unpleasant experience, resulting in a reduction of CS-elicited fear-motivated behavior (e.g., 
freezing; Johansen et al., 2011; Pape & Paré, 2010; Quirk & Mueller, 2008; VanElzakker et al., 
2013). The process of extinction begins immediately with the first unreinforced presentation of 
the CS, and continues to strengthen over the course of the extinction training trial (Cammarota et 
al., 2004).  
 Similar to fear conditioning, fear extinction recruits its own distinct acquisition, 
consolidation, and retrieval stages that must operate without interference in order to successfully 
modify conditioned behavioral responding (Quirk & Mueller, 2008). The acquisition of fear 
extinction is assessed by examining within-session CS-elicited conditioned responding during 
extinction training, while manipulations of the consolidation process are studied alongside 
memory retrieval through the expression of conditioned fear during a subsequent (typically next-
day) extinction recall test (Pape & Paré, 2010). Increases in between-session conditioned fear 
can be caused by a disruption of extinction consolidation (Quirk & Mueller, 2008), but also 
occur naturally with the passage of time due to the gradual decay of extinction memory, a 
phenomenon known as spontaneous conditioned fear recovery (Cruz, López, & Porter, 2014; 
Pape & Paré, 2010). In addition, extinction memories are poorly expressed in contexts 
incongruent with that in which extinction training occurred (unlike auditory fear conditioning, 
which is expressed in both the training context as well as novel environments), leading to a 
process referred to as conditioned fear renewal (Bouton, 2004; Bouton & Bolles, 1979a; Bouton 
& Bolles, 1979b; Bouton & King, 1983; Bouton, Westbrook, Corcoran, & Maren, 2006). Further 
demonstrating the fragile nature of extinction memory, conditioned fear can be rapidly reinstated 
in extinction trained animals through presentation of an unpaired US (Laurent & Westbrook, 
2010; McAllister & McAllister, 2006; Rescorla & Heth, 1975; Shen, Igarashi, Imamura, 
Matsuki, & Nomura, 2013), a sub-conditioning retraining procedure that pairs the CS with a 
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weak US (e.g., mild footshock) that is normally incapable of inducing fear conditioning in naive 
animals (Deschaux et al., 2013; Deschaux, Motanis, Spennato, Moreau, & Garcia, 2011a; 
Deschaux, Spennato, Moreau, & Garcia, 2011b; Laurent & Westbrook, 2010; Zheng et al., 
2013), or simply exposure to acute stress (Deschaux et al., 2013; Zheng et al., 2013). The ability 
for conditional fear responding to reemerge in previously fear-extinguished animals, even in the 
absence of full reconditioning procedures, suggests that extinction learning is not simply a 
process of forgetting or erasing previously conditioned fear associations. Conversely, fear 
extinction largely consists of the formation of a new memory that competes with and inhibits the 
CS-US association to reduce the expression of fear-motivated behavior (Pape & Paré, 2010; 
Quirk & Mueller, 2008; VanElzakker et al., 2013). However, while a considerable body of 
evidence supports fear extinction as a distinct form of novel learning, recent studies have 
demonstrated that the process of extinction also partially involves of the depotentiation and 
synaptic weakening of fear conditioning circuits (Clem & Huganir, 2010; Dalton, Wang, 
Floresco, & Phillips, 2008; Kim et al., 2007a). 
 Fear extinction is a valuable tool in the study of negative cognitive biases because it 
allows researchers to investigate the way an animal recalls memory for an emotionally-relevant 
interpretable stimulus (i.e., the CS). Since fear conditioning memories and fear extinction 
memories for the same CS co-exist in the brain, an extinction-trained animal that is presented 
with a CS can interpret it either pessimistically (i.e., the CS is predictive of a footshock) or 
optimistically (i.e., the CS is not predictive of a footshock), depending upon the relative strength 
of these memory associations (Pape & Paré, 2010; Quirk & Mueller, 2008; VanElzakker et al., 
2013). Both internal and external factors can modulate an animal’s behavioral response to an 
ambiguous CS (as can be seen in the renewal, recovery, and reinstatement of conditioned fear), 
which allows researchers the opportunity to test how exposure to various hormones or drugs alter 
the competing influence of conditioning and extinction memories. 
 
5.4.2. Neurobiology 
 The induction and recall of conditioned fear extinction recruits a complex system of 
neural circuitry involving communication between the mPFC, hippocampus, and amygdala. The 
ventromedial prefrontal cortex (vmPFC) was first suggested to be implicated in auditory fear 
extinction when it was observed that lesions of this structure impaired rats’ long-term recall of 
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extinction memories while leaving the initial acquisition of extinction intact (Morgan, Romanski, 
& LeDoux, 1993), a finding that has since been replicated (Fernandez, 2003; Lebrón, Milad, & 
Quirk, 2004; Morgan, Shulkin, & LeDoux, 2003; Quirk, Russo, Barron, & Lebron, 2000). 
Specifically, the infralimbic cortex (IL) was later identified as the crucial region of the vmPFC 
involved in extinction, as selective lesioning (Quirk et al., 2000) or chemical inactivation (Sierra-
Mercado, Corcoran, Lebrón-Milad, & Quirk, 2006) of this structure impairs between-session 
auditory fear extinction recall, but not the acquisition of fear conditioning nor the within-session 
short-term acquisition of extinction. Supporting a role in the consolidation of extinction memory, 
IL LTP (Farinelli, Deschaux, Hugues, Thevenet, & Garcia, 2006; Herry & Garcia, 2002; 
Hugues, Chessel, Lena, Marsault, & Garcia, 2006) and neuronal bursting (Burgos-Robles, Vidal-
Gonzalez, Santini, & Quirk, 2007) is induced shortly following extinction training, the presence 
or disruption of which is correlated with the success or failure of long-term extinction retention, 
respectively. Experimental manipulation of  IL activity further demonstrates its involvement in 
extinction behavior acquisition, as electrical stimulation of IL neurons reduces CS-elicited 
freezing in the absence of extinction training (Milad & Quirk, 2002; Milad, Vidal-Gonzalez, & 
Quirk, 2004; Vidal-Gonzalez, Vidal-Gonzalez, Rauch, & Quirk, 2006), but only when 
stimulation and CS presentation co-occur with a high degree of precision (Milad et al., 2004). 
 The IL is also directly implicated in the process of recalling extinction memories. 
Presentation of an extinguished auditory CS cue elicits temporally coincident firing of IL 
neurons during extinction recall testing, and the degree of IL neuron firing is correlated with the 
successful suppression of freezing behavior (Milad & Quirk, 2002; Wilber et al., 2011). 
Additionally, the retention of extinction memory is highly dependent upon the excitability and 
synaptic strength of mPFC neurons. Extinction training reverses a fear conditioning-induced 
depression of IL neuron excitability, but the return of IL depression after 17 days is associated 
with a corresponding recovery of CS-elicited freezing, implicating the IL in the long-term 
maintenance of extinction memories (Cruz et al., 2014; Herry & Mons, 2004). Furthermore, 
facilitation of LTP in the mPFC through high frequency stimulation prevents the reinstatement of 
conditioned fear following a sub-conditioning retraining procedure in extinction-trained rats 
(Deschaux et al., 2011a; Zheng et al., 2013). Thus, the mPFC can be viewed as a critical 
component of fear extinction, and since enhancement of mPFC function likewise strengthens 
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extinction memory, facilitation of this structure’s activity may prove to be a useful target for 
treating disorders characterized by extinction failure. 
 It is believed that the mPFC mediates conditioned fear responding through descending 
excitatory IL projections to the inhibitory, GABA receptor-expressing intercalated (ITC) neurons 
of the amygdala (Pape & Paré, 2010; Quirk & Mueller, 2008; VanElzakker et al., 2013). 
Accordingly, IL activation stimulates ITC neurons (Beretta, Pantazopoulos, Caldera, 
Pantazopoulos, & Paré, 2005), which in turn project to the CE (Paré & Smith, 1993) to inhibit 
conditioned responding (Jüngling et al., 2008; Likhtik, Popa, Apergis-Schoute, Fidacaro, & Paré, 
2008; Royer & Paré, 2002). This circuitry forms a system in which IL activity restricts the ability 
of LA stimulation (typically initiated by CS) to initiate CE output of fear-motivated behavior 
(Quirk, Likhtik, Pelletier, & Paré, 2003). ITC neurons also receive glutamatergic projections 
from the LA in addition to the IL, and undergo NMDA receptor-dependent LTP with repeated 
upstream stimulation of IL neurons (Royer & Paré, 2002). Thus, it seems possible that extinction 
utilizes a similar process of synaptic plasticity to that which occurs in the induction of fear 
conditioning: specifically, through NMDA receptor coincidence detection between LA and IL 
inputs on ITC neurons that subsequently strengthens the ability for the conditioned stimuli to 
produce a no-freezing response (Quirk & Mueller, 2008). 
 The expression of extinction memory is highly context-specific, as conditioned fear 
behavior is renewed when a CS is presented in an environment that is incongruent from that in 
which extinction training occurred (Bouton, 2004; Bouton & Bolles, 1979a; Bouton & Bolles, 
1979b; Bouton et al., 2006; Bouton & King, 1983). The context specificity of extinction 
necessitates a locus for processing contextual information and gating the output of emotional 
responses accordingly, a role to which the hippocampus has been suggested to fulfill. Extinction 
memory recall is associated with increased expression of c-Fos, a protein biomarker of recent 
neuronal activity, in several regions of the hippocampus (Knapska & Maren, 2009). Lesioning (Ji 
& Maren, 2007) or chemical inactivation (Corcoran, Desmond, Frey, & Maren, 2005; Corcoran 
& Maren, 2001; Corcoran & Maren, 2004; Hobin, Ji, & Maren, 2006) of the hippocampus prior 
to extinction memory retrieval abolishes the context-dependent expression of fear extinction. 
When hippocampal inactivation occurs prior to extinction training, extinction retrieval is 
impaired and conditioned responding is high, possibly due to a disruption of contextual encoding 
during the acquisition of extinction memory (Corcoran et al., 2005). It has been suggested that 
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the hippocampus may regulate fear output by transmitting contextual information to the mPFC 
(Quirk & Mueller, 2008), since LTP develops between the hippocampal-mPFC pathway shortly 
following extinction training, and interference with this process impairs extinction memory recall 
(Farinelli et al., 2006; Garcia, Spennato, Nilsson-Todd, Moreau, & Deschaux, 2008b; Hugues et 
al., 2006; Hugues & Garcia, 2007). It has also been demonstrated in fear extinguished rats that 
the hippocampus regulates the firing of prelimbic cortical neurons that are implicated in fear-
motivated behavior (Sotres-Bayon, Sierra-Mercado, Pardilla-Delgado, & Quirk, 2012), as well as 
neurons in the LA that demonstrate context-specific activity (Maren & Hobin, 2007). Similar to 
the IL of the mPFC, the hippocampus could be a useful target for pharmacological treatments 
aimed at enhancing extinction, due to its involvement in regulating conditioned fear. 
 A number of neurobiological processes have been identified to underlie conditioned fear 
extinction. As previously discussed, the NMDA receptor serves a vital function in the induction 
and expression of conditioned fear, but it is also heavily involved in extinction memory. 
Systemic NMDA receptor antagonism impairs the consolidation of extinction memory, while 
sparing the initial acquisition of fear inhibition (Liu et al., 2009; Santini, Muller, & Quirk, 2001; 
Suzuki et al., 2004). However, selective inactivation of the NMDA receptor subunit Grin2b 
through systemic administration of ifendprodil impairs extinction acquisition (Sotres-Bayon, 
Bush, & LeDoux, 2007) in addition to long-term consolidation (Sotres-Bayon, Diaz-Mataix, 
Bush, & LeDoux, 2009). Thus far, extinction-related NMDA receptor signaling has been 
localized to two regions of the brain: the amygdala, and the mPFC. Local amygdalar NMDA 
antagonism impairs the acquisition of extinction (Falls, Miserendino, & Davis, 1992), even when 
only targeting LA Grin2b subunits (Laurent, Marchand, & Westbrook, 2008; Laurent & 
Westbrook, 2008; Sotres-Bayon et al., 2007). Additionally, synaptic plasticity in ITC neurons is 
dependent upon NMDA receptor function (Royer & Paré, 2002). However, while NMDA 
receptors in the LA do not appear to serve a critical role in the consolidation of extinction 
memory, NMDA receptor activity is necessary for extinction consolidation in the vmPFC 
(Laurent & Westbrook, 2008; Sotres-Bayon et al., 2009). Specifically, NMDA receptors are 
required for the IL neuronal bursting that is associated with successful extinction consolidation 
(Burgos-Robles et al., 2007). 
 Another important neurobiological component underlying extinction learning is BDNF, a 
protein which binds to the Tyrosine kinase B (TrkB) receptor to promote elements of synaptic 
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plasticity, including synaptogenesis (Horch et al., 1999; Yoshii & Constantine-Paton, 2010) and 
dendritogenesis (Yoshii & Constantine-Paton, 2007). The BDNF protein’s ability to strengthen 
synapses, even in the absence of electrical stimulation, makes it a powerful modulator of 
memory and behavior (Autry et al., 2011; Liu et al., 2012; Messaoudi, Ying, Kanhema, Croll, & 
Bramham, 2002; Peters, Dieppa-Perea, Melendez, & Quirk, 2010). While fear conditioning 
impairs hippocampal BDNF transcription (Rasmusson, Shi, & Duman, 2002), fear extinction is 
associated with an upregulation of BDNF in fear suppression pathways (Bredy et al., 2007; 
Chhatwal, Stanek-Rattiner, Davis, & Ressler, 2006; Rosas-Vidal, Do-Monte, Sotres-Bayon, & 
Quirk, 2014). Following fear extinction, the presence of BDNF protein is increased in the ventral 
hippocampus (Rosas-Vidal et al., 2014), suggesting a role in the consolidation of extinction 
memory. BDNF also appears to mediate extinction memory retrieval, as hippocampal BDNF 
levels are correlated with the degree of successful long-term fear extinction recall (Peters et al., 
2010). Projection of hippocampal BDNF to the IL plays a fundamental role in the BDNF-
induced suppression of conditioned fear expression (Peters et al., 2010), and the presence of 
BDNF within the hippocampus even enhances the excitability of extinction-critical IL neurons 
(Rosas-Vidal et al., 2014). Furthermore, extinction training initiates epigenetic regulation of 
BDNF gene expression in the IL, increasing histone H4 acetylation of BDNF promoter regions 
to result in an upregulation of prefrontal BDNF mRNA (Bredy et al., 2007). Accordingly, 
administration of histone deacetylase inhibitors before extinction training augments this process, 
and produces a corresponding enhancement in extinction memory (Bredy et al., 2007). BDNF 
levels within the amygdala also appear to be implicated in fear extinction, since an upregulation 
of BDNF mRNA takes place in the LA following extinction training (Chhatwal et al., 2006). 
 Experimental manipulation of BDNF activity has demonstrated a clear mediatory role of 
the neurotrophin in the successful suppression of conditioned fear. For example, systemic 
administration of a TrkB agonist can facilitate extinction retrieval by preventing the renewal of 
conditioned fear in novel contexts (Baker-Andresen, Flavell, Li, & Bredy, 2013). Interestingly, 
the infusion of BDNF protein into the hippocampus (Peters et al., 2010) or IL (Peters et al., 
2010; Rosas-Vidal et al., 2014) also induces a long-term reduction in the expression of 
conditioned fear, even in animals that have never received extinction training (Peters et al., 
2010). Conversely, lentiviral inactivation of TrkB in the LA (Chhatwal et al., 2006), lentiviral 
deletion of the BDNF gene in the hippocampus (Heldt et al., 2007), or infusion of an anti-BDNF 
 48 
antibody in the IL (Rosas-Vidal et al., 2014) impairs the long-term expression of extinction 
behavior. Thus, BDNF in hippocampal-mPFC-amygdala circuitry is both necessary and 
sufficient for fear extinction, and likely exerts its behavioral influence by supporting neural 
activity in pathways that are fundamental to extinction learning (Heldt et al., 2007; Peters et al., 
2010; Rosas-Vidal et al., 2014). 
 The prevailing theory of fear extinction has been that extinction learning consists of the 
formation of a new memory that competes with the original conditioned fear association to 
inhibit fear-motivated behavioral output, as opposed to the fear memory being erased outright 
(Quirk & Mueller, 2008). However, while an immense body of research supports this view of 
extinction memory, it has become apparent that the process of fear extinction simultaneously 
involves a reversal of conditioning-induced enhancements of synaptic efficacy. As previously 
discussed, fear conditioning training enhances the surface expression of AMPA receptor subunits 
in LA pyramidal neuron synapses (Kim et al., 2007a; Nedelescu et al., 2010; Rumpel et al., 
2005; Yeh et al., 2006), a process that is required for successful fear conditioning (Rumpel et al., 
2005). Conversely, extinction decreases the surface expression of AMPA receptor subunits in 
LA neurons of previously conditioned animals through a process of endocytosis (Clem & 
Huganir, 2010; Kim et al., 2007a). Disruption of AMPA receptor endocytosis through 
administration of a GluR2-derived peptide accordingly impairs the acquisition and recall of fear 
extinction (Dalton et al., 2008; Kim et al., 2007a). Additionally, extinction reverses LTP in both 
cortical-LA (Hong et al., 2009) and thalamic-LA synapses (Hong et al., 2011; Kim et al., 2007a) 
that are essential to conditioned fear. However, the reversal of conditioning-induced LTP and 
AMPA receptor membrane insertion that occurs as a result of extinction should not be confused 
with memory erasure, which does not occur under normal extinction conditions, as conditioned 
fear can still be spontaneously recovered, or readily renewed or reinstated in the absence of re-
conditioning (Pape & Pare, 2010; Quirk & Mueller, 2008; VanElzakker et al., 2013).  
 
5.5. The Effects of Stress and Antidepressants on Fear Extinction 
5.5.1. Stress and fear extinction 
 Not only does the experience of stress facilitate fear conditioning, but it also induces 
several pathological alterations in the morphology and neurobiology of the brain that impair 
neuroplasticity and threaten the underlying processes of successful fear memory extinction. As 
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previously discussed, the morphological integrity of the PFC is essential to extinction memory 
retrieval, as damage to this structure is associated with a reemergence of conditioned responding 
(Fernandez, 2003; Lebrón et al., 2004; Morgan et al., 1993; Morgan et al., 2003; Quirk et al., 
2000; Sierra-Mercado et al., 2006). Posing a considerable threat to the healthy functioning of the 
PFC, both chronic behavioral stress and chronic exogenous CORT exposure have been found to 
induce significant dendritic atrophy and impairment of dendritic spine density in this region 
(Cook & Wellman, 2004; Dias-Ferreira et al., 2009; Izquierdo et al., 2006; Li et al., 2011; Liston 
et al., 2006; Liu & Aghajanian, 2008; Radley et al., 2004; Shansky & Morrison, 2009; Wellman, 
2001). In addition, the hippocampus plays a vital role in ensuring that extinction memory is 
recalled in the appropriate context in which it was encoded (Corcoran et al., 2005; Corcoran & 
Maren, 2001; Corcoran & Maren, 2004; Hobin et al., 2006; Ji & Maren, 2005), a function that is 
potentially endangered by the volume reduction, dendritic atrophy, and mossy fiber synapse loss 
that accompanies chronic stress exposure (Delgado et al., 2011; Magariños et al., 1996; 
Magariños et al., 1998; Magariños et al., 1999; Magariños & McEwen, 1995a; Magariños & 
McEwen, 1995b; Morales-Medina et al., 2009; Sousa et al., 2000; Tata et al., 2006; Watanabe et 
al., 1992a; Watanabe et al., 1992b; Woolley et al., 1990). Interestingly, patients with PTSD, a 
disorder characterized by extinction memory failure, exhibit reductions in hippocampal volume 
as revealed by magnetic resonance imaging (O’Doherty, Chitty, Saddiqui, Bennett, & 
Lagopoulos, 2015). 
 Ultimately, it is neuronal activity within the PFC and hippocampus that underlies the 
suppression of fear-motivated behavior, so changes in LTP mediated by NMDA receptor 
activation in these regions could have dramatic effects on fear extinction. NMDA receptors in 
the PFC are critical to the successful acquisition and consolidation of extinction memory 
(Burgos-Robles et al., 2007; Laurent & Westbrook, 2008; Sotres-Bayon et al., 2009). Stress-
induced damage to PFC dendrites and synapses could impair glutamatergic activation of local 
NMDA receptors, which would in turn impair LTP (Deutschenbaur et al., 2015; Pittenger et al., 
2007). 
 In addition to the aforementioned pathological alterations of neuronal morphology, 
chronic stress induces changes in neurotrophin expression within extinction circuits that could 
impair the ability to successfully suppress conditioned fear. BDNF activity within the 
hippocampal-mPFC pathway is essential to the long-term expression of fear extinction, and past 
 50 
research has demonstrated that interference with this mechanism results in the reemergence of 
conditioned fear responding (Heldt et al., 2007; Peters et al., 2010; Rosas-Vidal et al., 2014). 
Significantly undermining the integrity of fear extinction circuits, chronic stress and CORT 
exposure impairs BDNF expression in both the hippocampus and PFC (Aboul-Fotouh, 2015; 
Chen et al., 2008; Dwivedi et al., 2006; Filho et al., 2015; Fu et al., 2014; Gourley et al., 2008a; 
Grønli et al., 2006; Guo et al., 2014; Hamani et al., 2012; Jacobsen & Mørk, 2006; Jin et al., 
2015; Li et al., 2012; Liang et al., 2012a; Liang et al., 2012b; Liu et al., 2014; Liu et al., 2015; 
Luoni et al., 2014; Monsey et al., 2014; Nibuya et al., 1999; Nitta et al., 1997; Ray et al., 2011; 
Smith et al., 1995; Yan et al., 2015; Zhang et al., 2015a; Zhu et al., 2016). Since BDNF is an 
inducer of LTP (Kang et al., 1997; Korte et al., 1996; Patterson et al., 1996), a stress-induced 
downregulation of this important neurotrophin could produce impairments in neuronal activity as 
well. Accordingly, chronic stress impairs LTP in both the hippocampus and hippocampal-PFC 
pathway of rodents (Cerqueira et al., 2007; Foy et al., 1987; Garcia et al., 1997; Kim et al., 1996; 
Pavlides et al., 2002; Shors et al., 1989; Xu et al., 1997). This carries significant consequences 
for long-term extinction retention, as hippocampal and prefrontal LTP exerts powerful influence 
over the prevention of conditioned fear reinstatement (Deschaux, Koumar, Canini, Moreau, & 
Garcia, 2015; Herry & Garcia, 2002; Zheng et al., 2013). Conversely, the suppression of LTP in 
the hippocampal-PFC pathway (as occurs as result of chronic stress) impairs extinction 
consolidation, promoting the spontaneous recovery of conditioned fear (Garcia et al., 2008b). 
Interestingly, the mere exposure of rats to conditioned tone and contextual cues also causes a 
downregulation of hippocampal BDNF mRNA, further impairing plasticity (Rasmusson et al., 
2002). 
 Although impairment of hippocampal and prefrontal plasticity (and by extension, 
inhibitory control over the amygdala) would be sufficient to compromise fear extinction, this 
effect is likely exacerbated by the hypertrophy, reduced GABAergic inhibition, and enhanced 
excitability of the amygdala that results from stress and glucocorticoid exposure (Duvarci & 
Paré, 2007; Garcia et al., 1998; Kavushansky et al., 2006; Kavushansky & Richter-Levin, 2006; 
Mitra et al., 2005; Mitra & Sapolsky, 2008; Rodríguez Manzanares et al., 2005; Vyas et al., 
2002; Vyas et al., 2003; Vyas et al., 2004; Vyas et al., 2006). Stress-induced enhancements in 
initial fear learning and fear memory retrieval could also pose an additional challenge to 
extinction, since stronger fear memories would have to be overcome compared to nonstressed 
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animals. Stress hormones in the amygdala also appear to mediate extinction learning, as intra-
amygdalar infusion of CRF prior to extinction training impairs the long-term expression of 
extinction behavior (Abiri et al., 2014). Collectively, these studies suggest that stress produces a 
harmful combination of morphological, neurobiological, and functional alterations that impair 
the neural systems responsible for inhibiting fear, while simultaneously strengthening those that 
promote fear-motivated behavior. 
 Consistent with what can be predicted by studies on the neurophysiological consequences 
of stress exposure, behavioral animal research has confirmed that chronic stress compromises the 
ability to effectively extinguish fear memories and maintain suppression of conditioned fear. 
Several studies have reported that chronic behavioral stress or CORT exposure increases freezing 
during auditory cue extinction training and slows the rate at which conditioned responding is 
suppressed (Dagnino-Subiabre et al., 2012; Farrell et al., 2010; Gourley, Kedves, Olausson, & 
Taylor, 2009; Hoffman, Lorson, Nanabria, Olive, & Conrad, 2014; Zhang & Rozencranz, 2013). 
However, an initial impairment of extinction memory acquisition is not always observed (Baran, 
Armstrong, Niren, Hanna, & Conrad, 2009; Gourley et al., 2009; Miracle, Brace, Huyck, Singler, 
& Wellman, 2006; Wilber et al., 2011), and the effects of stress on fear extinction may not be 
apparent until subsequent tests for extinction memory recall are conducted. Research has reliably 
demonstrated that chronic behavioral stress impairs the recall of extinction memories, as 
evidenced by enhanced between-session freezing (i.e., spontaneous fear recovery) despite 
successful fear extinction by the end of the initial extinction training period (Baran et al., 2009; 
Farrell et al., 2010; Hoffman et al., 2014; Miracle et al., 2006; Wilber et al., 2011). Interestingly, 
stressed rats exhibiting poor extinction recall also display dendritic atrophy in IL neurons 
(Izquierdo et al., 2006), and fail to express an increase of CS-elicited IL neuronal activity that is 
normally observed in nonstressed animals (Wilber et al., 2011). Since IL activity is correlated 
with successful suppression of freezing behavior (Milad & Quirk, 2002), and the depression of 
IL neuron excitability is accompanied by spontaneous fear recovery (Cruz et al., 2014), this 
deficit of IL neuronal firing in stressed animals is a likely culprit for extinction memory recall 
failure. Although the effect of chronic exogenous CORT exposure on fear extinction recall has 
not yet received extensive investigation, one study has demonstrated a deficit in contextual 
extinction memory recall as a result of this treatment (Gourley et al., 2009). The results of this 
study also revealed a CORT-induced cortical reduction of Grin2b expression (Gourley et al., 
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2009). Activation of the Grin2b NMDA receptor subunit is essential to extinction memory 
acquisition and consolidation (Sotres-Bayon et al., 2007; Sotres-Bayon et al., 2009). 
Accordingly, it was found that vmPFC levels of Grin2b were correlated with conditioned 
responding throughout extinction (Gourley et al., 2009). 
 There is evidence that stress and depression can also influence fear extinction in humans. 
For example, high scores for depressive symptoms predict enhanced fear conditioning and 
impaired fear extinction in adolescents (Den, Graham, Newall, & Richardson, 2015). 
Additionally, the experience of acute stress prior to extinction training impairs next-day 
extinction memory retrieval in adults, despite having no effects on initial extinction acquisition 
(Raio, Brignoni-Perez, Goldman, & Phelps, 2014). Further supporting a role for stress in the 
impairment of extinction consolidation, post-extinction stress exposure enhances both 
spontaneous fear recovery and trained fear reinstatement in men (Hamacher-Dang, Merz, & 
Wolf, 2015). 
 
5.5.2. Antidepressants and fear extinction 
 Research on the efficacy of antidepressants in facilitating components of fear extinction 
has produced mixed results. In nonstressed rodents, chronic fluoxetine has been demonstrated to 
reduce conditioned responding during extinction acquisition (Camp et al., 2012; Lebrón-Milad et 
al., 2013), and impair or outright prevent the spontaneous recovery (Deschaux et al., 2011b; 
Deschaux et al., 2013; Karpova et al., 2011; Lebrón-Milad et al., 2013; Popova et al., 2014), 
contextual renewal (Karpova et al., 2011), sub-conditioning reinstatement (i.e., pairing the CS 
with a weak shock that is otherwise incapable of inducing fear conditioning in naive animals; 
Deschaux et al., 2013; Karpova et al., 2011; Spennato, Zerbib, Mondadori, & Garcia, 2008), or 
stress-induced reinstatement (Deschaux et al., 2013) of previously extinguished fear-motivated 
behavior. Acute and chronic treatment with venlafaxine has also been found to prevent 
spontaneous fear recovery and sub-conditioning reinstatement, respectively (Yang et al., 2012). 
In non-depressed humans, chronic pretreatment with escitalopram can accelerate the acquisition 
of fear extinction, but extinction memory retention was not investigated (Bui et al., 2013). 
However, chronic antidepressant treatment with either citalopram or tianeptine has surprisingly 
been found to impair the acquisition of fear extinction and downregulate expression of 
amygdalar Grin2b in rats (Burghardt, Sigurdsson, Gorman, McEwen, & LeDoux, 2013). 
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Likewise, acute fluoxetine or tianeptine treatment impairs both extinction acquisition and recall 
in rats (Godsil et al., 2015; Lebrón-Milad et al., 2013). These findings raise concerns that 
treatment with these drugs might be counter-productive to challenging negative emotional 
memory biases. Further research into the pharmacological facilitation of extinction is needed, as 
no studies have yet investigated the ability for antidepressants to prevent chronic stress-induced 
fear recovery. A fast-acting drug that can both accelerate the suppression of conditioned 
responding and support the long-term maintenance of extinction memory in chronically-stressed 
animals could prove valuable in the treatment of depression-associated negative cognitive biases.  
 
6. Ketamine as a Rapid-Acting Treatment for Depression 
6.1. Limitations of Standard Antidepressant Treatments 
 Most antidepressants prescribed today exert their influence on mood and behavior by 
regulating the availability of monoamines (e.g., serotonin, norepinephrine) in the brain. 
However, despite having rapid effects on extracellular monoamine availability, achieving 
remission with these drugs often takes several weeks or months of treatment and more than one 
unique drug treatment (Judd et al., 2002; Thase et al., 2005; Trivedi et al., 2006). These findings 
suggest that the antidepressant properties of monoamine-regulating drugs are the result of 
downstream neurobiological alterations in the brain, and not that of direct modulation of the 
monoaminergic system itself (Heninger, Delgado, & Charney, 1996; Maeng & Zarate, 2007; 
Sanacora et al., 2008; Sanacora et al., 2012). Since a third of depressed patients remain resistant 
to treatment even after trialling four unique antidepressant drugs (Gaynes et al., 2009), there is a 
clear need for new strategies in the pharmacological treatment of depression. 
 
6.2. Ketamine and the Treatment of Depression in Humans 
 A wealth of research has implicated disordered glutamatergic neurotransmission in the 
pathophysiology of depression (Deutschenbaur et al., 2015; Krystal et al., 2013; Pittenger & 
Duman, 2008; Pittenger et al., 2007; Sanacora et al., 2008; Sanacora et al., 2012), making the 
glutamatergic system a potential target for novel antidepressant treatments. One drug that has 
received particular attention due to its rapid-acting antidepressant effects is ketamine. Ketamine 
is primarily a noncompetitive antagonist of the NMDA receptor that blocks receptor activation 
by binding to the phencyclidine site of the complex’s cation channel (Sanacora et al., 2008). In 
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addition to being an NMDA receptor antagonist, ketamine can also block peripheral sodium 
(Na+) currents (Benoit, Carratù, Dubois, & Mitolo-Chieppa, 1986), and block the nicotinic 
acetylcholine receptor (Scheller et al., 1996). Furthermore, ketamine acts as a partial agonist of 
the D2 dopamine receptor (Kapur & Seeman, 2002), and as a weak agonist of the 5-
hydroxytryptamine 2A (5-HT2A) receptor (Kapur & Seeman, 2002), sigma receptor (Oye, 
Paulsen, & Maurset, 1992; Smith et al., 1987), delta opiod receptor (Hirota et al., 1999), kappa 
opioid receptor (Hirota et al., 1999; Hustveit, Maurset, & Oye, 1995), and mu opiod receptor 
(Gupta, Devi, & Gomes, 2011; Hirota et al., 1999). 
 In randomized, double-blind clinical trials of patients with major depression, acute 
subanesthetic infusions of ketamine have demonstrated robust antidepressant effects compared to 
placebo (Berman et al., 2000; Diazgranados et al., 2010; Zarate et al., 2006), a finding which has 
since been reliably replicated in several open-label studies (Cusin et al., 2012; Ibrahim et al., 
2011; Murrough et al., 2013; Phelps et al., 2009; Price et al., 2009; Rasmussen et al., 2013). 
Reductions in depression symptom severity are apparent within 2 hours of a single ketamine 
infusion, and full remission can be achieved in some patients in as little as 24 hours 
(Diazgranados et al., 2010; Murrough et al., 2013; Zarate et al., 2006). Patients who respond 
positively to ketamine treatment can experience antidepressant effects lasting more than 2 weeks 
from a single dose (Aan Het Rot, Zarate, Charney, & Matthew, 2012), and serial ketamine 
treatment can maintain remission for over 6 months (Cusin et al., 2012). When combined with 
ECT, ketamine produces a greater reduction in depressive symptoms than ECT alone (Kranaster, 
Krammerer-Ciernioch, Hoyer, & Sartorious, 2011; Okamoto et al., 2010; Wang, Liu, Patterson, 
Paule, & Slikker, 2013). Ketamine has even demonstrated remarkable efficacy in treating 
patients who have previously proved to be unresponsive to standard antidepressant drugs and 
ECT (Cusin et al., 2012; Diazgranados et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013; 
Phelps et al., 2009; Price et al., 2009; Zarate et al., 2006). While standard antidepressants drugs 
can take 8 weeks to achieve a response rate of 65% in non-treatment-resistant samples (Entsuah, 
Huang, & Thase, 2001; Thase et al., 2005), a single dose of subanesthetic ketamine produces 
over a 70% response rate in treatment-resistant patients after a mere 24 hours (Zarate et al., 
2006). 
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6.3. The Neurobiology of Ketamine’s Antidepressant Effects 
 The robust and fast-acting antidepressant effects of ketamine are without a doubt 
impressive. According to Machado-Vieira and colleagues, “There has never been a report of any 
other somatic or pharmacological intervention that consistently and reproducibly results in such a 
dramatically rapid and prolonged response—well beyond the half-life on the drug—with a single 
administration” (Machado-Vieira, Salvadore, DiazGranados, & Zarate, 2009). Research has 
begun to shed light on the complex mechanisms through which ketamine might exert these 
unique antidepressant qualities. First, ketamine stimulates presynaptic glutamate release by 
reducing the activity of inhibitory GABAergic interneurons in the PFC and hippocampus 
(Chowdhury et al., 2012; Homayoun & Moghaddam, 2007; Moghaddam, Adams, Verma, & 
Daly, 1997; Stone et al., 2012). At first glance, this glutamatergic efflux may appear to be 
counter-productive to the treatment of depression, since high levels of extracellular glutamate are 
neurotoxic and associated with depression itself (Hashimoto et al., 2007; Jun et al., 2014; Lan et 
al., 2009). However, glutamate-induced neurotoxicity and cell death is dependent upon the 
activation of extrasynaptic NMDA receptors, which are blocked by ketamine (Hardingham et al., 
2002; Manev et al., 1989; Ivanov et al., 2006). Furthermore, ketamine likely binds preferentially 
to extrasynaptic NMDA receptors as opposed to synaptic NMDA receptors, due to the greater 
presence of high-affinity Grin2b NMDA receptor subunits and reduced relative concentration of 
endogenous glutamate in extrasynaptic regions of the neuron (Pittenger & Duman, 2008). Thus, 
by preferentially blocking the activation of extrasynaptic NMDA receptors while simultaneously 
stimulating presynaptic glutamate release, ketamine enhances glutamatergic neurotransmission 
through synaptic AMPA and NMDA receptors without the risk of glutamate excitotoxicity. 
Accordingly, administration of ketamine has been shown to potentiate excitatory field potentials 
in the hippocampus (Autry et al., 2011; Nosyreva et al., 2013) and PFC (Li et al., 2011). The 
facilitation of glutamatergic neurotransmission is an essential underlying component of 
ketamine’s antidepressant behavioral effects, which are blocked by the co-administration of an 
AMPA receptor antagonist (Autry et al., 2011; Koike et al., 2011). 
 However, while this transient burst of glutamatergic throughput plays an important role 
in ketamine’s antidepressant qualities, the fact that a clinical response is maintained well beyond 
the drug’s 180 minute half-life suggests that there are further downstream mechanisms at work 
(Clements, Nimmo, & Grant, 1982). Ketamine’s second major therapeutic mechanism of action 
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appears to involve a positive modulation of neuroplasticity that causes a sustained reversal of 
stress-induced neuronal damage. Notably, ketamine has been shown to modulate the expression 
of the BDNF protein, which plays an important role in promoting synaptic plasticity (Horch et 
al., 1999; Yoshii & Constantine-Paton, 2007; Yoshii & Constantine-Paton, 2010) and LTP 
(Kang et al., 1997; Korte et al., 1996; Patterson et al., 1996). While chronic stress induces a long-
lasting inhibition of hippocampal and prefrontal BDNF transcription and synthesis (Aboul-
Fotouh, 2015; Chen et al., 2008; Dwivedi et al., 2006; Filho et al., 2015; Fu et al., 2014; Gourley 
et al., 2008; Grønli et al., 2006; Guo et al., 2014; Hamani et al., 2012; Jacobsen & Mørk, 2006; 
Jin et al., 2015; Li et al., 2012; Liang et al., 2012a; Liang et al., 2012b; Liu et al., 2014; Liu et al., 
2015; Luoni et al., 2014; Monsey et al., 2014; Nibuya et al., 1999; Nitta et al., 1997; Ray et al., 
2011; Smith et al., 1995; Yan et al., 2015; Zhang et al., 2015a; Zhu et al., 2016), administration 
of a subanesthetic dose of ketamine reverses this effect by inducing an increase of BDNF protein 
expression in the hippocampus and prefrontal cortex within 30 minutes (Autry et al., 2011; 
Garcia et al., 2008a; Zhang et al., 2015a; Zhang et al., 2015b). A single dose of ketamine can 
attenuate stress-induced reductions in hippocampal and prefrontal BDNF for at least 8 days 
(Zhang et al., 2015a), resembling the time course of its long-lasting antidepressant effects in 
rodent models of depression (Autry et al., 2011; Jett et al., 2015; Li et al., 2011; Maeng et al., 
2008). This upregulation of BDNF is likely the result of ketamine’s temporary facilitation of 
glutamatergic neurotransmission, since both synaptic AMPA and NMDA receptor activation 
induces BDNF (Hardingham et al., 2002; Jourdi et al., 2009). BDNF induction plays a necessary 
role in the antidepressant-like behavioral effects of ketamine, which are abolished when 
ketamine is administered to animals with BDNF gene mutation or knockout (Autry et al., 2011; 
Liu et al., 2012), or TrkB receptor knockout (Autry et al., 2011). Consistent with increased 
BDNF activity, subanesthetic ketamine also upregulates a number of synaptic proteins within an 
hour of administration, including synapsin I, PSD-95, and AMPA subunit Gria1, reversing 
stress-induced impairments in the expression of these proteins (Li et al., 2010; Li et al., 2011; 
Zhang et al., 2015a). The ultimate neurophysiological result of ketamine’s neurotrophin and 
synaptic protein upregulation is an enhancement of PFC dendritic spine density and maturity that 
occurs within 24 hours of infusion, reversing damage caused by chronic stress (Li et al., 2010; Li 
et al., 2011; Monsey et al., 2014). It is likely this facilitation of neuroplasticity that allows 
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ketamine to maintain an antidepressant response long after NMDA receptor antagonism has 
ceased and the drug has been cleared from the body. 
 
6.4. Ketamine in Animal Models of Depression 
 The rapid antidepressant-like effects of ketamine have been reliably reproduced in rodent 
models of depression and tests of depression-like behavior. Within an hour of acute 
subanesthetic ketamine injection, nonstressed rodents exhibit reduced immobility in the forced 
swim test (Autry et al., 2011; Carrier & Kabbaj, 2013; Gigliucci et al., 2013; Maeng et al., 2008; 
Nosyreva et al., 2013), reduced escape failures and latency to escape in a learned helplessness 
paradigm (Autry et al., 2011; Maeng et al., 2008), and increased sucrose solution consumption in 
the sucrose preference test of anhedonia (Carrier & Kabbaj, 2013). Furthermore, ketamine 
abolishes enhancements in depression-like behavior that result from chronic behavioral stress or 
exogenous CORT injection. Chronic stress impairs cognitive flexibility in the attentional set-
shifting task (Jett et al., 2015), promotes passivity in the shock-probe defensive burying task (Jett 
et al., 2015), increases immobility in the forced swim test (Autry et al., 2011; Gigliucci et al., 
2013; Jett et al., 2015; Koike et al., 2013; Perrine et al., 2014), and evokes anhedonic behavior in 
the sucrose preference test (Autry et al., 2011; Garcia et al., 2009; Li et al., 2011), all of which 
are normalized following a single infusion of ketamine. Similar to humans, antidepressant-like 
effects in rodents are maintained for at least a week after a single injection of ketamine (Autry et 
al., 2011; Jett et al., 2015; Li et al., 2011; Maeng et al., 2008). 
 The potential for ketamine to alleviate depression-associated negative cognitive biases 
has not yet received extensive investigation. Given the fundamental role that NMDA receptors 
play in the acquisition (Bauer et al., 2002; Campeau et al., 1992; Fanselow & Kim, 1994; Fendt, 
2001; Gewirtz & Davis, 1997; Lee & Kim, 1998; Lee et al., 2001; Maren et al., 1996b; 
Miserendino et al., 1990; Walker & Davis, 2000), consolidation (Shimizu et al., 2000), and recall 
(Fendt, 2001; Lee et al., 2001; Lee & Kim, 1998; Maren et al., 1996b) of conditioned fear, it 
seems likely that the NMDA receptor antagonist ketamine could influence memory processing of 
negative emotional information. Early rodent studies have demonstrated that a subanesthetic 
dose of ketamine, administered 30 minutes prior to training, neutralizes conditioned freezing to 
auditory cues during recall testing, and reduces neuronal activity in the LA as indicated by c-Fos 
expression (Pietersen et al., 2006; Pietersen et al., 2007). Ketamine also impairs the long-term 
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recall of contextual fear memory when administered 15 minutes before contextual fear 
conditioning training (Calzavara et al., 2009). Interestingly, chronic treatment with ketamine, 
terminated 48 hours before both training and recall testing, similarly reduces context-elicited 
freezing during fear recall assessment in mice, suggesting long-term effects on memory 
processing that are independent of transient NMDA receptor antagonism (Amann et al., 2009). 
Some research has also suggested that ketamine can even mediate the retrieval of fear memory 
after successful memory consolidation has taken place. Mice treated with subanesthetic ketamine 
injections for 14 days following contextual fear conditioning display reduced freezing to 
contextual cues compared to controls (Zhang et al., 2015b). In humans, a single subanesthetic 
infusion of ketamine has demonstrated efficacy in reducing symptoms of PTSD, a disorder 
characterized by pathological recurrent fear memory retrieval (Feder et al., 2014). 
 
7. Objectives and Hypotheses 
 Although animal research does support a modulatory role for ketamine in negative 
emotional memory, there is still some uncertainty regarding exactly which stages of memory 
processing ketamine influences. Ketamine’s long-lasting neurophysiological effects could 
theoretically alter fear memory acquisition, consolidation, recall, or any combination of the three 
from a single pre-conditioning injection, so further research is needed in order to elucidate the 
specific cognitive processes that are influenced by this drug. Furthermore, no study to my 
knowledge has yet explored the potential for ketamine to relieve pathological enhancements in 
fear memory caused by chronic stress. Since a number of standard antidepressants are either 
ineffective or counter-productive in challenging negative cognitive biases with acute treatment 
(Browning et al., 2007; Burghardt et al., 2004; Burghardt et al., 2013; Burhans et al., 2013; 
Cassaday & Thur, 2015; Godsil et al., 2015; Lebrón-Milad et al., 2013; Montezinho et al., 2010; 
Mørk et al., 2013; Ravinder et al., 2013; Takahashi et al., 2006), a drug which can rapidly 
suppress negative emotional memory in conjunction with other potent antidepressant effects 
could prove incredibly valuable in the treatment of depression. 
 One issue that has not yet been examined in any capacity is the effect that ketamine might 
have on the extinction, recovery, and reinstatement of conditioned fear. This is an important 
topic to address, since acute and chronic treatment with some antidepressants actually impairs 
the acquisition and recall of fear extinction memory (Burghardt et al., 2013), a result that could 
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be counter-productive to the goal of challenging negative cognitive biases in depression. 
However, ketamine produces a number of neurobiological changes and functional alterations in 
the brain that could theoretically facilitate fear extinction, at least in chronically stressed animals. 
Chronic stress exposure impairs neuroplasticity and LTP in the hippocampus and PFC 
(Cerqueira et al., 2007; Cook & Wellman, 2004; Delgado et al., 2011; Dias-Ferreira et al., 2009; 
Foy et al., 1987; Garcia et al., 1997; Izquierdo et al., 2006; Kim et al., 1996; Li et al., 2011; 
Liston et al., 2006; Liu & Aghajanian, 2008; Magariños et al., 1996; Magariños et al., 1998; 
Magariños et al., 1999; Magariños & McEwen, 1995a; Magariños & McEwen, 1995b; Morales-
Medina et al., 2009; Palvides et al., 2002; Radley et al., 2004; Shansky & Morrison, 2009; Shors 
et al., 1989; Sousa et al., 2000; Tata et al., 2006; Watanabe et al., 1992a; Watanabe et al., 1992b; 
Wellman, 2001; Woolley et al., 1990; Xu et al., 1997), compromising the ability for these 
structures to inhibit the amygdala and resulting fear output during extinction training and recall 
(Baran et al., 2009; Dagnino-Subiabre et al., 2012; Farrell et al., 2010; Gourley et al., 2009; 
Hoffman et al., 2014; Izquierdo; Miracle et al., 2006; Wilber et al., 2011; Zhang & Rozencranz, 
2013). Conversely, ketamine enhances neuronal activity and mechanisms of neuroplasticity in 
the PFC and hippocampus of stressed animals (Chowdhury et al., 2012; Li et al, 2011; 
Moghaddam et al., 1997; Stone et al., 2012; Zhang et al., 2015a; Zhang et al., 2015b), which 
could allow these structures to regain inhibitory control over the amygdala, and thus successfully 
suppress fear-motivated behavior. However, NMDA receptor function is required for the 
acquisition and consolidation of extinction memory (Falls et al., 1992; Laurent et al., 2008; 
Laurent & Westbrook, 2008; Liu et al., 2009; Santini et al., 2001; Sotres-Bayon et al., 2007; 
Sotres-Bayon et al., 2009; Suzuki et al., 2004), so it is also possible that the NMDA receptor 
antagonist ketamine could impair these processes if enough of the drug is still present in the 
brain at this time. Resolving this uncertainty is a necessary step in evaluating the efficacy of 
subanesthetic ketamine infusions in challenging stress-induced negative cognitive biases. 
 The aim of this dissertation is to address these notable gaps in the literature by further 
characterizing the effects of ketamine on negative emotional memory in both healthy animals 
and those with chronic CORT exposure. The first experiment sought to dissociate the effects of 
ketamine on the acquisition, consolidation, and recall of auditory fear conditioning in rats. 
Furthermore, it was also designed to resolve prior uncertainty regarding the influence of 
ketamine on the induction and recall of fear extinction. To accomplish this, rats were fear 
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conditioned and extinguished, and a subanesthetic dose of ketamine was administered at one of 
three different time points: before fear conditioning training, immediately after fear conditioning 
training, or before fear extinction training. Fear-motivated behavior in the form of defensive 
freezing was recorded to measure the effects of ketamine on behavior throughout the 
conditioning and extinction trails. I hypothesized that ketamine would impair the long-term 
expression of freezing when administered at any of the three time points, but would not 
adversely affect extinction behavior. 
 The second experiment aimed to expand upon the findings of the first by examining the 
efficacy of ketamine in preventing chronic CORT-induced alterations in auditory fear 
conditioning and extinction behavior. Of particular interest was the effect of CORT and ketamine 
on the long-term retention of extinction behavior following a sub-conditioning reinstatement 
challenge. Rats were fear conditioned, extinction trained, and then submitted to a sub-
conditioning retraining procedure that is designed to reinstate conditioned fear in previously 
trained, but not conditioning-naive rats. I hypothesized that chronic CORT treatment would 
impair the long-term retention of fear extinction between extinction training sessions and 
following sub-conditioning retraining. Furthermore, I hypothesized that a pre-extinction 
subanesthetic dose ketamine would reduce freezing during extinction training in both CORT-
treated and healthy rats, and prevent CORT-induced deficits in extinction retention. 
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Abstract 
Negative cognitive biases in memory skew an individual’s recollection of past experiences 
towards negative emotional content, and contribute significantly to the burden of psychiatric 
disorders such as PTSD and major depressive disorder. Pharmacotherapeutic agents which can 
inhibit the recall of unpleasant memories are thus of significant value to the treatment of these 
disorders. By using fear conditioning tasks to assess the recall of negatively-valenced memory in 
rodents, past research has revealed that a single subanesthetic dose of the NMDA receptor 
antagonist ketamine can markedly suppress the long-term expression of context- and cue-elicited 
freezing behavior. However, these studies were unable to discern whether pre-conditioning 
ketamine treatment primarily interferes with the acquisition, consolidation, or recall of 
conditioned fear memory, and ketamine’s influence on fear extinction has remained unexamined. 
The aim of the present study was to dissociate the effects of ketamine on distinct stages of 
auditory fear conditioning and extinction in order to gain a better understanding of the 
underlying cognitive processes that the NMDA receptor antagonist might modulate. Rats 
underwent auditory fear conditioning, and after a 9 day rest period were extinction trained and 
tested for fear recall. A subanesthetic 10 mg/kg dose of ketamine was systemically administered 
to rats at one of three different time points: before fear conditioning training, immediately after 
fear conditioning training, or before fear extinction training. Fear conditioning was unimpaired in 
rats that received pre-conditioning ketamine, but post-conditioning and pre-extinction ketamine 
treatment attenuated freezing during fear recall assessment. None of the ketamine treatment 
protocols examined had any effect on the final acquisition or long-term recall of fear extinction 
behavior. The findings of the present study suggest that ketamine likely exerts its influence on 
fear-motivated behavior by interfering with the consolidation and recall of auditory fear memory.
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1. Introduction 
 Memory for negative emotional information is strongly modulated by the presence of 
stress hormones (Rodrigues et al., 2009), and is thus highly susceptible to pathological 
modification in stress-related psychiatric disorders. While it is well-known that PTSD is 
characterized by the recurrent involuntary recollection of traumatic events, individuals with 
depression also experience maladaptive alterations in memory that skew the recollection of past 
events towards negative emotional information (Balut et al., 2013; Gerritsen et al., 2012; Gupta 
& Kar, 2012; Harmer et al., 2009a; Hsu et al., 2010; Liu et al., 2012; Mogg et al., 2014; Taylor 
& John, 2004). These negative cognitive biases are believed to support the development and 
maintenance of depression (Elliott et al., 2011; Harmer et al., 2009a; Nolen-Hoeksema, 2000; 
Robinson & Sahakian, 2008), emphasizing the need for antidepressant treatments to effectively 
combat these insidious symptoms (Clark, Chamberlain, & Sahakian, 2009; Elliott et al., 2011; 
Roiser et al., 2012). 
 To experimentally investigate memory for negatively valenced stimuli in animals, 
researchers often use classical fear conditioning, a behavioral paradigm that promotes a learned 
association between an emotionally neutral conditioned stimulus (e.g., tone cue) and an innately 
aversive and negatively valenced unconditioned stimulus (e.g., footshock). Following successful 
fear conditioning, presentation of the conditioned stimulus alone will elicit fear-motivated 
responses such as defensive freezing behavior. Fear learning is rapidly acquired and generally 
very robust, but under proper circumstances can later be challenged through a form of novel 
learning known as extinction. Extinction learning occurs when a conditioned stimulus is 
repeatedly presented in the absence of unconditioned stimulus reinforcement, and consists of the 
formation of a new memory that competes with the original fear memory to suppress fear-
motivated behavior (Pape & Paré, 2010; Quirk & Mueller, 2008; VanElzakker et al., 2013). 
Together, fear conditioning and extinction paradigms have proved to be valuable assets in the 
study of pharmacotherapeutic agents used to treat psychiatric disorders and their effects on 
negatively-valenced memory. 
 SSRIs are often prescribed to treat depression and PTSD, but several common SSRIs 
have surprisingly been shown to enhance fear memory (Burghardt et al., 2004; Burhans et al., 
2013; Cassaday & Thur, 2015; Montezinho et al., 2010; Ravinder et al., 2013) and impair 
extinction (Burghardt et al., 2013) in animal models of conditioned fear. This apparent 
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facilitation of negatively-biased memory might be counter-productive in the treatment of 
depression and PTSD, so the identification of drugs that instead inhibit fear memory could prove 
to be of great value to patients affected by these disorders. One promising drug is ketamine, a 
noncompetitive antagonist of the NMDA receptor that blocks receptor activation by binding to 
the phencyclidine site of the complex’s cation channel (Sanacora et al., 2008). Subanesthetic 
infusions of ketamine produce rapid and robust antidepressant effects in patients with treatment-
resistant depression (Aan Het Rot et al., 2012; Berman et al., 2000; Cusin et al., 2012; 
Diazgranados et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013; Phelps et al., 2009; Price 
et al., 2009; Rasmussen et al., 2013; Zarate et al., 2006), and also reduce symptom severity in 
patients with PTSD (Feder et al., 2014). Ketamine is well-equipped to mediate memory for 
negatively valenced stimuli, since the NMDA receptors it inactivates (specifically, those in the 
lateral amygdala) play an important role in the acquisition (Bauer et al., 2002; Campeau et al., 
1992; Fanselow & Kim, 1994; Fendt, 2001; Gewirtz & Davis, 1997; Lee et al., 2001; Lee & 
Kim, 1998; Maren et al., 1996b; Miserendino et al., 1990; Walker & Davis, 2000), consolidation 
(Shimizu et al., 2000), and recall (Fendt, 2001; Lee et al., 2001; Lee & Kim, 1998; Maren et al., 
1996b) of conditioned fear. Accordingly, infusion of a subanesthetic dose of ketamine prior to 
fear training impairs both auditory (Pietersen et al., 2006) and contextual (Calzavara et al., 2009) 
fear conditioning in rats.  
 While the results of these early studies support the hypothesis that ketamine can impair 
fear conditioning, they cannot identify the precise stages of memory that ketamine might 
influence. The effects of ketamine on the neurobiology of the brain extend far beyond transient 
NMDA receptor antagonism, and involve a complex downstream signaling cascade that 
upregulates the presence of BDNF in brain regions intimately involved in the processing of fear 
memory (Autry et al., 2011; Duman et al., 2012; Zhang et al., 2015a; Zhang et al., 2015b). The 
BDNF protein is an important regulator of neuroplasticity and synaptic transmission (Black, 
1999; Jourdi et al., 2009), so this long-lasting impact on neuronal functioning means that a single 
infusion of ketamine might influence any combination of the acquisition, consolidation, and 
recall processes of fear memory. Although one study has suggested that repeated administration 
of ketamine can impair contextual fear recall in mice after undisturbed training (Zhang et al., 
2015b), further research is needed to more fully characterize the effects that acute treatment with 
ketamine has on every stage of auditory fear learning. 
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 To our knowledge, the short- and long-term effects of ketamine on fear extinction has not 
yet been examined in any capacity. Similar to fear conditioning, the acquisition (Falls et al., 
1992; Laurent et al., 2008; Laurent & Westbrook, 2008; Sotres-Bayon et al., 2007) and 
consolidation (Laurent & Westbrook, 2008; Liu et al., 2009; Santini et al., 2001; Sotres-Bayon et 
al., 2009; Suzuki et al., 2004) of extinction memory relies heavily upon NMDA receptor 
activation, so it is possible that ketamine might impair these cognitive processes at a high enough 
dose and with sufficient temporal proximity to extinction training. However, since the 
endogenous promotion of prefrontal and hippocampal BDNF production plays a critical role in 
the long-term retention of fear extinction (Bredy et al., 2007; Heldt et al., 2007; Rosas-Vidal et 
al., 2014), a ketamine-induced upregulation of BDNF could potentially facilitate fear suppression 
instead. Resolving this uncertainty is an important step in characterizing the effects of ketamine 
on negative emotional memory, since either a facilitation or impairment of extinction memory 
could have significant clinical implications on the treatment of depression and PTSD with 
ketamine.  
 The aim of the present study was to dissociate the effects of ketamine on distinct stages 
of auditory fear conditioning and extinction in order to gain a better understanding of the 
underlying cognitive processes that the NMDA receptor antagonist might modulate. A 
subanesthetic dose of ketamine was administered to rats at one of three time points: before fear 
conditioning training, immediately after fear conditioning training, or before fear extinction 
training. Defensive freezing behavior was analyzed throughout the conditioning and extinction 
trials, and then compared to a non-drug-treated control group. We hypothesized that ketamine 
would impair the long-term expression of freezing when administered at any of the three time 
points, but would not adversely affect extinction behavior. 
 
2. Materials and Methods 
2.1. Animals 
 Thirty-three adult male Long-Evans rats (Charles River Laboratories; Montreal, Quebec, 
Canada), weighing 200-250 g upon arrival, were used in the study. Rats were housed 
individually in clear plastic cages with free access to food and water. The thermally-controlled 
colony room maintained a 12 hr/12 hr light/dark cycle. All procedures were approved by the 
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University of Saskatchewan Animal Research Ethics Board, and conducted in accordance with 
the Canadian Council on Animal Care. 
 
2.2. Experimental Design and Drug Injection Paradigm 
 Prior to any fear conditioning procedures, rats were assigned to one of four weight-
matched experimental conditions: untreated control (n = 9), pre-conditioning ketamine injection 
(n = 8), post-conditioning ketamine injection (n = 8), and pre-extinction ketamine injection (n = 
8).  
 Ketamine hydrochloride (Vetalar; Bioniche Animal Health Canada Inc.; Belleville, 
Ontario, Canada) was suspended in saline and injected intraperitoneally at a dose of 10 mg/kg, 
and a volume of 1 ml/kg. This dose was selected as it has been shown to be efficacious in 
impairing fear conditioning when administered before training (Amann et al., 2009; Calzavara et 
al., 2009; Li et al., 2011). In the case of pre-conditioning and pre-extinction ketamine groups, 
rats received injections 60 minutes prior to fear conditioning training and extinction training, 
respectively. This delay between drug injection and behavioral testing was implemented to avoid 
the potentially confounding transient effects of ketamine on spontaneous locomotor activity. 
Since general locomotor activity in rats is normalized within 30 minutes of a 10 mg/kg dose of 
ketamine (Koike et al., 2011; Koike et al., 2013), any ketamine-associated changes in freezing 
beyond this time point cannot be attributed to alterations in baseline movement. Rats in the post-
conditioning ketamine group received injections immediately following the conclusion of fear 
conditioning training. Administration of all injections took place in a procedure room separate 
from the animal colony and fear conditioning apparatus. 
 
2.3. Fear Conditioning 
 Fear conditioning and extinction followed a modified version of a protocol previously 
used by Burghardt et al. (2013). 
 
2.3.1. Apparatus 
 All behavioral testing procedures took place in standard operant chambers (VFC-008; 
Med Associates Inc., St. Albans, Vermont, United States) contained within sound-attenuating 
cubicles. Each operant chamber was constructed of aluminum walls and a clear plastic door 
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through which a video camera could record the rat’s behavior in both visible and near-infrared 
light. An overhead white or near-infrared lamp illuminated the chamber through a clear plastic 
roof. A high-frequency speaker (ENV-224BM) mounted high within the chamber wall delivered 
auditory cues. The floor of the chamber consisted of a grid of stainless steel rods that delivered 
aversive footshocks through a shock generator (ENV-414S). Video Freeze Software (Med 
Associates Inc.) controlled the delivery of tone and shock stimuli, and recorded video from the 
camera at 30 frames per second.  
 
2.3.2. Conditioning 
 Handling of all rats took place for 7 consecutive days before any behavioral procedures 
began to habituate the animals to the researcher. Following the conclusion of handling, rats were 
then habituated to the conditioning context of the operant chamber for 8 minutes (day 1). On day 
2, each rat was placed inside the operant chamber again and given 180 s to habituate before fear 
conditioning began. Conditioning consisted of 2 tone cues (2 kHz, 20 s, 90 dB) that co-
terminated with an aversive footshock (0.7 mA, 500 ms). Each tone-shock pairing was followed 
by a 120 s inter-trial interval. Upon completion of fear conditioning, rats were transported back 
to the colony room, and the operant chamber was cleaned with 0.4% glacial acetic acid before 
training for the next subject began. 
 
2.3.3. Novel context extinction 
 Since the rats would form fearful associations with the contextual cues of the training 
environment in addition to the discrete tone cues, the context during extinction was altered in a 
number of ways so that only auditory-cued conditioned fear would be measured and 
extinguished during this phase. During transit to and from the conditioning room, the rats’ cages 
were covered with dark curtain, and an alternative route was followed. The fluorescent lighting 
of the conditioning room was replaced with a red overhead lamp. Vanilla-scented deodorizer 
provided novel olfactory cues in the extinction context. Most importantly, the operant chambers 
were modified in shape and appearance with a colorful curved wall insert, and the metal grid 
floor was replaced with a smooth white plastic cover. A striped ceiling cover panel altered the 
lighting pattern within the chamber, and only near-infrared lighting was used. Contextual 
auditory cues were obscured with white noise played through the chamber’s speaker (65 dB). 
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After each extinction session, the chamber was cleaned with 75% ethanol so that any residual 
scent of the cleaner would be unfamiliar. 
 Rats rested for 9 consecutive days before extinction training began (day 12). Rats were 
placed into the novel extinction context and given 180 s to habituate. Extinction consisted of 10 
tone cues (2 kHz, 20 s, 90 dB) presented in the absence of footshock. Each tone was followed by 
a 120 s inter-trial interval. Upon completion of extinction training, rats were transported back to 
the colony room. On day 13, long-term retention of extinction memory was evaluated by 
presenting an additional 10 tone cues, using the same extinction protocol as described above. 
Once extinction retention testing concluded, animals were transported back to the colony room 
and sacrificed the following day. 
 
2.3.4. Behavioral measurement 
 Fear conditioning was measured by freezing, defined as the absence of any movement not 
required for respiration. Using Video Freeze Software (Med Associates Inc.; St. Albans, 
Vermont, United States), movement was calculated as a change in pixel composition between 
adjacent video frames. To account for individual variation in baseline breathing movement, a 
motion threshold was set for each rat that defined the absolute limit beyond which movement 
would be registered as non-respiratory in nature. Immobility was required to last for at least 1 s 
before a freezing episode would be recorded in the data output. The percentage of time spent 
freezing during discrete time points (e.g. habituation, tones) was then calculated by Video Freeze 
Software and used as the dependent variable in analysis. 
 
2.4. Statistical Analysis 
 Freezing behavior during pre-conditioning and pre-extinction habituation was analyzed 
using one-way ANOVAs to reveal any potential differences in baseline freezing between groups. 
A one-way ANOVA was also used to identify possible group differences in freezing behavior 
during fear conditioning training, as enhanced or impaired fear acquisition could affect the 
interpretation of subsequent measures. The treatment effects of ketamine on cue-elicited freezing 
during extinction training and extinction recall were analyzed using independent samples t-tests, 
which compared the average level of freezing for each treatment group (i.e. pre-conditioning 
ketamine, post-conditioning ketamine, and pre-extinction ketamine) to that of the control group 
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(i.e. no injection) in separate analyses. Animals that exhibited levels of freezing exceeding 1.5 
standard deviations of the mean during extinction training or recall were considered outliers and 
excluded from statistical analysis.  
 
3. Results 
3.1. Fear Conditioning Training Day 
 Ketamine treatment did not affect freezing during the 180 s habituation period prior to 
training [F(3, 21) = 1.656, p = 0.207] (Fig. 2-1A). Average freezing during tone cue presentation 
was also not significantly affected by ketamine in the fear conditioning training phase [F(3, 21) = 
0.681, p = 0.573] (Fig. 2-1B).  
 
3.2. Fear Extinction Training Day 
 No significant group differences in freezing were found during the 180 s habituation 
period prior to extinction training, indicating that ketamine treatment did not affect behavior in a 
novel context [F(3, 21) = 2.593, p = 0.080] (Fig. 2-2A; Fig. 2-3A; Fig. 2-4A). 
 The long-term expression of conditioned fear was investigated by analyzing the average 
level of freezing across the first five tone cues of extinction training (early phase extinction 
training; T1-T5). Rats in the pre-conditioning ketamine group exhibited average levels of cue-
elicited freezing similar to that of rats in the control group [t(10) = 0.890, p = 0.413] (Fig. 2-2B). 
However, rats in the post-conditioning ketamine [t(11) = 2.550, p = 0.027] (Fig. 2-3B) and pre-
extinction ketamine [t(12) = 2.926, p = 0.013] (Fig. 2-4B) groups froze significantly less across 
the first five tones of extinction training than rats in the control group. Average freezing across 
the last five tone cues of extinction training (late phase extinction training; T6-T10) was 
analyzed to assess the relative level of extinction behavior acquisition during the latter half of the 
session. Each ketamine treatment group froze comparably to the control group in response to 
these final tones [pre-conditioning ketamine: t(10) = -0.856, p = 0.412; post-conditioning 
ketamine: t(11) = -0.690, p = 0.505; pre-extinction ketamine: t(12) = -0.417, p = 0.684] (Fig. 2-
2C; Fig. 2-3C; Fig. 2-4C). 
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Figure 2-1. (A) Percentage of time spent freezing during fear conditioning training. None of the 
treatments examined significantly affected freezing during habituation. (B) None of the 
treatments examined significantly affected the acquisition of fear conditioning.  
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3.3. Fear Extinction Recall Day 
 No significant group differences in freezing were found during the 180 s habituation 
period prior to extinction recall testing [F(3, 21) = 1.171, p = 0.344] (Fig. 2-2D; Fig. 2-3D; Fig. 
2-4D). 
 Average freezing across first five tones of extinction recall testing (early phase extinction 
recall; T1-T5) was analyzed to determine if ketamine treatment affected the long-term expression 
of extinction behavior. No significant differences in freezing were found between the ketamine 
treatment groups and the control group [pre-conditioning ketamine: t(10) = 0.177, p = 0.863; 
post-conditioning ketamine: t(11) = 1.676, p = 0.122; pre-extinction ketamine: t(12) = 0.300, p = 
0.770] (Fig. 2-2E; Fig. 2-3E; Fig. 2-4E). Across the last five tones of extinction recall testing 
(late phase extinction recall; T6-T10), rats in each ketamine treatment group exhibited similar 
levels of freezing to those of the control group [pre-conditioning ketamine: t(10) = 0.770, p = 
0.459; post-conditioning ketamine: t(11) = 0.378, p = 0.712; pre-extinction ketamine: t(12) = 
0.252, p = 0.805] (Fig. 2-2F; Fig. 2-3F; Fig. 2-4F). 
 
4. Discussion 
 The aim of this study was to characterize the effects of subanesthetic ketamine on fear 
conditioning and extinction when administered during various stages of behavioral testing. We 
observed that administration of a 10 mg/kg dose of ketamine an hour before fear conditioning 
training was insufficient to disrupt the expression of conditioned freezing behavior 10 days later. 
However, when administered either immediately following fear conditioning training or one hour 
prior to extinction training, ketamine impaired the long-term expression of cue-elicited freezing 
compared to untreated controls. None of the ketamine treatments examined affected the long-
term retention of extinction behavior. Our results suggest that the time point at which ketamine is 
administered relative to fear conditioning and recall testing has a significant effect on the 
expression of fear-motivated behavior. These findings are discussed in further detail below. 
 
4.1. The Effect of Pre-Conditioning Ketamine on Auditory Fear Conditioning and Extinction 
 In the present study, treatment with 10 mg/kg ketamine one hour before fear conditioning 
training did not impair the acquisition of cue-elicited freezing during associative learning.  
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Figure 2-2. (A) Percentage of time spent freezing during extinction training in control vs. pre-
conditioning ketamine conditions. Pre-conditioning ketamine did not significantly affect freezing 
during habituation. (B) Pre-conditioning ketamine did not significantly impact freezing across 
the first five tones of extinction training. (C) Pre-conditioning ketamine did not significantly 
impact freezing across the last five tones of extinction training. (D) Percentage of time spent 
freezing during extinction recall testing. Pre-conditioning ketamine did not significantly affect 
freezing during habituation. (E) Pre-conditioning ketamine did not significantly impact freezing 
across the first five tones of extinction recall testing. (F) Pre-conditioning ketamine did not 
significantly impact freezing across the last five tones of extinction recall testing.
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Figure 2-3. (A) Percentage of time spent freezing during extinction training in control vs. post-
conditioning ketamine conditions. Post-conditioning ketamine did not significantly affect 
freezing during habituation. (B) Post-conditioning ketamine significantly reduced freezing across 
the first five tones of extinction training. (C) Post-conditioning ketamine did not significantly 
impact freezing across the last five tones of extinction training. (D) Percentage of time spent 
freezing during extinction recall testing. Post-conditioning ketamine did not significantly affect 
freezing during habituation. (E) Post-conditioning ketamine did not significantly impact freezing 
across the first five tones of extinction recall testing. (F) Post-conditioning ketamine did not 
significantly impact freezing across the last five tones of extinction recall testing. 
* (p < 0.05)
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Figure 2-4. (A) Percentage of time spent freezing during extinction training in control vs. pre-
extinction conditions. Pre-extinction ketamine did not significantly affect freezing during 
habituation. (B) Pre-extinction ketamine significantly reduced freezing across the first five tones 
of extinction training. (C) Pre-extinction ketamine did not significantly impact freezing across 
the last five tones of extinction training. (D) Percentage of time spent freezing during extinction 
recall testing. Pre-extinction ketamine did not significantly affect freezing during habituation. (E) 
Pre-extinction ketamine did not significantly impact freezing across the first five tones of 
extinction recall testing. (F) Pre-extinction ketamine did not significantly impact freezing across 
the last five tones of extinction recall testing. 
* (p < 0.05)  
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Although NMDA receptor activation plays an essential role in the acquisition of conditioned 
fear, the significant delay between ketamine administration and behavioral training in our study 
is likely responsible for the lack of learning impairment that is typically observed when NMDA 
receptor antagonists are administered only 5-10 minutes before conditioning (Bauer et al., 2002; 
Campeau et al., 1992; Fanselow & Kim, 1994; Fendt, 2001; Gewirtz & Davis, 1997; Lee et al., 
2001; Lee & Kim, 1998; Maren et al., 1996b; Miserendino et al., 1990; Walker & Davis, 2000). 
Ketamine has a short half-life of approximately 1.3 hours in rats (Veilleux-Lemieux, Castel, 
Carrier, Beaudry, & Vachon, 2013), so ketamine binding to NMDA receptors would be 
significantly reduced by the time animals began training in our conditioning paradigm. 
Furthermore, ketamine likely preferentially inactivates extrasynaptic NMDA receptors, which 
promote synaptic long-term depression, instead of inactivating synaptic NMDA receptors, which 
promote the LTP that underlies associative learning (Papouin & Oliet, 2014; Pittenger & Duman, 
2008). To our knowledge, no other study has examined the effect of ketamine on auditory fear 
conditioning acquisition with the same dose and administration schedule used in the present 
investigation; however, one other lab has reported that chronic daily administration of 2.5 mg/kg 
ketamine did not affect the acquisition of contextual fear conditioning when administered 48 
hours prior to training (Amann et al., 2009). 
 Although previous research has demonstrated that pre-conditioning subanesthetic 
ketamine injection suppresses the long-term expression of contextual (Calzavara et al., 2009) and 
auditory fear conditioning (Pietersen et al., 2006), we found no such treatment effect in the 
present study. While these findings may at first appear contradictory, previous studies have 
separated ketamine administration and recall testing by only 24 hours, whereas animals in the 
current investigation underwent recall assessment 10 days following ketamine treatment. This 
considerable delay between drug treatment and behavioral assessment opens the possibility for 
the long-term cognitive and behavioral effects of ketamine to wear off during this time period. 
Ketamine has been shown to induce antidepressant-like behavior in the forced swim test and 
sucrose preference test for at least 7 days (Autry et al., 2011; Li et al., 2011), but the ability for 
ketamine to affect rodent behavior beyond a week in any measure, let alone fear conditioning, 
has never before been explored. Thus, while subanesthetic ketamine has demonstrated efficacy in 
impairing the long-term expression of conditioned fear behavior for at least 24 hours (Calzavara 
et al., 2009; Pietersen et al., 2006), the results of the present study indicate that this effect lasts 
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fewer than 10 days. Furthermore, our findings suggest that the pre-conditioning ketamine-
induced impairment of conditioned freezing that has been observed in past studies is not the 
result of impaired fear induction, but rather impaired fear recall. If pre-conditioning ketamine 
were to disrupt either the acquisition or consolidation of conditioned fear, then its resulting 
reduction of long-term fear expression should be permanent and not dependent upon the amount 
of time separating training and recall testing. 
 The present study is the first to our knowledge to investigate the effects of ketamine on 
the acquisition and retention of auditory fear extinction. We observed that pre-conditioning 
ketamine treatment did not affect the expression of freezing at the end of extinction training, 
suggesting that both pre-conditioning ketamine and control animals achieved a similar degree of 
extinction acquisition. The next-day expression of extinction was also unaffected by ketamine, as 
all animals displayed high levels of freezing at the beginning of extinction recall testing, 
regardless of treatment. This lack of treatment effect is unsurprising given the previously 
discussed absence of ketamine interference with conditioning recall, and is again likely the result 
of the long delay between ketamine administration and extinction training/testing. 
 
4.2. The Effect of Post-Conditioning Ketamine on Auditory Fear Conditioning and Extinction 
 As anticipated, animals in the post-conditioning ketamine group exhibited similar levels 
of freezing acquisition during fear conditioning training to that of untreated controls, since no 
drug treatment had taken place yet at that time. However, immediate post-conditioning 
administration of 10 mg/kg ketamine was found to attenuate the long-term expression of auditory 
fear 10 days later, as evidenced by a 16% reduction in cue-elicited freezing across the first half 
of extinction training compared to control.  
 This ketamine-induced reduction in conditioned responding cannot be ascribed to a 
generalized increase in locomotor activity, as both post-conditioning ketamine and control 
animals displayed equivalent levels of freezing during the 180 s habituation period prior to 
extinction training. Furthermore, since pre-conditioning ketamine administration (which took 
place less than 70 minutes earlier than post-conditioning administration) did not affect 
conditioned responding after a 10 day delay, it is highly unlikely that reduced freezing behavior 
observed in the pre-conditioning ketamine group is the result of impaired memory recall. If 
ketamine were capable of impairing the cognitive process of fear recall after 10 days, it would be 
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expected that both pre-conditioning and post-conditioning ketamine groups would exhibit 
reductions in freezing behavior. Rather, the most parsimonious explanation for these findings is 
that post-conditioning ketamine treatment impaired the consolidation of conditioned fear 
memory, leading to a weakened expression of cue-elicited freezing during recall assessment. It is 
plausible that ketamine could impair fear memory consolidation, as previous research has 
demonstrated that temporary post-conditioning genetic suppression of hippocampal NMDA 
receptor function causes deficits in subsequent fear retrieval testing (Shimizu et al., 2000). 
Although post-conditioning administration of the NMDA receptor antagonist APV has failed to 
interfere with fear memory consolidation in the past, APV must bind competitively with 
endogenous glutamate to inhibit receptor activity, and thus might induce different behavioral 
effects than the non-competitive NMDA receptor antagonist ketamine (Kim et al., 1991; Maren 
et al., 1996b). 
 Immediate post-conditioning ketamine treatment did not affect the final acquisition of 
extinction training, and also had no influence on the next-day expression of extinction. Once 
again, we believe that the long delay between ketamine administration and extinction 
training/testing likely precluded the ability for drug treatment to influence new learning and 
memory recall 10 days later. 
 
4.3. The Effect of Pre-Extinction Ketamine on Auditory Fear Extinction 
 Animals in both the pre-extinction ketamine group and control group exhibited similar 
levels of freezing acquisition during fear conditioning training, which was expected since no 
drug treatment had taken place yet at that time. Ten days later, we observed that treatment with 
10 mg/kg ketamine one hour before extinction training attenuated the long-term expression of 
auditory fear, as evidenced by a 21% reduction in cue-elicited freezing across the first half of 
extinction training compared to control. A similar attenuation of conditioned responding has 
previously been found when chronic low-dose ketamine treatment precedes the assessment of 
contextual fear memory recall (Amann et al., 2009; Zhang et al., 2015b). 
 Once again, our observed ketamine-induced reduction in conditioned responding cannot 
be ascribed to a generalized increase in locomotor activity, as both pre-extinction ketamine and 
control animals displayed equivalent levels of freezing during the 180 s habituation period prior 
to extinction training. Furthermore, previous research has established that spontaneous locomotor 
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activity in the open field test is normalized within 40 minutes following a 16 mg/kg injection of 
ketamine in rats (Imre et al., 2006), and as little as 30 minutes following a 10 mg/kg injection 
(Koike et al., 2011; Koike et al., 2013). Since we maintained an hour delay between drug 
administration and extinction training, ketamine-treated animals in the present study had ample 
time for locomotor normalization, and exhibited behavior that was indistinguishable from control 
animals before extinction training began. It is also unlikely that ketamine induced perceptual 
distortions that impaired the perception of conditioned stimuli, as previous research has shown 
that 10 mg/kg ketamine does not affect auditory evoked potentials in rats (de Bruin, Ellenbroek, 
Cools, Coenen, & van Luijelaar, 1999). 
 One potential explanation for the attenuation of cue-elicited freezing is that ketamine 
impaired the cognitive process of memory recall by inactivating NMDA receptors in the 
amygdala. The lateral amygdala in particular plays a crucial role in integrating fear-relevant 
stimuli, and mediates the induction and expression of conditioned fear (Pape & Paré, 2010). 
Infusion of the NMDA receptor antagonist APV into the lateral amygdala prior to fear recall 
testing has been shown to attenuate conditioned responding, so it is possible that a systemic 
injection of ketamine in a high enough dose and close enough temporal proximity to behavioral 
testing could elicit a similar effect. However, we believe that transient NMDA receptor 
inactivation itself likely plays a minor and non-essential role in the present study’s observed 
effects of pre-extinction ketamine on the expression of conditioned fear. Past studies that 
impaired conditioned fear recall through NMDA receptor antagonism administered APV only 5 
minutes prior to behavioral testing, ensuring that APV binding to NMDA receptors would be 
high at the time of conditioned stimulus presentation. Conversely, animals in the present study 
received ketamine at least one hour before extinction training, which considering ketamine’s 
short 1.3 hour half-life (Veilleux-Lemieux et al., 2013), likely reduced binding to NMDA 
receptors significantly at the time of behavioral assessment. Furthermore, previous research has 
demonstrated that ketamine can induce a similar attenuation of conditioned fear recall long after 
NMDA receptor antagonism has ceased. Chronic administration of 5 mg/kg ketamine, 
terminated 48 hours before recall testing, was shown to significantly reduce freezing in a 
contextual fear conditioning paradigm (Amann et al., 2009). Thus, while transient NMDA 
receptor antagonism at the time of fear recall may play a role in ketamine’s suppression of 
conditioned freezing, it is likely an insufficient explanation for our observed results. 
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 Instead, we propose that ketamine likely facilitates the suppression of conditioned fear by 
stimulating enhancements in neurotransmission and synaptic plasticity that mirror those 
underlying the natural process of fear extinction. As previously mentioned, the amygdala is 
responsible for forming a predictive association between conditioned and unconditioned fear 
stimuli, and acts as a gateway for the expression of conditioned responding (e.g. freezing; Pape 
& Paré, 2010). However, amygdalar output of conditioned fear can be suppressed through 
descending projections from the mPFC, which stimulate inhibitory GABAergic ITC neurons in 
the amygdala (Pape & Paré, 2010; Quirk & Mueller, 2008; VanElzakker et al., 2013). The 
hippocampus also mediates activity within fear memory circuitry (Maren & Hobin, 2009; Sotres-
Bayon et al., 2012), and communicates with the mPFC to facilitate extinction memory recall and 
suppress conditioned fear in a contextually appropriate manner (Farinelli et al., 2006; Garcia et 
al., 2008b; Hugues et al., 2006; Hugues & Garcia, 2007; Peters et al., 2010; Quirk & Mueller, 
2008). Together, the mPFC and hippocampus can be viewed as the fundamental structures 
underlying the induction and expression of fear extinction, so pharmacological manipulation of 
activity within these structures has the potential to induce significant alterations in cognition and 
behavior (Burgos-Robles et al., 2007; Corcoran et al., 2005; Fernandez, 2003; Lebrón et al., 
2004; Morgan et al., 1993; Morgan et al., 2003; Quirk et al., 2000; Sotres-Bayon et al., 2009). 
 Past research has illustrated a clear relationship between prefrontal and hippocampal 
neuronal activity and the successful suppression of conditioned fear. During the consolidation 
and recall of extinction memory, activity within the IL mPFC is positively correlated with the 
degree to which extinction behavior is successfully expressed (Burgos-Robles et al., 2007; Milad 
& Quirk, 2002; Wilber et al., 20011). Extinction recall is also associated with increased 
expression of c-Fos, a protein biomarker of recent neuronal activity, within the IL, hippocampus 
(CA1, CA3, dentate gyrus), and ITC neurons of the amygdala (Knapska & Maren, 2009). 
Interestingly, experimentally applied electrical stimulation of IL neurons can successfully inhibit 
fear expression and induce extinction-like behavior in the absence of extinction training (Milad 
et al., 2004; Milad & Quirk, 2002; Vidal-Gonzalez et al., 2006). Ketamine possesses the 
potential to similarly modulate conditioned fear suppression because it stimulates presynaptic 
excitatory neurotransmitter release (i.e. glutamate) in the PFC and hippocampus, namely by 
reducing the activity of inhibitory GABAergic interneurons in these regions (Chowdhury et al., 
2012; Homayoun & Moghaddam, 2007; Moghaddam et al., 1997; Stone et al., 2012). 
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Accordingly, subanesthetic ketamine has been found to increase c-Fos expression in the mPFC 
(including the IL) and hippocampus (CA1, CA3, dentate gyrus) at rest (Imre, Fokkema, Boer, & 
Ter Horst, 2006). It is possible that an enhancement of activity in these regions facilitates the 
downstream inhibition of amygdalar fear output, as ketamine has also demonstrated efficacy in 
preventing conditioning-induced enhancement of c-Fos expression in the amygdala, while 
simultaneously inhibiting the expression of conditioned fear (Pietersen et al., 2006). Based on 
these findings, an immediate enhancement of presynaptic glutamate release in the mPFC and 
hippocampus might be one of the mechanisms underlying ketamine’s immediate suppression of 
conditioned responding. 
 A transient ketamine-induced burst of glutamatergic neurotransmission could also 
promote long-term changes in synaptic plasticity, since activation of the AMPA glutamate 
receptor stimulates BDNF release in the brain (Jourdi et al., 2009). BDNF is a growth factor that 
mediates synaptic plasticity by promoting dendritic protein synthesis, dendritogenesis, 
synaptogenesis, and the induction of LTP (Horch et al., 1999; Jourdi et al., 2009; Kang et al., 
1997; Korte et al., 1996; Patterson et al., 1996; Takei et al., 2004; Yoshii & Constantine-Paton, 
2007; Yoshii & Constantine-Paton, 2010). The BDNF protein’s ability to strengthen synapses, 
even in the absence of electrical stimulation, makes it a powerful modulator of memory and 
behavior (Autry et al., 2011; Liu et al., 2012; Messaoudi et al., 2002; Peters et al., 2010). While 
fear conditioning impairs hippocampal BDNF transcription (Rasmusson et al., 2002), fear 
extinction is associated with an upregulation of BDNF in fear suppression pathways (Bredy et 
al., 2007; Chhatwal et al., 2006; Rosas-Vidal et al., 2014). Following fear extinction, the 
presence of BDNF protein is increased in the ventral hippocampus (Rosas-Vidal et al., 2014), 
and hippocampal BDNF levels are correlated with the degree of successful fear extinction recall 
(Peters et al., 2010). Hippocampal BDNF is projected to the IL to suppress conditioned fear 
expression (Peters et al., 2010), and the presence of BDNF within the hippocampus even 
enhances the excitability of extinction-critical IL neurons (Rosas-Vidal et al., 2014). 
Furthermore, extinction training initiates epigenetic regulation of BDNF gene expression in the 
IL, increasing histone H4 acetylation of BDNF promoter regions to result in an upregulation of 
prefrontal BDNF mRNA (Bredy et al., 2007). Interference with BDNF activity in these regions 
is associated with extinction failure and the return of conditioned fear (Heldt et al., 2007; Peters 
et al., 2010; Rosas-Vidal et al., 2014). Interestingly, ketamine induces a rapid upregulation of 
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neuronal BDNF that is reminiscent of the natural changes in neurotrophin expression that are 
induced by fear extinction learning. Subanesthetic ketamine stimulates a significant enhancement 
of BDNF protein expression in the prefrontal cortex and hippocampus that occurs within only 30 
minutes of administration (Autry et al., 2011; Garcia et al., 2008a; Zhang et al., 2015a; Zhang et 
al., 2015b). Consistent with increased BDNF activity, ketamine also upregulates several synaptic 
proteins (including synapsin I, PSD-95, and the AMPA subunit Gria1), increases dendritic spine 
density, and enhances dendritic spine maturity in the mPFC within one hour of treatment (Li et 
al., 2010; Li et al., 2011; Zhang et al., 2015a). Since the present study introduced an hour delay 
between ketamine administration and behavioral testing, it is possible that these changes in 
neurotrophin expression and synaptic plasticity could contribute to the enhanced suppression of 
conditioned responding we observed during extinction training. It is noteworthy that a similar 
facilitation of conditioned fear suppression can be produced by directly infusing BDNF into 
either the IL or hippocampus of rats (Peters et al., 2010). Within an hour of BDNF infusion, 
these treatments produce a significant reduction in cue-elicited freezing that begins with the first 
unreinforced stimulus, even in the absence of extinction training (Peters et al., 2010). Peters and 
colleagues (2010) refer to this phenomenon as “BDNF-extinction,” because the successful and 
immediate suppression of conditioned responding induced by BDNF infusion was not a 
facilitation of extinction training (since no extinction training took place), but rather an effective 
substitution for it. We believe that a similar phenomenon, resulting from a ketamine-induced 
upregulation of prefrontal and hippocampal BDNF, could underlie the impaired conditioned fear 
expression observed in the present study. 
 Since BDNF expression promotes the strength and maturity of synapses in the brain, and 
increases postsynaptic membrane insertion of AMPA receptor subunits, it is unsurprising that 
ketamine also induces a long-lasting facilitation of neurotransmission (Autry et al., 2011; Li et 
al., 2010; Li et al., 2011). This has potentially significant consequences for extinction, since 
enhancements in prefrontal and hippocampal synaptic efficacy play an important role in the 
suppression of conditioned fear. Extinction learning is associated with the induction of LTP in 
the IL, which reverses a conditioning-induced depression of neuron excitability in this region 
(Cruz et al., 2014; Farinelli et al., 2006; Herry & Garcia, 2002; Hugues et al., 2006). Conversely, 
depressed IL neuron excitability accompanies the spontaneous weakening of extinction 
expression over time, illustrating the important role that LTP plays in the maintenance of 
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extinction memory (Cruz et al., 2014; Farinelli et al., 2006; Herry & Garcia, 2002; Herry & 
Mons, 2004; Hugues et al., 2006). Furthermore, extinction enhances synaptic efficacy between 
the hippocampus and mPFC, a process that is critical in the long-term maintenance of fear 
suppression (Farinelli et al., 2006; Garcia et al., 2008b; Hugues et al., 2006; Hugues & Garcia, 
2007). Once again, ketamine appears to induce changes in neurotransmission that parallel those 
seen in the natural process of extinction. Past research has demonstrated that subanesthetic 
ketamine potentiates synaptic efficacy in both the hippocampus (Autry et al., 2011; Nosyreva et 
al., 2013) and PFC (Li et al., 2011), elaborating upon the means by which ketamine could 
facilitate the suppression of conditioned fear. 
 By the end of extinction training, animals in both the pre-conditioning ketamine group 
and control group expressed similar levels of conditioned freezing. Interestingly, despite having 
significantly reduced freezing at the beginning of extinction training, pre-extinction ketamine 
treatment had no effect on behavior during extinction recall testing on the following day. While 
it may appear contradictory that ketamine can suppress conditioned responding during fear recall 
but not during extinction recall, it is possible that the induction of extinction learning involves 
processes that retroactively interfere with ketamine’s ability to further influence behavior. Since 
previous research has shown that ketamine retains the ability to reduce conditioned responding 
for at least 48 hours after administration (when administration and testing are separated by a rest 
period), it is doubtful that the behavioral effects of ketamine in the present study expired due to 
the 24 hour passage of time between drug administration and extinction recall testing (Amann et 
al., 2009; Zhang et al., 2015b). It is also unlikely that the lack of treatment effect during 
extinction recall is a result of state-dependent memory recall, since animals in the pre-
conditioning ketamine group exhibited no more cue-elicited freezing than animals in the control 
group did. Instead, the process of extinction learning appears to override the behavioral effects of 
ketamine, leading to a weakened suppression of conditioned fear in subsequent recall tests. 
Further research is needed in order to evaluate this possibility. 
 
4.4. Clinical Implications 
 Subanesthetic doses of ketamine have demonstrated impressive efficacy in the treatment 
of human depression (Aan Het Rot et al., 2012; Berman et al., 2000; Cusin et al., 2012; 
Diazgranados et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013; Phelps et al., 2009; Price 
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et al., 2009; Rasmussen et al., 2013; Zarate et al., 2006), but it has been uncertain if ketamine 
also helps challenge negative cognitive biases in memory that are associated with this disorder. 
The findings from the present study suggest that ketamine rapidly suppresses the expression of 
negative emotional memory in rats, even when the initial acquisition of aversive learning is 
undisturbed. If a similar attenuation of negatively biased memories is induced in humans, this 
could contribute to the antidepressant qualities of ketamine. Additional research is needed to 
determine if ketamine produces a similar effect on memory in animal models of depression and 
in human patients with depression. 
 The ability for a pharmacological intervention to inhibit fear associations after they have 
been acquired is also of potential value to the treatment of PTSD. Individuals with PTSD express 
poor extinction memory, which is accompanied by decreased activation in the hippocampus and 
mPFC, and enhanced activity in the amygdala (Milad et al., 2009b). The present study found that 
a single subanesthetic dose of ketamine was capable of attenuating the long-term expression of 
conditioned fear in rats when administered immediately following an aversive learning task. This 
observation appears consistent with a study by McGhee and colleagues, which found that 
military servicemen who received ketamine anesthesia during post-trauma surgery had a lower 
future prevalence of PTSD than those who were administered other anesthetic compounds 
(McGhee, Maani, Garza, Gaylord, & Black, 2008). However, attempts to replicate this finding 
have been mixed. A larger study by the same group found no effect of ketamine on reducing 
future PTSD prevalence, although these results may have been confounded by the fact that 
ketamine-treated individuals experienced injuries of greater severity than those who did not 
receive ketamine (McGhee et al., 2014). Furthermore, a separate investigation found that 
peritraumatic administration of (s)-ketamine (esketamine) in moderately injured accident victims 
elevated the future expression of PTSD symptoms, while racemic ketamine (as used in the 
present study) had no effect (Schönenberg, Reichwald, Domes, Badke, & Hautzinger, 2005). 
Further research is needed in order to better characterize the ways that the dosage, stereoisomer 
mixture, and time point of ketamine administration can influence the consolidation of negative 
emotional memory. 
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5. Conclusions 
 The results of this study demonstrate that the effect of a single subanesthetic dose of 
ketamine on the expression of auditory fear conditioning is dependent upon the time at which 
ketamine is administered relative to fear learning and recall. When administered during the 
consolidation phase of fear learning, ketamine impaired the expression of cue-elicited freezing in 
a recall test 10 days later. However, the same dose of ketamine was ineffective at inducing a 
long-lasting changes in behavior when injected prior to fear conditioning training. Ketamine 
treatment an hour before recall assessment attenuated conditioned responding immediately at the 
start of the trial, promoting an extinction-like suppression of conditioned fear. We believe that 
the differential effects of pre-conditioning, post-conditioning, and pre-extinction ketamine arise 
from interference with different cognitive processes of memory. None of the ketamine treatments 
examined in this study had a significant effect on the final degree of extinction acquisition, nor 
the recall of extinction behavior the next day. The findings of the present study could have 
implications for the treatment of disorders that feature a pathological bias towards negative 
memory, such as PTSD and depression. 
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Ketamine Prevents Repeated Corticosterone-Induced Reemergence of Extinguished 
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Abstract 
The experience of chronic stress plays an important role in the pathogenesis of major depressive 
disorder. Prolonged stress induces a state of chronically elevated glucocorticoid exposure in the 
brain, which is neurotoxic and can lead to the dysfunction of glutamatergic signaling. Since 
memory is highly dependent upon glutamatergic neurotransmission, patients with depression 
commonly display alterations memory processing that bias the recollection of past events 
towards negative emotional information. Past research has revealed that prolonged exposure to 
the glucocorticoid CORT produces a number of depression-like behaviors in rats, and makes 
extinguished negatively-valenced associations more prone to reinstatement in a contextual fear 
conditioning and extinction paradigm. The aim of the present study was to investigate the effects 
of chronic exogenous CORT exposure on auditory fear conditioning and extinction, and to 
evaluate the efficacy of the NMDA glutamate receptor antagonist ketamine in modulating long-
term fear and extinction recall in repeated CORT- and vehicle-treated rats. Rats received 40 
mg/kg injections of either CORT or vehicle for 21 consecutive days. Following repeated 
CORT/vehicle treatment, all animals were fear conditioned, extinction trained (two sessions), 
and then submitted to a sub-conditioning retraining procedure that is designed to reinstate 
conditioned fear in previously trained, but not conditioning-naive rats. Regardless of prior CORT 
exposure, pre-extinction administration of a subanesthetic 15 mg/kg dose of ketamine induced an 
immediate and substantial attenuation of cue-elicited freezing during conditioned fear recall 
assessment. Repeated CORT treatment provoked a spontaneous recovery of conditioned freezing 
between extinction sessions and induced a reinstatement of freezing following sub-conditioning 
retraining, an effect which was entirely prevented by pre-extinction ketamine administration. The 
present study therefore demonstrates that chronic exposure to the glucocorticoid CORT induces a 
failure of long-term extinction retrieval, and establishes ketamine as a powerful modulator of 
fear memory and emotionally-driven behavior.
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1. Introduction 
 The recent experience of an adverse life event frequently precedes the onset of a major 
depressive episode (Farmer & McGuffin, 2003; Kessing et al., 2003; Slavich et al., 2010), which 
has lead researchers to identify chronic stress as an important factor in the pathogenesis of 
depression (Deutschenbaur et al., 2015; Pittenger & Duman, 2008; Willner et al., 2013). Stress 
initiates a cascade of endocrine responses within the HPA axis, which culminate in the secretion 
of glucocorticoids (cortisol in humans; CORT in rodents) into the bloodstream (Herman & 
Cullinan, 1997). Although acute glucocorticoid release is an adaptive response that serves to 
promote an organism’s survival when faced with adversity, prolonged glucocorticoid exposure is 
neurotoxic and produces a number of serious maladaptive alterations in morphological 
neuroplasticity and behavior (de Kloet et al., 1999). In animal studies, chronic exogenous CORT 
administration has been shown to produce significant dendritic atrophy in the hippocampus 
(Magariños et al., 1998; Magariños et al., 1999; Morales-Medina et al., 2009; Sousa et al., 2000; 
Watanabe et al., 1992a; Woolley et al., 1990) and PFC (Liu & Aghajanian, 2008; Wellman, 
2001), while stimulating dendritic hypertrophy in the amygdala (Mitra & Sapolsky, 2008). A 
similar pattern of hippocampal/prefrontal atrophy and amygdalar hypertrophy has been observed 
in the brains of human patients with depression (Campbell et al., 2004; Cole et al., 2010; Colla et 
al., 2007; Lange & Irle, 2004; Phillips et al., 2003; Savitz & Drevets, 2009; Sheline et al., 1999; 
Sheline et al., 2003; van Tol et al., 2010; Videbech & Ravnkilde, 2004). In addition to 
morphological deficits, chronic CORT exposure also produces depression-like behaviors in 
rodents, such as anhedonia (David et al., 2009; Gorzalka et al., 1999; Gorzalka et al., 2001; 
Gorzalka et al., 2003; Gorzalka & Hanson, 1998; Gourley et al., 2008a; Gourley et al., 2008b; 
Gupta et al., 2015; Wu et al., 2013; Yau et al., 2014) and learned helplessness (Brummelte et al., 
2006; David et al., 2009; Fenton et al., 2015; Gourley et al., 2008a; Gregus et al., 2005; Hill et 
al., 2003; Johnson et al., 2006; Kalynchuk et al., 2004; Koike et al., 2013; Marks et al., 2009; 
Murray et al., 2008; Wu et al., 2013; Zhao et al., 2008a; Zhao et al., 2008b). 
 Given the fundamental role that these limbic structures play in learning and emotional 
regulation, it is unsurprising that depression-associated changes in neuronal morphology are 
accompanied by pathological modifications in cognition and behavior. For example, individuals 
with depression experience maladaptive alterations in memory that skew the recollection of past 
events towards negative emotional information (Balut et al., 2013; Gerritsen et al., 2012; Gupta 
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& Kar, 2012; Harmer et al., 2009a; Harmer et al., 2009b; Hsu et al., 2010; Liu et al., 2012; Mogg 
et al., 2014; Taylor & John, 2004). Negative cognitive biases in attention, processing, 
interpretation, and memory are believed to support the development and maintenance of 
depression (Elliott et al., 2011; Harmer et al., 2009a; Nolen-Hoeksema, 2000; Robinson & 
Sahakian, 2008), emphasizing the need for antidepressant treatments to effectively combat these 
insidious symptoms (Clark et al., 2009; Elliott et al., 2011; Roiser et al., 2012). 
 To experimentally investigate stress-induced memory biases in animals, researchers often 
use classical fear conditioning, a behavioral paradigm that promotes a learned association 
between an emotionally neutral conditioned stimulus (e.g., tone cue) and an innately aversive 
and negatively-valenced unconditioned stimulus (e.g., footshock). Following successful fear 
conditioning, presentation of the conditioned stimulus alone will elicit fear-motivated behavioral 
responses such as defensive freezing. Fear learning is rapidly acquired and generally very robust, 
but under proper conditions can later be challenged through a form of novel learning known as 
extinction. Extinction learning occurs when a conditioned stimulus is repeatedly presented in the 
absence of unconditioned stimulus reinforcement, and consists of the formation of a new 
memory that competes with the original fear memory to suppress fear-motivated behavior (Pape 
& Paré, 2010; Quirk & Mueller, 2008; VanElzakker et al., 2013). However, extinction memory 
is far less robust than conditioned fear memory, and conditioned responding can easily return 
under a number of circumstances. Previously extinction-trained animals can experience a 
recovery of conditioned fear spontaneously with the passage of time (Cruz et al., 2014; Pape & 
Paré, 2010), and are particularly susceptible to trained fear reinstatement with weak aversive 
stimuli that are incapable of inducing fear conditioning in naive animals (Deschaux et al., 2011a; 
Deschaux et al., 2011b; Deschaux et al., 2013; Laurent & Westbrook, 2010; Zheng et al., 2013). 
 Successful retention of fear extinction relies upon the integrity of prefrontal and 
hippocampal circuits that serve to inhibit activity of the amygdala, which is the primary locus of 
conditioned stimuli convergence and conditioned response output. Accordingly, high levels of 
circulating glucocorticoids and stress-induced amygdalar hypertrophy strengthen the ability to 
form fearful memories, while prefrontal and hippocampal atrophy simultaneously compromise 
the means by which the brain regulates fear-motivated behavior (Pape & Paré, 2010; Rodrigues 
et al., 2009). Previous research has shown that chronic stress exposure impairs extinction 
memory recall in rodents (despite successful short-term extinction acquisition), leading to the 
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spontaneous recovery of fear-motivated behaviors such as defensive freezing (Baran et al., 2009; 
Farrell et al., 2010; Gourley et al., 2009; Hoffman et al., 2014; Miracle et al., 2006; Wilber et al., 
2011). This apparent stress-induced bias towards negative emotional memory makes fear 
conditioning and extinction paradigms particularly valuable in the study of negative cognitive 
biases and the pursuit of pharmacotherapeutic agents capable of correcting them.  
 SSRIs are often prescribed to treat depression, but several common SSRIs have 
surprisingly been shown to enhance fear memory (Burghardt et al., 2004; Burhans et al., 2013; 
Cassaday & Thur, 2015; Montezinho et al., 2010; Ravinder et al., 2013) and impair extinction 
(Burghardt et al., 2013) in animal models of conditioned fear. This apparent facilitation of 
negatively-biased memory might be counter-productive in the treatment of depression, so the 
identification of drugs that instead inhibit fear memory could prove to be of great clinical value. 
One promising drug is ketamine, a noncompetitive antagonist of the NMDA receptor that blocks 
receptor activation by binding to the phencyclidine site of the complex’s cation channel 
(Sanacora et al., 2008). Clinical trials have demonstrated that subanesthetic infusions of 
ketamine produce rapid and long-lasting antidepressant effects in patients with treatment-
resistant depression (Aan Het Rot et al., 2012; Berman et al., 2000; Cusin et al., 2012; 
Diazgranados et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013; Phelps et al., 2009; Price 
et al., 2009; Rasmussen et al., 2013; Zarate et al., 2006). Ketamine is well-equipped to mediate 
memory for negatively valenced stimuli, since it upregulates synthesis of the plasticity-
enhancing BDNF protein in the hippocampus and frontal cortex (Autry et al., 2011; Zhang et al., 
2015a; Zhang et al., 2015b), and reverses stress-induced dendritic atrophy in the PFC (Li et al., 
2011). In nonstressed animals, infusion of a subanesthetic dose of ketamine prior to fear training 
reduces fear-motivated behavior in both auditory (Pietersen et al., 2006) and contextual 
(Calzavara et al., 2009) fear conditioning, while simultaneously inhibiting neuronal activity in 
the amygdala (Pietersen et al., 2006). However, the ability for ketamine to prevent stress-induced 
impairments in long-term extinction memory retention has not yet been examined. Furthermore, 
past investigations into the effects of ketamine on auditory fear conditioning have only 
administered ketamine prior to fear conditioning training, which could potentially interfere with 
the initial consolidation of fear memory. Since patients with depression typically only seek 
medical treatment following the development of depressive symptoms, administering ketamine 
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at a time point subsequent to successful and undisturbed fear conditioning training could offer a 
more valid animal model of treating negative cognitive biases with antidepressants. 
 The aim of the present study was twofold: first, to characterize the effects of chronic 
glucocorticoid exposure on auditory fear conditioning, extinction, and reinstatement using a 
repeated exogenous CORT animal model of depression; and second, to evaluate the efficacy of 
ketamine in facilitating the expression and retention of extinction behavior in both CORT-
exposed and nonstressed animals. To induce a stress-like state, rats were injected with 40 mg/kg 
CORT for 21 consecutive days prior to fear conditioning. All animals were fear conditioned, 
extinction trained, and then submitted to a sub-conditioning retraining procedure that is designed 
to reinstate conditioned fear in previously trained, but not conditioning-naive rats. Defensive 
freezing was analyzed throughout the conditioning, extinction, and reinstatement trials to 
evaluate the effects of each treatment condition on the expression of fear-motivated behavior and 
the retention of extinction training. We hypothesized that repeated CORT treatment would 
impair the long-term retention of fear extinction between extinction training sessions and 
following sub-conditioning retraining. In addition, we hypothesized that a pre-extinction 
subanesthetic dose of ketamine would reduce freezing during extinction training in both CORT-
treated and healthy rats, and prevent any potential CORT-induced deficits in extinction retention. 
 
2. Materials and Methods 
2.1. Animals 
 Thirty-three adult male Long-Evans rats (Charles River Laboratories; Montreal, Quebec, 
Canada), weighing 200-250 g upon arrival, were used in the study. Rats were housed 
individually in clear plastic cages with free access to food and water. The thermally-controlled 
colony room maintained a 12 hr/12 hr light/dark cycle. All procedures were approved by the 
University of Saskatchewan Animal Research Ethics Board, and conducted in accordance with 
the Canadian Council on Animal Care. 
 
2.2. Experimental Design and Drug Injection Paradigm 
 Handling of all rats took place for 7 consecutive days to habituate the animals to the 
procedure room and researcher before the first injection day. On the final day of handling, rats 
were assigned to one of four weight-matched experimental conditions: repeated vehicle injection 
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+ pre-extinction vehicle injection (Veh-21/Veh; n=9; i.e., control), repeated vehicle injection + 
pre-extinction 15 mg/kg ketamine injection (Veh-21/Ket; n=8), repeated 40 mg/kg CORT 
injection + pre-extinction vehicle injection (CORT-21/Veh; n=8), and repeated 40 mg/kg CORT 
injection + pre-extinction 15 mg/kg ketamine injection (CORT-21/Ket; n=8). 
 
2.2.1. CORT 
 Animals in the CORT-21/Veh and CORT-21/Ket group received subcutaneous injections 
of CORT for 21 consecutive days at a dose of 40 mg/kg and a volume of 1 ml/kg. CORT 
(Steraloids Inc.; Newport, Rhode Island, United States) was suspended in saline with 2% Tween-
80 (VWR International; West Chester, Pennsylvania, United States). This dose and injection 
paradigm was selected based on previous findings that 21 days of 40 mg/kg CORT produces 
reliable increases in depression-like behavior in rodents (Fenton et al., 2015; Gregus et al., 2005; 
Johnson et al., 2006; Kalynchuk et al., 2004; Lussier et al., 2013; Mao et al., 2012; Marks et al., 
2009; O’Donovan et al., 2014; Wu et al., 2013; Yau et al., 2011). Animals in the Veh-21/Veh 
and Veh-21/Ket group received subcutaneous injections of saline with 2% Tween-80 for 21 days 
instead. 
 
2.2.2. Ketamine 
 For animals in the Veh-21/Ket and CORT-21/Ket group, ketamine hydrochloride 
(Vetalar; Bioniche Animal Health Canada Inc.; Belleville, Ontario, Canada) was suspended in 
saline and injected intraperitoneally at a dose of 15 mg/kg, and a volume of 1 ml/kg. This dose 
was selected as it has been shown to be efficacious in disturbing behavioral and neural correlates 
of fear conditioning when administered before training (Amann et al., 2009; Li et al., 2011; 
Pietersen et al., 2006), as well as reducing depression-like behaviors in chronically stressed rats 
(Garcia et al., 2009; Koike et al., 2013; Li et al., 2011). Injections took place 60 minutes prior to 
extinction training to avoid the potentially confounding transient effects of ketamine on 
spontaneous locomotor activity. Since general locomotor activity in rats is normalized within 40 
minutes of a 16 mg/kg dose of ketamine (Imre et al., 2006), any ketamine-associated changes in 
freezing beyond this time point testing cannot be attributed to alterations in baseline movement. 
Administration of all injections took place in a procedure room separate from the animal colony 
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and fear conditioning apparatus. Animals in the Veh-21/Veh and CORT-21/Veh group received 
a subcutaneous injection of saline with 2% Tween-80 at this time instead. 
 
2.3. Fear Conditioning and Extinction 
 Fear conditioning and extinction followed a modified version of a protocol previously 
used by Deschaux et al. (2013). 
 
2.3.1. Apparatus 
 All behavioral testing procedures took place in standard operant chambers (VFC-008; 
Med Associates Inc., St. Albans, Vermont, United States) contained within sound-attenuating 
cubicles. Each operant chamber was constructed of aluminum walls and a clear plastic door 
through which a video camera could record the rat’s behavior. An overhead fluorescent lamp 
illuminated the chamber through a clear plastic roof. A high-frequency speaker (ANL-926) 
mounted high within the chamber wall delivered auditory cues. The floor of the chamber 
consisted of a grid of stainless steel rods that delivered aversive footshocks through a shock 
generator (ENV-414S). Video Freeze Software (Med Associates Inc.) controlled the delivery of 
tone and shock stimuli, and recorded video from the camera at 30 frames per second.  
 
2.3.2. Conditioning 
 One day after the final CORT or vehicle injection, rats were habituated to the 
conditioning context of the operant chamber for 10 minutes (day 22). On day 23, each rat was 
placed inside the operant chamber again and given 60 s to habituate before fear conditioning 
began. Conditioning consisted of 5 tone cues (2 kHz, 32 s, 90 dB) that co-terminated with an 
aversive footshock (0.7 mA, 250 ms). Each tone-shock pairing was followed by a 60 s inter-trial 
interval. Upon completion of fear conditioning, rats were transported back to the colony room, 
and the operant chamber was cleaned with 0.4% glacial acetic acid before training for the next 
subject began. 
 
2.3.3. Novel context extinction 
 Since the rats would form fearful associations with the contextual cues of the training 
environment in addition to the discrete tone cues, the context during extinction was altered in a 
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number of ways so that only auditory-cued conditioned fear would be measured and 
extinguished during this phase. During transit to and from the conditioning room, the rats’ cages 
were covered with dark curtain, and an alternative route was followed. The general environment 
of the conditioning room was changed with colored curtains draped over the walls, and overhead 
fluorescent lighting was replaced with a red lamp. Vanilla-scented deodorizer provided novel 
olfactory cues in the extinction context. Most importantly, the operant chambers were modified 
in shape and appearance with a colorful curved wall insert, and the metal grid floor was replaced 
with a smooth white plastic cover. A striped ceiling cover panel altered the lighting pattern 
within the chamber. Contextual auditory cues were obscured with white noise played through the 
chamber’s speaker (65 dB). After each extinction session, the chamber was cleaned with 75% 
ethanol so that any residual scent of the cleaner would be unfamiliar. 
 Rats rested for 2 consecutive days before extinction training began (day 26). Rats were 
placed into the novel extinction context and given 60 s to habituate. Extinction consisted of 20 
tone cues (2 kHz, 32 s, 90 dB) presented in the absence of footshock. Each tone was followed by 
a 60 s inter-trial interval. On day 27, long-term retention of extinction memory was evaluated by 
presenting an additional 10 tone cues, using the same extinction protocol as described above. 
Upon completion of each extinction trial, rats were transported back to the colony room. 
 
2.3.4. Sub-conditioning retraining 
 After a day of rest, rats underwent a sub-conditioning retraining procedure on day 29. All 
contextual cues were reverted back to those present during fear conditioning training. Each rat 
was placed inside the operant chamber and given 60 s to habituate before retraining began. 
Retraining consisted of 5 tone cues (2 kHz, 32 s, 90 dB) that co-terminated with a low-amperage 
footshock (0.3 mA, 250 ms), followed by a 60 s inter-trial interval. These mild footshocks are 
not strong enough to induce significant fear conditioning in naive animals, but can successfully 
reinstate fear responses in previously trained rats that have undergone extinction (Deschaux et 
al., 2013). Rats were returned to the colony room upon completion of the retraining trial. 
 
2.3.5. Extinction retention test 
 Following a day of rest, the rats were tested for retention of extinction behavior (day 31). 
Contextual cues present during this test were consistent with those used during the extinction 
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phase. Rats were placed inside the operant chambers, and after 60 s of acclimation received 5 
tone cues (2 kHz, 32 s, 90 dB) in the absence of footshock. Once extinction retention testing 
concluded, animals were transported back to the colony room and sacrificed the following day. 
 
2.3.6. Behavioral measurement 
 Fear conditioning was measured by freezing, defined as the absence of any movement not 
required for respiration. Using Video Freeze Software (Med Associates Inc.; St. Albans, 
Vermont, United States), movement was calculated as a change in pixel composition between 
adjacent video frames. To account for individual variation in baseline breathing movement, a 
motion threshold was set for each rat that defined the absolute limit beyond which movement 
would be registered as non-respiratory in nature. Immobility was required to last for at least 1 s 
before a freezing episode would be recorded in the data output. The percentage of time spent 
freezing during habituation and tone cue presentation was then calculated by Video Freeze 
Software and used as the dependent variable in analysis. 
 
2.3.7. Body weight 
 Rats were weighed daily during the 21 days of CORT or vehicle injections, and the data 
was recorded for later analysis of change in body weight. 
 
2.4. Statistical Analysis 
 Mean freezing data was analyzed using a 2x2 factorial ANOVA, with ketamine treatment 
(vehicle or 15 mg/kg ketamine) and CORT treatment (vehicle or 40 mg/kg CORT) as between 
subjects factors. Post-hoc analyses were performed using independent samples t-tests, which 
examined group differences in cue-elicited freezing behavior in order to test our hypotheses. 
First, mean freezing was compared between the Veh-21/Veh and Veh-21/Ket group to 
investigate the effect of ketamine on the behavior of nonstressed rats. Second, mean freezing was 
compared between the Veh-21/Veh and CORT-21/Veh group to assess the effect of CORT on 
behavior. Third, mean freezing was compared between the CORT-21/Veh and CORT-21/Ket 
group to evaluate the influence of ketamine on the behavior of CORT-exposed animals. Finally, 
mean freezing was compared between Veh-21/Veh and CORT-21/Ket groups was compared to 
determine if ketamine treatment in CORT-exposed animals modified behavior compared to 
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nonstressed and untreated animals. Within subjects t-tests were used to investigate changes in 
average tone-elicited freezing across fear extinction for each group. 
 Body weight data was analyzed using a 2x4 mixed design ANOVA, with CORT 
treatment (vehicle or 40 mg/kg CORT) as a between subjects factor and injection day (1, 7, 14, 
or 21) as a within subjects factor. 
 Animals that exhibited levels of freezing exceeding 1.5 standard deviations of the mean 
during extinction training or recall were considered outliers and excluded from statistical 
analysis. 
 
3. Results 
3.1. Fear Conditioning Training Day 
 Freezing during the 60 s habituation period prior to fear conditioning training was 
analyzed to determine if CORT treatment affected baseline behavior in the training context. All 
treatment groups exhibited near-zero levels of freezing during habituation, and no significant 
main effects [CORT Treatment: F(1, 26) = 1.156, p = 0.292; Ket Treatment: F(1, 26) = 1.156, p 
= 0.292] or interactions [F(1, 26) = 1.156, p = 0.292] were found (Fig. 3-1A). 
 Average freezing during tone cue presentation was also analyzed to assess potential 
treatment effects on behavior during fear conditioning acquisition. No significant main effects 
[Ket Treatment: F(1, 26) = 0.008, p = 0.931; CORT Treatment: F(1, 26) = 0.149, p = 0.702] or 
interaction effects [F(1, 26) = 1.661, p = 0.209] were found (Fig. 3-1B). 
 
3.2. Fear Extinction Training Day 
 Freezing during the 60 s habituation period prior to fear extinction training was analyzed 
to determine if CORT or Ket treatment affected baseline behavior in the novel extinction 
context. All treatment groups exhibited near-zero levels of freezing during novel context 
habituation, and no significant main effects [CORT Treatment: F(1, 26) = 0.149, p = 0.702; Ket 
Treatment: F(1, 26) = 0.008, p = 0.931] or interaction effects [F(1, 26) = 1.661, p = 0.209] were 
found (Fig. 3-2A; Fig. 3-3A; Fig. 3-3C; Fig 3-3E). 
 The long-term expression of auditory fear conditioning was investigated by analyzing the 
average level of freezing across the first five tone cues of extinction training (early phase 
extinction training; T1-T5). No significant main effect of CORT [F(1, 26) = 0.227, p = 0.638] or 
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Figure 3-1. (A) Percentage of time spent freezing during fear conditioning training. None of the 
treatments examined significantly affected freezing during habituation. (B) None of the 
treatments examined significantly affected the acquisition of fear conditioning.  
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interaction effect was noted [F(1, 26) = 0.121, p = 0.731], although a significant main effect of 
Ketamine treatment on freezing across T1-T5 was found [F(1, 26) = 19.391, p < 0.001] (Fig. 3-
2C). Post-hoc analysis confirmed that repeated CORT treatment alone did not affect initial 
conditioned responding; both the CORT-21/Veh and Veh-21/Veh group exhibited similar levels 
of average freezing across T1-T5 [t(13) = 0.080, p = 0.938]. Post-hoc analysis also revealed that 
ketamine treatment successfully reduced freezing in both nonstressed and CORT-treated 
animals. Rats in the Veh-21/Veh control group exhibited high levels of freezing across T1-T5, 
while rats in the Veh-21/Ket group immediately displayed significantly less freezing behavior 
during these initial tones [t(14) = 2.874, p = 0.012]. Similarly, the CORT-21/Ket treatment group 
demonstrated less cue-elicited freezing during the first quarter of extinction training than either 
the Veh/Veh [t(13) = 3.352, p = 0.005] or CORT/Veh group [t(12) = 3.388, p = 0.005]. 
 Average freezing across the last five tone cues of extinction training was analyzed to 
assess the relative level of extinction behavior acquisition at the end of the session (late phase 
extinction training; T16-T20). All treatment groups exhibited low levels of freezing at this time, 
and no significant main effects [CORT Treatment: F(1, 26) = 0.606, p = 0.443; Ket Treatment: 
F(1, 26) = 0.180, p = 0.675] or interaction effects [F(1, 26) = 0.876, p = 0.358] were found (Fig. 
3-2D). 
 A within subjects analysis was performed to investigate changes in average tone-elicited 
freezing between the first quarter (T1-T5) and last quarter (T16-T20) of extinction training 
within each group. Rats in the Veh-21/Veh group [t(7) = -1.967, p = 0.090] and CORT-21/Veh 
group [t(6) = 2.754, p = 0.033] exhibited significantly more freezing behavior across the first 
quarter of extinction training than across the latter quarter of the session. However, rats in the 
Veh-21/Ket group [t(7) = -1.032, p = 0.337] and CORT-21/Ket group [t(6) = 0.042, p = 0.968] 
exhibited uniformly low levels of freezing across both time periods .  
 
3.3. Fear Extinction Recall Day 
 All treatment groups exhibited near-zero levels of freezing during the 60 s habituation 
period preceding fear extinction recall testing, and no significant main effects [CORT Treatment: 
F(1, 26) = 0.040, p = 0.844; Ket Treatment: F(1, 26) = 0.035, p 
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interaction effects [F(1, 26) = 1.893, p = 0.181] were found (Fig. 3-2B; Fig. 3-3B; Fig. 3-3D; Fig 
3-3F). 
 The initial long-term expression of extinction behavior was investigated by analyzing 
freezing behavior during the first tone cue of extinction recall testing (early phase extinction 
recall; T1). No significant main effect of ketamine treatment [F(1, 26) = 1.379, p = 0.251] or 
interaction effect [F(1, 26) = 2.160, p = 0.154] was found. Although the main effect of CORT 
treatment [F(1, 26) = 3.085, p = 0.091] failed to reach our pre-established threshold of 
significance, further post-hoc analysis revealed that CORT treatment alone produced a 
statistically significant enhancement in freezing behavior, an effect which was prevented by co-
treatment with CORT and ketamine (Fig. 3-2E). Rats in the CORT-21/Veh group froze 
significantly more during T1 than rats in either the Veh-21/Veh [t(13) = -2.403, p = 0.034] or 
CORT-21/Ket group [t(12) = 2.617, p = 0.022]. However, ketamine treatment did not affect 
freezing at T1 when compared to nonstressed animals, as no significant differences were found 
between the Veh-21/Veh and Veh-21/Ket group [t(14) = -0.180, p = 0.860] or Veh-21/Veh and 
CORT-21/Ket group [t(13) = -0.433, p = 0.673]. 
 Average freezing across the second to fifth tones of extinction recall testing was also 
analyzed to investigate any possible treatment effects on behavior during the remainder of the 
test session’s first quarter (sustained extinction recall; T2-T5). No significant main effects 
[CORT Treatment: F(1, 26) = 1.221, p = 0.279; Ket Treatment: F(1, 26) = 0.303, p = 0.587, p = 
0.853] or interaction effects [F(1, 26) = 0.011, p = 0.917] were found (Fig. 3-2F). 
 Average freezing across the final five tones of extinction recall testing (late phase 
extinction recall; T16-T20) was analyzed to assess the relative level of extinction behavior at the 
end of the session. No significant main effects [CORT Treatment: F(1, 26) = 0.426, p = 0.520; 
Ket Treatment: F(1, 26) = 1.460, p = 0.238] or interaction effects [F(1, 26) = 1.326, p = 0.260] 
were found (Fig. 3-2G). 
 
3.4. Sub-Conditioning Retraining Day 
 Freezing during the 60 s habituation period prior to sub-conditioning retraining was 
analyzed to determine if CORT or Ket treatment affected baseline behavior when animals were 
reintroduced to the training context. All groups exhibited minimal freezing, and no significant  
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Figure 3-2. (A) Percentage of time spent freezing during extinction training. None of the 
treatments examined significantly affected freezing during habituation. (B) Percentage of time 
spent freezing during extinction recall testing. None of the treatments examined significantly 
affected freezing during habituation. (C) Ketamine significantly reduced freezing in both 
repeated vehicle- and CORT-treated rats across the first five tones of extinction training. (D) 
None of the treatments examined significantly impacted freezing across the last five tones of 
extinction training. (E) CORT significantly increased freezing during the first tone of extinction 
recall testing, and co-treatment with ketamine prevented this effect. (F) None of the treatments 
examined significantly impacted freezing across the second through fifth tones of extinction 
recall testing. (G) None of the treatments examined significantly impacted freezing across the 
last five tones of extinction recall testing. 
* Significantly different from Veh-21/Veh group (p < 0.05) 
** Significantly different from Veh-21/Veh group and CORT-21/Veh group (p < 0.05) 
*** Significantly different from CORT-21/Veh group (p < 0.05)
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Figure 3-3. (A-F) Group comparisons in percentage of time spent freezing during extinction 
training and extinction recall testing. 
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main effects [CORT Treatment: F(1, 26) = 0.009, p = 0.924; Ket Treatment: F(1, 26) = 1.008, p 
= 0.325] or interaction effects [F(1, 26) = 1.715, p = 0.202] were found (Fig. 3-4A). 
 Average freezing during tone cue presentation was also analyzed to assess potential 
treatment effects on behavior during sub-conditioning fear acquisition. No significant main 
effects [CORT Treatment: F(1, 26) = 0.107, p = 0.746; Ket Treatment: F(1, 26) = 0.618, p = 
0.439;] or interaction effects [F(1, 26) = 0.012, p = 0.915] were found (Fig. 3-4B). 
 
3.5. Fear Extinction Retention Test 
 All treatment groups exhibited near-zero levels of freezing during the 60 s habituation 
period preceding fear extinction retention testing, and no significant main effects [CORT 
Treatment: F(1, 26) = 2.458, p = 0.129; Ket Treatment: F(1, 26) = 2.458, p = 0.129] or 
interaction effects [F(1, 26) = 2.458, p = 0.129] were found (Fig. 3-5A; Fig. 3-5B; Fig. 3-5C; 
Fig. 3-5D). 
 The initial retention of extinction memory was investigated by analyzing freezing 
behavior during the first tone cue of extinction retention testing (T1). A significant main effect of 
CORT treatment [F(1, 26) = 4.532, p = 0.043], a significant main effect of ketamine treatment 
[F(1, 26) = 5.526, p = 0.027], and a significant interaction effect [F(1, 26) = 11.398, p = 0.002] 
was found (Fig. 3-5E). Post-hoc analysis revealed that CORT treatment alone enhanced freezing 
compared to nonstressed animals, and that this effect that was prevented by co-treatment with 
CORT and ketamine. Rats in the CORT-21/Veh group froze significantly more at T1 than rats in 
either the Veh-21/Veh group [t(13) = -2.839, p = 0.028] or CORT-21/Ket group [t(12) = 2.997, p 
= 0.024]. Near-zero levels of freezing in both the Veh-21/Veh and CORT-21/Ket group yielded 
no statistically significant differences [t(13) = 0.555, p = 0.589]. Ketamine had no effect on 
behavior at T1 in nonstressed animals, as rats in both the Veh-21/Veh and Veh-21/Ket group 
exhibited comparably low levels of freezing [t(14) = -1.201, p = 0.258]. 
 Average freezing across the second to fifth tones of extinction retention testing was also 
analyzed to investigate any possible treatment effects on behavior during the remainder of the 
test session (sustained extinction retention; T2-5). No significant main effects [CORT Treatment: 
F(1, 26) = 0.012, p = 0.914; Ket Treatment: F(1, 26) = 0.121, p = 0.731] were found, although a 
significant interaction effect was noted [F(1, 26) = 4.551, p = 0.042] (Fig. 3-5F). However,  
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Figure 3-4. (A) Percentage of time spent freezing during sub-conditioning retraining. None of 
the treatments examined significantly affected freezing during habituation. (B) None of the 
treatments examined significantly affected the acquisition of sub-conditioning retraining. 
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Figure 3-5. (A-D) Percentage of time spent freezing during extinction retention testing. None of 
the treatments examined significantly affected freezing during habituation. (E) CORT 
significantly increased freezing during the first tone of extinction retention testing, and co-
treatment with ketamine prevented this effect. (F) None of the treatments examined significantly 
impacted freezing across the last five tones of extinction retention testing. 
* Significantly different from Veh-21/Veh group (p < 0.05) 
*** Significantly different from CORT-21/Veh group (p < 0.05) 
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post-hoc analyses revealed no statistically significant differences between groups (all p values ≥ 
0.110).  
 
3.6. Body Weight 
 Daily injections of 40 mg/kg CORT prevented weight gain in rats over time, while 
animals injected with vehicle instead displayed continuous weight gain throughout the 21 days 
preceding behavioral testing. A mixed design ANOVA revealed a significant main effect of 
injection day [F(3, 48) = 115.205, p < 0.001], a significant main effect of CORT treatment (F(1, 
28) = 113.934, p < 0.001), and a significant injection day x CORT treatment interaction effect 
[F(3, 48) = 135.058, p < 0.001]. Post-hoc analyses revealed that no significant differences in 
weight between CORT and vehicle groups were present on the first injection day [t(28) = 0.512, 
p = 0.613]. However, rats in the CORT-treated group weighed significantly less on average than 
rats in the vehicle-treated group on day 7 [t(28) = 10.391, p < 0.001], day 14 [t(28) = 11.242, p < 
0.001], and day 21 [t(28) = 12.765, p < 0.001] (Fig. 3-6A). 
 
4. Discussion 
 The aim of this study was to characterize the effects of a single subanesthetic dose of 
ketamine on the extinction and reinstatement of auditory conditioned fear in animals exposed to 
repeated CORT or vehicle injections. We observed that regardless of CORT treatment, 
administration of a 15 mg/kg dose of ketamine significantly impaired the expression of 
conditioned freezing during early phase extinction training. Chronic CORT exposure had no 
effect on extinction acquisition, but was found to enhance initial cue-elicited freezing during 
extinction recall and sub-conditioning retention testing. These CORT-induced enhancements in 
the spontaneous recovery and trained reinstatement of conditioned fear were prevented by pre-
extinction ketamine treatment, which produced a normalization of freezing comparable to that of 
control animals. Together, our results suggest that a single subanesthetic dose of ketamine can 
restore the long-term expression of extinction behavior in animals with a history of chronic 
exogenous CORT exposure, and dramatically suppress the initial recall of conditioned fear 
irrespective of past CORT treatment. The findings of the present study are discussed in further 
detail below.
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Figure 3-6. (A) Rats treated with CORT weighed significantly less than vehicle-injected rats on 
injection days 7, 14, and 21. 
* Significantly different from CORT group (p < 0.05) 
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4.1. The Effect of Repeated CORT on Auditory Fear Conditioning, Extinction, and 
Reinstatement in Animals Not Treated With Ketamine 
 The present study demonstrated that 21 days of CORT treatment did not enhance the 
acquisition of cue-elicited freezing during fear conditioning training compared to vehicle-treated 
controls. This finding is corroborated by several past studies, which have reported that chronic 
CORT treatment either has no effect on fear acquisition, or induces a slight reduction of freezing 
during associative fear learning (Conrad et al., 2004; Dagnino-Subiabre et al., 2012; Gourley et 
al., 2009; Marks et al., 2015; Monsey et al., 2014). Similarly, repeated restraint models of 
chronic stress have shown that both stressed and nonstressed animals exhibit comparable 
auditory fear acquisition (Baran et al., 2009; Conrad et al., 1999; Miracle et al., 2006; Zhang & 
Rozencranz, 2013). The absence of a treatment effect on fear acquisition may be the result of a 
failure for CORT to affect short-term memory. Chronic CORT exposure does not enhance the 
recall of conditioned fear 1-2 hours after training, despite being capable of increasing cue-
elicited freezing 1-14 days later (Gourley et al., 2009). In addition, chronic stress does not alter 
the level of electrical current needed to induce a pain response in rats (Baran et al., 2009; Conrad 
et al., 1999; Dagnino-Subiabre et al., 2012; Zhang & Rozencranz, 2013), so the unconditioned 
stimuli used in the current study should be equally aversive to both CORT- and vehicle-treated 
groups, and thus produce a similar behavioral response. 
 Repeated CORT treatment in our study did not significantly affect the long-term 
expression of auditory conditioned fear during early phase and late phase extinction training. The 
acquisition of extinction behavior was unimpaired by prolonged exogenous CORT exposure, and 
both CORT-21/Veh and Veh-21/Veh animals displayed a significant reduction in freezing 
between the beginning and end of extinction training. Previous research on the effect of chronic 
stress on conditioned fear recall has yielded inconsistent results. While a couple studies have 
reported that chronic CORT exposure produces an enhancement of freezing during auditory fear 
recall testing (Dagnino-Subiabre et al., 2012; Monsey et al., 2014), others have found no effect 
of chronic CORT on initial long-term auditory (Conrad et al., 2004; Marks et al., 2015) and 
contextual (Gourley et al., 2009) fear retrieval. Similarly, studies using behavioral models of 
chronic stress have been unable to reliably produce an enhancement of initial conditioned fear 
recall (Baran et al., 2009; Bisaz & Sandi, 2010; Conrad et al., 1999; Farrell et al., 2010; Hoffman 
et al., 2014; Miracle et al., 2006; Wilber et al., 2011; Zhang & Rozenkranz, 2013). It is possible 
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that conflicting reports on the effect of chronic stress on long-term fear memory could be the 
result of differences in experimental protocol, especially when auditory and contextual fear are 
examined within the same study. Our lab has previously demonstrated that repeated CORT 
treatment increases auditory cue-elicited freezing when tone testing follows contextual testing, 
but that CORT has no effect on auditory fear memory when tone testing occurs first (Marks et 
al., 2015). It is unlikely that the effect of CORT on cognition and behavior “wore off” in the 4 
days between the final CORT injection and extinction training, as previous studies have reported 
that much lower does of CORT than those used in the present study can continue to influence 
fear-motivated behavior for at least 2 weeks after cessation of administration (Gourley et al., 
2009; Monsey et al., 2014). 
 Despite unimpaired extinction acquisition, animals in the CORT treatment group 
displayed a 2X increase in freezing compared to control during the first tone of extinction recall 
testing. This enhancement in cue-elicited freezing is consistent with a spontaneous recovery of 
conditioned fear, and suggests that either the consolidation or recall of extinction memory was 
impaired. However, since CORT-treated animals quickly returned to normal freezing levels after 
the first tone, it seems likely that the recovery of conditioned responding is primarily the result of 
extinction retrieval failure. Previous studies using restraint and chronic mild stress models have 
similarly produced enhancements in cue-elicited freezing during early phase, but not late phase 
extinction recall testing (Baran et al., 2009; Garcia et al., 2008b; Hoffman et al., 2014; Miracle et 
al., 2006; Wilber et al., 2011). Although one study found that chronic administration of CORT in 
drinking water did not affect the recall of auditory fear extinction, rats in that experiment were 
exposed to a significantly smaller dose of CORT compared to the present investigation 
(Dagnino-Subiabre et al., 2012). Since CORT facilitates conditioned freezing in a dose-
dependent manner (Marks et al., 2015), it is possible that the dosage of CORT used in this 
previous study was not high enough to produce a long-term change in freezing behavior during 
extinction recall assessment. However, another study found that when CORT was chronically 
administered through drinking water before contextual fear conditioning and extinction, the 
between-session recall of extinction behavior was impaired and CORT-treated animals exhibited 
a spontaneous recovery of contextual fear (Gourley et al., 2009). 
 The spontaneous recovery of conditioned freezing we observed cannot be ascribed to a 
generalized inhibition of locomotor activity, as both CORT-21/Veh and Veh-21/Veh rats 
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exhibited comparable levels of freezing during the 60 s habituation period prior to extinction 
recall testing. Furthermore, past research has established that chronic behavioral stress has no 
effect on cue-elicited freezing during fear conditioning, extinction acquisition, and extinction 
recall when tone and shock cues are unpaired during training, suggesting that prolonged stress 
does not enhance non-associative fear-motivated behavior (Baran et al., 2009; Conrad et al., 
2001; Wilber et al., 2011). CORT treatment in the present study also did not alter freezing 
behavior during fear conditioning or fear extinction training, so increased freezing during 
extinction recall testing can neither be accounted for by a facilitation of fear acquisition, nor an 
impairment of extinction acquisition, respectively. 
 The present study is the first to our knowledge to examine the effects of chronic 
exogenous CORT exposure on the sub-conditioning reinstatement of conditioned fear. Similar to 
initial fear conditioning, repeated CORT treatment did not alter freezing behavior during the sub-
conditioning retraining session. However, CORT-treated animals displayed a 16X increase in 
freezing behavior compared to controls during the first tone of extinction retention testing, which 
is consistent with conditioned fear reinstatement. This reinstatement of conditioned freezing was 
limited to the first unreinforced cue presentation, suggesting that extinction retrieval, rather than 
consolidation, was impaired by CORT. Once again, the CORT-induced enhancement of cue-
elicited freezing cannot be ascribed to a generalized inhibition of locomotor activity, as both 
CORT-21/Veh and Veh-21/Veh rats exhibited comparable levels of freezing during the 60 s 
habituation period prior to extinction retention testing. These findings suggest that chronic 
exposure to glucocorticoids can induce a long-lasting impairment of fear extinction that lasts for 
at least 10 days following the cessation of exogenous CORT administration. Contrary to our 
expectations, animals in the Veh-21/Veh group did not display a reinstatement of conditioned 
fear following sub-conditioning retraining. The extensive extinction training protocol used in this 
study, which consisted of 40 total unreinforced tone cues, apparently created a robust extinction 
memory that was resistant to change in healthy animals. However, our sub-conditioning 
retraining protocol appeared to be sensitive to animals with a history of CORT exposure, whose 
ability to retain long-term extinction expression was visibly impaired in our testing. 
 Endogenous glucocorticoids play an essential role in normal associative fear learning 
(Conrad et al., 2001; Cordero et al., 2002; Donley et al., 2005; Jin et al., 2007; Kolber et al., 
2008; Pugh et al., 1997a; Pugh et al., 1997b; Rodrigues & Sapolsky, 2009; Roozendaal & 
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McGaugh, 1997), but excessive glucocorticoid exposure can significantly alter the morphology 
and function of brain regions responsible for the processing of fear-related stimuli. Neurons in 
the hippocampus, PFC, and amygdala are abundant in glucocorticoid receptors, making these 
structures highly vulnerable to the deleterious effects of chronic CORT exposure (Feldman & 
Weidenfeld, 1999; Herman et al., 2003; Herman et al., 2005; Mitra & Sapolsky, 2008; Morimoto 
et al., 1996). These same structures are also heavily implicated in the expression and suppression 
of fear memory, so pathological alterations to their morphology and function could underlie the 
CORT-induced recovery and reinstatement of conditioned fear that we observed in the current 
study.  
 As previously mentioned, the amygdala is responsible for forming a predictive 
association between conditioned and unconditioned fear stimuli, and acts as a gateway for the 
expression of conditioned responding (e.g. freezing; Pape & Paré, 2010). However, amygdalar 
output of conditioned fear can be suppressed through descending projections from the IL mPFC, 
which stimulate inhibitory GABAergic ITC neurons within the amygdala (Quirk & Mueller, 
2008; Pape & Paré, 2010; VanElzakker et al., 2013). The mPFC plays an essential role in the 
long-term retention of fear extinction, as lesioning or chemical inactivation of this region causes 
the spontaneous recovery of cue-elicited freezing, despite unimpaired extinction acquisition 
(Fernandez, 2003; Lebrón et al., 2004; Morgan et al., 1993; Morgan et al., 2003; Quirk et al., 
2000; Sierra-Mercado et al., 2006). The hippocampus also mediates activity within fear memory 
circuitry (Maren & Hobin, 2009; Sotres-Bayon et al., 2012), and communicates with the mPFC 
to facilitate extinction memory recall and suppress conditioned fear in a contextually appropriate 
manner (Farinelli et al., 2006; Garcia et al., 2008b; Hugues et al., 2006; Hugues & Garcia, 2007; 
Peters et al., 2010; Quirk & Mueller, 2008). Impairment of hippocampal neuronal activity during 
extinction learning results in the recovery of conditioned fear, presumably due to disturbed 
consolidation of contextual information (Corcoran et al., 2005). Together, the mPFC and 
hippocampus comprise the fundamental structures underlying the induction and long-term 
expression of fear extinction, but the integrity of these structures is pathologically altered by 
exposure to chronic stress. Posing a significant threat to the prefrontal inhibition of conditioned 
fear, chronic behavioral stress and chronic exogenous CORT exposure have been found to 
induce dendritic atrophy and an impairment of dendritic spine density in both the PFC and 
hippocampus of rodents (Cook & Wellman, 2004; Delgado et al., 2011; Dias-Ferreira et al., 
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2009; Izquierdo et al., 2006; Li et al., 2011; Liston et al., 2006; Liu & Aghajanian, 2008; 
Magariños et al., 1996; Magariños et al., 1998; Magariños et al., 1999; Magariños & McEwen, 
1995a; Magariños & McEwen, 1995b; Morales-Medina et al., 2009; Radley et al., 2004; Shansky 
& Morrison, 2009; Sousa et al., 2000; Tata et al., 2006; Watanabe et al., 1992a; Watanabe et al., 
1992b; Wellman, 2001; Woolley et al., 1990). Based on the findings that chronic stress impairs 
prefrontal and hippocampal morphology, and that damage to these structures impairs extinction 
memory recall, it appears plausible that the spontaneous recovery of conditioned freezing we 
observed in CORT-exposed rats could in part be the result of stress-induced prefrontal and 
hippocampal morphological damage. 
 In addition to morphological deficits, chronic stress induces pathological neurobiological 
changes in extinction circuits that endanger the ability to successfully suppress conditioned fear. 
One particularly important component underlying extinction learning is BDNF, a growth factor 
that mediates synaptic plasticity by promoting dendritic protein synthesis, dendritogenesis, 
synaptogenesis, and the induction of LTP (Horch et al., 1999; Jourdi et al., 2009; Kang et al., 
1997; Korte et al., 1996; Patterson et al., 1996; Takei et al., 2004; Yoshii & Constantine-Paton, 
2007; Yoshii & Constantine-Paton, 2010). While fear conditioning impairs hippocampal BDNF 
transcription (Rasmusson et al., 2002), fear extinction is associated with an upregulation of 
BDNF in fear suppression pathways (Bredy et al., 2007; Chhatwal et al., 2006; Rosas-Vidal et 
al., 2014). Following fear extinction, the presence of BDNF protein is increased in the ventral 
hippocampus (Rosas-Vidal et al., 2014), and BDNF mRNA is upregulated in the PFC (Bredy et 
al., 2007), suggesting a role in the consolidation of extinction memory. BDNF also appears to 
mediate extinction memory retrieval, as hippocampal BDNF levels are correlated with the degree 
of successful long-term fear extinction recall (Peters et al., 2010). Past research has demonstrated 
that suppression of BDNF activity in the hippocampal-mPFC pathway impairs the long-term 
expression of fear extinction, resulting in the recovery of conditioned fear (Heldt et al., 2007; 
Peters et al., 2010; Rosas-Vidal et al., 2014). Chronic stress and CORT exposure oppose the 
natural changes in BDNF expression that underlie fear extinction by inducing a downregulation 
of BDNF expression in the hippocampus and PFC (Aboul-Fotouh, 2015; Chen et al., 2008; 
Dwivedi et al., 2006; Filho et al., 2015; Fu et al., 2014; Gourley et al., 2008; Grønli et al., 2006; 
Guo et al., 2014; Hamani et al., 2012; Jacobsen & Mørk, 2006; Jin et al., 2015; Li et al., 2012; 
Liang et al., 2012a; Liang et al., 2012b; Liu et al., 2014; Liu et al., 2015; Luoni et al., 2014; 
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Monsey et al., 2014; Nibuya et al., 1999; Nitta et al., 1997; Ray et al., 2011; Smith et al., 1995; 
Yan et al., 2015; Zhang et al., 2015a; Zhu et al., 2016). Since BDNF is an inducer of LTP (Kang 
et al., 1997; Korte et al., 1996; Patterson et al., 1996), a stress-induced downregulation of this 
important neurotrophin could produce impairments in neuronal activity as well. Accordingly, 
chronic stress impairs LTP in both the hippocampus and hippocampal-PFC pathway of rodents 
(Cerqueira et al., 2007; Foy et al., 1987; Garcia et al., 1997; Kim et al., 1996;  Pavildes et al., 
2002; Shors et al., 1989; Xu et al., 1997). This carries significant consequences for long-term 
extinction retention, since the long-term maintenance of extinction behavior depends upon the 
sustained reversal of a conditioning-induced depression of IL neuron excitability (Cruz et al., 
2014; Herry & Mons, 2004), but stress impairs IL neuronal activity during extinction recall 
(Wilber et al., 2011). Hippocampal and prefrontal LTP also exerts powerful influence over the 
prevention of sub-conditioning fear reinstatement (Deschaux et al., 2015; Herry & Garcia, 
2008b; Zheng et al., 2013), so an impairment of LTP in these regions might underlie the 
reinstatement of conditioned freezing we observed in rats exposed to chronic CORT. 
 Although an impairment of hippocampal and prefrontal plasticity could be sufficient to 
compromise fear extinction alone, a stress-induced facilitation of amygdalar function might also 
contribute to these behavioral deficits. Acute or chronic exposure to CORT induces dendritic 
hypertrophy, enhances neuronal excitability, and reduces GABAergic inhibition within the BLA 
(Duvarci & Paré, 2007; Kavushansky & Richter-Levin, 2006; Mitra & Sapolsky, 2008). Thus, by 
facilitating neuroplasticity and neuronal activity within the amygdala, exposure to CORT might 
result in an even greater imbalance between the strength of fear conditioning and extinction 
memory circuits.   
 
4.2. The Effect of Subanesthetic Ketamine on Auditory Fear Extinction and Reinstatement in 
Repeated Vehicle- and CORT-Treated Animals 
 We observed that pre-extinction administration of 15 mg/kg ketamine significantly 
attenuated the long-term expression of auditory fear in repeated vehicle-injected animals, as 
evidenced by a 63% reduction in cue-elicited freezing during early phase extinction training 
compared to control. This same dose of ketamine was also effective at reducing the cue-elicited 
freezing of CORT-exposed rats by 75% compared to their vehicle-treated CORT-exposed 
counterparts. Interestingly, rats in the CORT-21/Ket group displayed even less freezing at this 
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time than rats in the Veh-21/Veh control group, indicating a supranormal suppression of 
conditioned responding despite their history of chronic CORT exposure. Although this inhibition 
of freezing is reminiscent of successful extinction learning behavior, the fact that ketamine 
suppressed conditioned responding immediately at the start of the trial (before extinction 
learning could begin) suggests that this is not a facilitation of natural extinction learning, but 
rather an induction of extinction-like behavior. Using nonstressed rats, our lab has previously 
demonstrated a milder 21% reduction in cue-elicited freezing during early phase extinction as a 
result of a lower pre-extinction 10 mg/kg dose of ketamine (unpublished data). A similar 
attenuation of conditioned responding has previously been found when chronic low-dose 
ketamine treatment precedes the assessment of contextual fear memory recall in nonstressed 
rodents (Amann et al., 2009; Zhang et al., 2015b), but the present study is the first to our 
knowledge to investigate the effect of ketamine on animals with a history of CORT exposure. 
We also found that ketamine significantly altered the acquisition profile of auditory fear 
extinction. While vehicle-treated rats displayed a reduction of cue-elicited freezing between early 
phase and late phase extinction training, ketamine-treated rats exhibited an immediate inhibition 
of cue-elicited freezing that remained consistently low throughout the learning trial. However, 
the lack of a change in freezing behavior over time should not be interpreted as a failure for these 
animals to acquire fear extinction, since they demonstrated normal extinction recall in 
subsequent testing sessions. Instead, the acquisition process is “invisible” in ketamine-treated 
animals due to the drug’s dramatic and immediate suppression of conditioned freezing. 
 Since all treatment groups exhibited similar levels of freezing during fear conditioning 
training, the ketamine-induced reduction in conditioned responding we observed during early 
phase extinction training cannot be explained by group differences in initial fear acquisition. Our 
findings can also not be ascribed to a generalized increase in locomotor activity, as ketamine- 
and vehicle-treated groups displayed equivalent levels of freezing during the 60 s habituation 
period prior to extinction training. Furthermore, previous research has established that 
spontaneous locomotor activity in the open field test is normalized within 40 minutes following a 
16 mg/kg injection of ketamine in rats (Imre et al., 2006). Since we maintained an hour delay 
between drug administration and extinction training, ketamine-treated animals in the present 
study had ample time for locomotor normalization, and exhibited behavior that was 
indistinguishable from control animals before extinction training began. It is also unlikely that 
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ketamine induced perceptual distortions that impaired the perception of conditioned stimuli, as 
previous research has shown that subanesthetic ketamine does not affect auditory evoked 
potentials in rats (de Bruin et al., 1999). 
 When administered to rats with a history of repeated vehicle injections, ketamine had no 
effect on the long-term expression of fear extinction 24 hours after training. Past research in our 
lab has similarly demonstrated that a lower dose of 10 mg/kg ketamine is also unable to 
influence long-term fear extinction retrieval in nonstressed rats (unpublished data). Since other 
researchers have shown that ketamine retains the ability to reduce conditioned responding for at 
least 48 hours after administration (when administration and testing are separated by a rest 
period), it is doubtful that the behavioral effects of ketamine in the present study expired due to 
the 24 hour passage of time between drug administration and extinction recall testing (Amann et 
al., 2009; Zhang et al., 2015b). It is also unlikely that the lack of treatment effect during 
extinction recall is a result of state-dependent memory recall, since animals in the pre-extinction 
ketamine group exhibited no more cue-elicited freezing than animals in the control group did. 
Rather, it appears that ketamine’s ability to facilitate fear suppression is limited to the first 
extinction session following drug administration in healthy animals. However, the present study 
revealed that ketamine has an enduring impact on extinction retention in rats with a history of 
chronic CORT exposure. While CORT-21/Veh rats exhibited a 2X increase in cue-elicited 
freezing compared to control during initial extinction recall assessment, this abnormal recovery 
of conditioned fear was abolished in the CORT-21/Ket group. Ketamine treatment induced a 
complete normalization of long-term extinction expression in these animals, who displayed a low 
level of freezing in both early and late phase extinction recall testing that was comparable to that 
of control subjects. Since all groups exhibited similarly low levels of freezing at the end of 
extinction training, this prevention of conditioned freezing recovery cannot the result of 
between-group differences in extinction acquisition. Nor can it be attributed to a ketamine-
induced enhancement of general locomotor activity, since ketamine had no effect on freezing 
during the 60 s habituation period prior to extinction recall testing.  
 Ketamine did not influence freezing behavior during the sub-conditioning retraining 
session, and all treatment groups reacted similarly when re-exposed to the training context and 
tone-shock pairings. When extinction retention was tested 48 hours later, Veh-21/Ket animals 
exhibited low levels of freezing that did not significantly differ from control animals. This 
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finding is not surprising, since ketamine also failed to affect freezing behavior during the first 
extinction recall assessment; however, control group freezing during this trial was also so low 
that further conditioned fear suppression could not even be possible. Despite a lack of treatment 
effect in nonstressed animals, ketamine continued to demonstrate an enduring facilitation of 
extinction retention in animals given chronic CORT. While CORT-21/Veh rats underwent a 
significant reinstatement of cue-elicited freezing during the first tone of extinction retention 
testing, this effect was completely abolished in the CORT-21/Ket group. Ketamine successfully 
prevented the reinstatement of conditioned responding in animals with a history of chronic 
CORT exposure, producing near-zero levels of freezing that did not differ significantly from the 
control group. Once again, general locomotor behavior was unchanged in ketamine-treated 
animals. 
 Overall, ketamine demonstrated remarkable efficacy in suppressing initial conditioned 
fear expression, regardless of an animal’s history of CORT exposure. However, the benefits of 
ketamine treatment were limited to the first extinction session in nonstressed rats, which showed 
no differences in freezing behavior compared to control for the remainder of the study. 
Conversely, ketamine induced a long-lasting normalization of fear extinction retention in animals 
with chronic exogenous CORT exposure, preventing both the spontaneous recovery and sub-
conditioning reinstatement of conditioned freezing. Furthermore, the present study demonstrated 
that ketamine’s facilitation of healthy fear extinction function lasts for at least 5 days following 
drug administration, which is consistent with the duration of ketamine’s other antidepressant-like 
behavioral effects in animal models (Autry et al., 2011; Jett et al., 2015; Li et al., 2011; Maeng et 
al., 2008).  
 Although the present study’s focus was limited to the effects of CORT and ketamine on 
behavior, past research on the morphological and neurobiological changes induced by these 
agents can help inform speculation into some of the mechanisms that might underlie our 
observed results. One potential explanation for the attenuation of cue-elicited freezing we 
observed during early phase extinction training is that ketamine impaired the cognitive process 
of memory recall by inactivating NMDA receptors in the amygdala. The lateral amygdala in 
particular plays a crucial role in integrating fear-relevant stimuli, and mediates the induction and 
expression of conditioned fear (Pape & Paré, 2010). Infusion of the NMDA receptor antagonist 
APV into the lateral amygdala prior to fear recall testing has been shown to attenuate 
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conditioned responding, so it is possible that a systemic injection of ketamine in a high enough 
dose and close enough temporal proximity to behavioral testing could elicit a similar effect. 
However, we believe that transient NMDA receptor inactivation itself likely plays a minor and 
non-essential role in the present study’s observed effects of pre-extinction ketamine on the 
expression of conditioned fear. Past studies that impaired conditioned fear recall through NMDA 
receptor antagonism administered APV only 5 minutes prior to behavioral testing, ensuring that 
drug binding to NMDA receptors would be high at the time of conditioned stimulus presentation. 
Conversely, animals in the present study received ketamine at least one hour before extinction 
training, which considering ketamine’s short 1.3 hour half-life (Veilleux-Lemieux et al., 2013), 
likely reduced binding to NMDA receptors significantly at the time of behavioral assessment. 
Furthermore, previous research has demonstrated that ketamine can induce a similar attenuation 
of conditioned fear recall long after NMDA receptor antagonism has ceased. Chronic 
administration of 5 mg/kg ketamine, terminated 48 hours before recall testing, was shown to 
significantly reduce freezing in a contextual fear conditioning paradigm (Amann et al., 2009). 
We also observed in the present study that ketamine continued to suppress conditioned freezing 
in CORT-treated animals for 5 days following drug administration, an effect which cannot be 
explained by short-lived NMDA receptor inactivation. Thus, while transient NMDA receptor 
antagonism at the time of fear recall may play a role in the ketamine’s early phase suppression of 
conditioned freezing, it is likely an insufficient explanation for the short- and long-term 
facilitation of extinction-like behavior we observed.  
 Instead, we propose that ketamine likely facilitates the suppression of conditioned fear by 
stimulating enhancements in neurotransmission and synaptic plasticity that mirror those 
underlying the natural process of fear extinction. In addition, we suggest that ketamine prevents 
the recovery and reinstatement of conditioned fear in CORT-treated rats by reversing 
neurobiological impairments in fear extinction circuits caused by chronic glucocorticoid 
exposure.  
 Past research has illustrated a clear relationship between prefrontal and hippocampal 
neuronal activity and the successful suppression of conditioned fear. During the consolidation 
and recall of extinction memory, activity within the IL mPFC is positively correlated with the 
degree to which extinction behavior is successfully expressed (Burgos-Robles et al., 2007; Milad 
& Quirk, 2002; Wilber et al., 20011). Extinction recall is also associated with increased 
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expression of c-Fos, a protein biomarker of recent neuronal activity, within the IL, hippocampus 
(CA1, CA3, dentate gyrus), and ITC neurons of the amygdala (Knapska & Maren, 2009). 
Interestingly, experimentally applied electrical stimulation of IL neurons can successfully inhibit 
fear expression and induce extinction-like behavior in the absence of extinction training (Milad 
& Quirk, 2002; Milad et al., 2004; Vidal-Gonzalez et al., 2006). Ketamine possesses the 
potential to similarly modulate conditioned fear suppression because it stimulates presynaptic 
excitatory neurotransmitter release (i.e. glutamate) in the PFC and hippocampus, namely by 
reducing the activity of inhibitory GABAergic interneurons in these regions (Chowdhury et al., 
2012; Homayoun & Moghaddam, 2007; Moghaddam et al., 1997; Stone et al., 2012). This 
facilitation of glutamatergic neurotransmission is an essential underlying component of 
ketamine’s antidepressant behavioral effects (Autry et al., 2011; Koike et al., 2011). 
Accordingly, subanesthetic ketamine has been found to increase c-Fos expression in the mPFC 
(including the IL) and hippocampus (CA1, CA3, dentate gyrus) at rest (Imre et al., 2006). It is 
possible that an enhancement of activity in these regions facilitates the downstream inhibition of 
amygdalar fear output, as ketamine has also demonstrated efficacy in preventing conditioning-
induced enhancement of c-Fos expression in the amygdala, while simultaneously inhibiting the 
expression of conditioned fear (Pietersen et al., 2006). Based on these findings, an immediate 
enhancement of presynaptic glutamate release in the mPFC and hippocampus might be one of 
the mechanisms underlying the immediate ketamine-induced suppression of conditioned 
responding we observed during early phase extinction training in both nonstressed and CORT-
exposed rats. 
 A transient ketamine-induced burst of glutamatergic neurotransmission could also 
promote long-term changes in synaptic plasticity, since activation of the AMPA glutamate 
receptor stimulates BDNF release in the brain (Jourdi et al., 2009). The BDNF protein’s ability 
to strengthen synapses, even in the absence of electrical stimulation, makes it a powerful 
modulator of memory and behavior (Autry et al., 2011; Liu et al., 2012; Messaoudi et al., 2002; 
Peters et al., 2010). As previously discussed, fear extinction reverses a conditioning-induced 
inhibition of hippocampal BDNF transcription (Rasmusson et al., 2001; Rosas-Vidal et al., 
2014). Hippocampal BDNF is projected to the IL to suppress conditioned fear expression (Peters 
et al., 2010), and the presence of BDNF within the hippocampus even enhances the excitability 
of extinction-critical IL neurons (Rosas-Vidal et al., 2014). Furthermore, extinction training 
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initiates epigenetic regulation of BDNF gene expression in the IL, increasing histone H4 
acetylation of BDNF promoter regions to result in an upregulation of prefrontal BDNF mRNA 
(Bredy et al., 2007). Interestingly, ketamine induces a rapid upregulation of neuronal BDNF that 
is reminiscent of the natural changes in neurotrophin expression that are induced by fear 
extinction learning. Subanesthetic ketamine stimulates a significant enhancement of BDNF 
protein expression in the prefrontal cortex and hippocampus that occurs within only 30 minutes 
of administration (Autry et al., 2011; Garcia et al., 2008a; Zhang et al., 2015a; Zhang et al., 
2015b). Consistent with increased BDNF activity, ketamine also upregulates several synaptic 
proteins (including synapsin I, PSD-95, and the AMPA subunit Gria1), increases dendritic spine 
density, and enhances dendritic spine maturity in the mPFC within one hour of treatment (Li et 
al., 2010; Li et al., 2010; Zhang et al., 2015a). Since the present study introduced an hour delay 
between ketamine administration and behavioral testing, it is possible that these changes in 
neurotrophin expression and synaptic plasticity could contribute to the suppression of 
conditioned responding we observed during early phase extinction training. It is noteworthy that 
a similar facilitation of conditioned fear suppression can be produced by directly infusing BDNF 
into either the IL or hippocampus of rats (Peters et al., 2010). Within an hour of BDNF infusion, 
these treatments produce a significant reduction in cue-elicited freezing that begins with the first 
unreinforced stimulus, even in the absence of extinction training (Peters et al., 2010). Peters and 
colleagues (2010) refer to this phenomenon as “BDNF-extinction,” because the successful and 
immediate suppression of conditioned responding induced by BDNF infusion was not a 
facilitation of extinction training (since no extinction training took place), but rather an effective 
substitution for it. We believe that a similar phenomenon, resulting from a ketamine-induced 
upregulation of prefrontal and hippocampal BDNF, could underlie the impaired conditioned fear 
expression observed in the present study. 
 Not only does ketamine upregulate BDNF expression in the brains of nonstressed rats, 
but it also reverses stress-induced neurobiological impairments in memory circuits that could 
contribute to long-term extinction failure. In the present study, animals with chronic CORT 
exposure showed a spontaneous recovery and sub-conditioning reinstatement of conditioned 
freezing (suggesting that their ability to recall extinction memory was impaired), an effect that 
was prevented by ketamine treatment. As previously discussed, prefrontal and hippocampal 
BDNF play a critical role in the long-term recall of fear extinction (Heldt et al., 2007; Peters et 
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al., 2010; Rosas-Vidal et al., 2014), but BDNF expression is impaired by chronic stress exposure 
(Aboul-Fotouh, 2015; Chen et al., 2008; Dwivedi et al., 2006; Filho et al., 2015; Fu et al., 2014; 
Gourley et al., 2008; Grønli et al., 2006; Guo et al., 2014; Hamani et al., 2012; Jacobsen & 
Mørk, 2006; Jin et al., 2015; Li et al., 2012; Liang et al., 2012a; Liang et al., 2012b; Liu et al., 
2014; Liu et al., 2015; Luoni et al., 2014; Monsey et al., 2014; Nibuya et al., 1999; Nitta et al., 
1997; Ray et al., 2011; Smith et al., 1995; Yan et al., 2015; Zhang et al., 2015a; Zhu et al., 2016). 
Conversely, ketamine ameliorates the suppression of prefrontal and hippocampal BDNF seen in 
stressed rats, supporting healthy neuronal function in these extinction-critical structures (Zhang 
et al., 2015a; Zhang et al., 2015b). Furthermore, this ketamine-induced enhancement of BDNF 
expression lasts for at least 8 days (Zhang et al., 2015a), which is consistent with the duration of 
therapeutic effect we observed in CORT-treated rats in the present study. Since BDNF induction 
plays a necessary role in the antidepressant behavioral effects of ketamine (Autry et al., 2011; 
Liu et al., 2012), it is plausible that BDNF modulation could also underlie the long-term 
extinction facilitation seen in CORT + ketamine-treated rats. Subanesthetic ketamine also 
reverses stress-induced deficits in synaptic proteins such as synapsin I, PSD-95, and AMPA 
subunit Gria1 (Li et al., 2010; Li et al., 2011; Zhang et al., 2015a). On a larger morphological 
scale, ketamine reverses chronic stress-induced impairments in prefrontal dendritic spine density 
and maturity within 24 hours of administration, offering an additional means by which ketamine 
might support long-term extinction retention (Li et al., 2010; Li et al., 2011; Monsey et al., 
2014). 
 Since BDNF expression promotes the strength and maturity of synapses in the brain, and 
increases postsynaptic membrane insertion of AMPA receptor subunits, it is unsurprising that 
ketamine also induces a long-lasting facilitation of neurotransmission (Autry et al., 2011; Li et 
al., 2010; Li et al., 2011). This potentially has significant consequences for extinction, since 
enhancements in prefrontal and hippocampal synaptic efficacy play an important role in the 
continued suppression of conditioned fear. Extinction learning is associated with the induction of 
LTP in the IL, which reverses a conditioning-induced depression of neuron excitability in this 
region (Cruz et al., 2014; Farinelli et al., 2006; Herry & Garcia, 2002; Hugues et al., 2006). 
Conversely, depressed IL neuron excitability accompanies the spontaneous weakening of 
extinction expression over time, illustrating the important role that LTP plays in the maintenance 
of extinction memory (Cruz et al., 2014; Farinelli et al., 2006; Herry & Garcia, 2002; Herry & 
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Mons, 2004; Hugues et al., 2006). Fear extinction also enhances synaptic efficacy between the 
hippocampus and mPFC, and experimental disruption of this process results in long-term 
extinction recall failure (Farinelli et al., 2006; Garcia et al., 2008b; Hugues et al., 2006; Hugues 
& Garcia, 2007). Posing a significant threat to the long-term retention of fear extinction, chronic 
stress impairs LTP in both the hippocampus and hippocampal-PFC pathway of rodents 
(Cerqueira et al., 2007; Foy et al., 1987; Garcia et al., 1997; Kim et al., 1996; Pavlides et al., 
2002; Shors et al., 1989; Xu et al., 1997), and suppresses extinction-critical IL neuronal activity 
during extinction recall testing (Wilber et al., 2011). Once again, ketamine appears to induce a 
facilitation of neurotransmission which parallels that seen in the natural process of extinction, 
and ameliorates deficits in synaptic efficacy that are caused by chronic stress. Past research has 
demonstrated that subanesthetic ketamine potentiates synaptic efficacy in the hippocampus 
(Autry et al., 2011; Nosyreva et al., 2013), and reverses stress-induced prefrontal synaptic 
depression (Li et al., 2011). Facilitation of LTP in the mPFC has been shown to prevent the 
reinstatement of conditioned fear following sub-conditioning retraining (Deschaux et al., 2011a; 
Zheng et al., 2013), so it is plausible that ketamine-induced synaptic potentiation might similarly 
strengthen long-term extinction. 
 If ketamine is facilitating long-term extinction retention by reversing impairments in 
BDNF expression, neuronal morphology, and synaptic efficacy, then this might explain why an 
enduring therapeutic response was only found in CORT-treated rats. Since animals that were 
administered vehicle injections for 21 days should have generally unimpaired neuronal 
functioning, their ability to suppress conditioned fear during extinction recall testing and 
following sub-conditioning retraining should remain intact. Indeed, we observed that Veh-
21/Veh and Veh-21/Ket animals exhibited comparable levels of freezing during these times to 
that of control animals. Only CORT-21/Veh rats displayed an abnormal spontaneous recovery 
and sub-conditioning reinstatement of conditioned fear, suggesting an underlying pathology that 
impairs long-term extinction memory recall. Addressing this pathology through pharmacological 
treatment would then be expected to produce a facilitation long-term fear suppression only in 
CORT-treated animals, which is what we observed in the present study. Furthermore, CORT-
treated rats that received ketamine behaved no differently than control animals, exhibiting 
normal responses to tone cue re-exposure. Thus, ketamine’s enduring effects on extinction 
retention in CORT-treated animals likely reflect a reinstatement of normal neurological function, 
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as opposed to a supranormal augmentation of freezing suppression like we observed during early 
phase extinction training. 
 
4.3. Clinical Implications 
 Subanesthetic doses of ketamine have demonstrated impressive efficacy in the treatment 
of human depression (Aan Het Rot et al., 2012; Berman et al., 2000; Cusin et al., 2012; 
Diazgranados et al., 2010; Ibrahim et al., 2011; Murrough et al., 2013; Phelps et al., 2009; Price 
et al., 2009; Rasmussen et al., 2013; Zarate et al., 2006), but it has been uncertain if ketamine 
also helps challenge negative cognitive biases in memory that are associated with this disorder. 
The findings from the present study suggest that a single subanesthetic dose of ketamine can 
rapidly suppress the expression of negative emotional memory in rats with chronic CORT 
exposure, even when the initial acquisition of aversive learning undisturbed. Furthermore, 
ketamine treatment can ameliorate CORT-induced failures in long-term extinction retrieval, and 
restore normal extinction memory function. By shifting recollection away from emotionally 
aversive events, ketamine could possess utility in overcoming depression-associated negative 
cognitive biases. Additional research is needed to determine if ketamine produces a similar 
facilitation of fear extinction in human patients with depression. 
 
5. Conclusions 
This study is the first to demonstrate the efficacy of ketamine in treating the negative emotional 
biases in memory that result from chronic glucocorticoid exposure. We found that a single 
subanesthetic dose of ketamine can induce a rapid and long-lasting suppression of auditory fear 
expression, particularly in animals exposed to chronic exogenous CORT. Within an hour of 
ketamine administration, both repeated vehicle- and CORT-treated animals exhibited a 
significant reduction of cue-elicited freezing when conditioned fear recall was assessed. Chronic 
CORT exposure induced a spontaneous recovery of conditioned freezing, and a reinstatement of 
freezing following sub-conditioning retraining, suggesting a failure of long-term extinction 
retention in these animals. However, ketamine treatment completely eliminated these CORT-
induced extinction retrieval deficits, an effect which lasted for at least 5 days following drug 
administration. Since negative cognitive biases are believed to support the development and 
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maintenance of depression in humans, the findings of the present study could have implications 
for the treatment of pathologically altered memory in this disorder. 
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CHAPTER 4 
General Discussion 
1. Overview of Main Findings 
 The aim of this dissertation was to explore ketamine’s ability to modulate the expression 
of negative emotional memory and prevent stress-induced deficits in the regulation of 
emotionally-driven behavior. To accomplish this, I conducted two experiments that examined the 
effect of acute ketamine treatment on fear-motivated behavior in fear conditioning and extinction 
paradigms. 
 In Chapter 2, I sought to dissociate the effects of ketamine on distinct stages of auditory 
fear conditioning and extinction in order to gain a better understanding of the underlying 
cognitive processes that the NMDA receptor antagonist might modulate. I found that ketamine’s 
influence on cue-elicited freezing in rats is dependent upon the time at which ketamine is 
administered relative to fear learning and recall. Ketamine did not disturb the long-term 
expression of conditioned fear behavior when administered prior to fear conditioning training, 
suggesting that the drug does not interfere with the acquisition of fear memories. However, 
immediate post-conditioning ketamine administration attenuated conditioned freezing in a recall 
test 10 days later, suggesting that NMDA receptor antagonism impaired fear memory 
consolidation. Pre-extinction ketamine treatment induced a similar reduction of long-term fear 
expression, a phenomenon which could either be explained by an impairment of fear memory 
recall or a facilitation of extinction-like fear suppression. None of the ketamine treatments 
examined affected the long-term recall of extinction behavior. The results from this study help 
fill an important gap in the literature by identifying the specific stages of fear learning that are 
affected by subanesthetic ketamine injection.  
 Chapter 3 aimed to expand upon these findings by examining the effect of ketamine on 
the long-term retention of extinction behavior in a repeated CORT animal model of depression. 
Regardless of prior CORT exposure, pre-extinction administration of a subanesthetic 15 mg/kg 
dose of ketamine induced an immediate and substantial attenuation of cue-elicited freezing 
during conditioned fear recall assessment. Chronic CORT exposure provoked a spontaneous 
recovery of conditioned freezing between extinction sessions and induced a reinstatement of 
freezing following sub-conditioning retraining, suggesting that the ability to recall extinction 
memory had been impaired. However, ketamine treatment completely abolished these CORT-
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induced extinction retrieval deficits and facilitated healthy fear extinction expression for at least 
5 days following drug administration. The findings of this study contribute to our understanding 
of the influence that prolonged glucocorticoid exposure has on memory for aversive emotional 
events, and further demonstrate the rapid and long-lasting antidepressant-like effects of ketamine 
on negatively biased memory. 
 
2. The Effects of Ketamine on Fear Conditioning 
 The findings of this dissertation make a significant contribution to our understanding of 
the effects that ketamine has on the induction and expression of conditioned fear. Although 
previous studies have repeatedly demonstrated ketamine’s ability to impair fear conditioning, the 
experimental designs used in these investigations limited the conclusions that could be drawn 
regarding the specific stages of fear conditioning that ketamine modulates. For example, most 
experiments have only administered ketamine prior to fear conditioning training, which makes it 
difficult to identify the cognitive processes that are affected by the drug, since ketamine has 
long-lasting effects on neurobiology and behavior (Amann et al., 2009; Calzavara et al., 2009; 
Pietersen et al., 2006; Pietersen et al., 2007; Zhang et al., 2015). When alternative administration 
timelines have been investigated using chronic ketamine injections, a lack of comparable 
comparison groups has confounded the ability to distinguish the unique effects of each treatment 
(Amann et al., 2009; Zhang et al., 2015). 
 Thus, characterizing the effects of acute ketamine treatment on auditory fear conditioning 
requires special consideration in methodological design, and this is the issue I sought to address 
in Chapter 2. Surprisingly, I found that pre-conditioning ketamine treatment had no effect on the 
long-term expression of conditioned fear when recall was assessed 10 days after administration. 
However, when ketamine was administered an hour before recall assessment, an attenuation of 
conditioned freezing was observed. This suggests that ketamine impairs fear conditioning by 
interfering with the expression of conditioned responding, rather than the initial acquisition of 
fear learning. One implication of this finding is that most fear conditioning studies have been 
administering ketamine at a time point at which the drug has little to no effect on fear-relevant 
cognition and behavior. Therefore, future research on the modulatory effects of ketamine on fear 
conditioning should instead administer ketamine before recall assessment, when the drug is most 
effective. Furthermore, pre-recall ketamine injection paradigms possess greater clinical relevance 
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in the study of depression-associated negative cognitive biases, since patients typically only seek 
medical treatment once symptoms of the disorder have already developed (and thus negative 
associations have been formed). 
 This was also the first study to my knowledge to experimentally investigate the effect of 
ketamine on the consolidation of conditioned fear memory. Immediate post-conditioning 
ketamine administration induced a significant attenuation of cue-elicited freezing during recall 
assessment 10 days later. Since pre-conditioning ketamine failed to impair conditioned 
responding after this same time delay, post-conditioning ketamine likely reduced conditioned 
responding by impairing the consolidation, rather than the recall, of associative fear memory. 
Past research has failed to influence long-term fear expression with post-conditioning APV 
infusion, which has lead some researchers to hypothesize that acute NMDA receptor antagonism 
is unable to interfere with the process of fear memory consolidation. (Kim et al., 1991; Maren et 
al., 1996b). However, the present findings suggest that this might not be the case, and past 
studies may have produced different results due to the competitive binding characteristics of 
APV, compared to the non-competitive binding of ketamine. Furthermore, a study of wounded 
military servicemen found that post-trauma ketamine anesthesia reduced the likelihood of 
developing PTSD in the future, supporting the possibility that ketamine interferes with the 
consolidation of aversive memories (McGhee et al., 2008). These preliminary findings warrant 
further experimental investigation into the matter, as the ability to modulate the consolidation of 
negative emotional memory following a trauma could be of great clinical value in the prevention 
of PTSD. 
 
3. The Delicate Balance of Fear Extinction 
 Fear extinction is a unique cognitive and behavioral phenomenon, the expression of 
which is guided by a delicate balance between the competing influence of opposing associative 
memories. Since fear extinction involves the formation of a new benign associative memory, as 
opposed to the erasure of the original fear memory, an extinguished animal that is presented with 
a CS can interpret and respond to the cue in two different ways (Pape & Paré, 2010; Quirk & 
Mueller, 2008; VanElzakker et al., 2013). Utilization of the predictive fear memory will provoke 
a freezing response, while utilization of the extinction memory will elicit a suppression of 
freezing behavior. The level of freezing that is expressed in response to a CS is dependent upon 
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the relative strength of fear and extinction memories and the neuronal circuits that underlie them 
(Cruz et al., 2014; Deschaux et al., 2011; Herry & Mons, 2004; Milad & Quirk, 2002; Wilber et 
al., 2011; Zheng et al., 2013).  
 Extinction memory is strong shortly after acquisition (Deschaux et al., 2011a; Deschaux 
et al., 2011b; Deschaux et al., 2013; Zheng et al., 2013), but research has shown that a number of 
internal and external factors can erode the strength of this fragile predictive association, causing 
a reemergence of cue-elicited fear-motivated behavior. The mere passage of time is sufficient to 
induce progressive extinction retrieval failure (Cruz et al., 2014; Pape & Paré, 2010), a 
phenomenon that is associated with the decay of extinction-induced IL potentiation (Cruz et al., 
2014; Herry & Mons, 2004). Extinction is also poorly expressed in novel contexts, as the 
requisite environmental cues of the extinction training context are no longer present to trigger 
extinction retrieval (Bouton, 2004; Bouton & Bolles, 1979a; Bouton & Bolles, 1979b; Bouton et 
al., 2006; Bouton & King, 1983). Re-exposure to the US alone or a weak CS-US pairing 
provokes a reinstatement of conditioned responding in previously extinguished animals 
(Deschaux et al., 2011a; Deschaux et al., 2011b; Deschaux et al., 2013; McAllister & McAllister, 
2006; Laurent & Westbrook, 2010; Rescorla & Heth, 1975; Shen et al., 2013; Zheng et al., 
2013). Fear reinstatement is the result of a relearning process that strengthens the original CS-US 
fear association that was acquired during fear conditioning, causing it to overwhelm the ability 
for extinction memory circuits to suppress amygdalar fear output (Deschaux et al., 2011a; 
Deschaux et al., 2015; Shen et al., 2013; Zheng et al., 2013). Interestingly, acute post-extinction 
stress exposure elicits a similar reemergence of extinguished fear (Deschaux et al., 2013; 
Izquierdo et al., 2006; Zheng et al., 2013). Acute stress likely impairs extinction expression 
through the depotentiation and dendritic atrophy of prefrontal extinction circuits (Maroun & 
Richter-Levin, 2003; Rocher, Spedding, Monoz, & Jay, 2004; Zheng et al., 2013) in addition to a 
stress hormone-induced facilitation of fear memory recall (Izquierdo et al., 2002).  
 Past research has found that chronic pre-conditioning behavioral stress and CORT 
exposure also impairs the long-term expression of fear extinction (Baran et al., 2009; Farrell et 
al., 2010; Gourley et al., 2009; Hoffman et al., 2014; Miracle et al., 2006; Wilber et al., 2011). 
The results from Chapter 3 corroborate this inverse relationship between chronic stress and long-
term extinction retrieval, as repeated CORT injections induced a spontaneous recovery of 
conditioned fear between extinction sessions. In addition, this study further demonstrated the 
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vulnerability of extinction memory to stress through the sub-conditioning reinstatement of 
conditioned freezing that occurred exclusively in CORT-exposed animals. Although vehicle-
treated animals did not exhibit fear reinstatement following sub-conditioning retraining (perhaps 
due to the extensive extinction training protocol used), it appears that chronic CORT exposure 
lowered the threshold required for weak tone-shock pairings to restrengthen the CS-US fear 
association.  
 I propose that chronic stress and prolonged glucocorticoid exposure compromises the 
long-term retention of extinction behavior by impairing the ability for prefrontal and 
hippocampal extinction circuits to regulate the fear output of the amygdala. Both chronic 
behavioral stress and repeated CORT treatment damage the dendritic morphology of the PFC 
and hippocampus in rodents (Cook & Wellman, 2004; Delgado et al., 2011; Dias-Ferreira et al., 
2009; Izquierdo et al., 2006; Li et al., 2011; Liston et al., 2006; Liu & Aghajanian, 2008; 
Magariños et al., 1996; Magariños et al., 1998; Magariños et al., 1999; Magariños & McEwen, 
1995a; Magariños & McEwen, 1995b; Morales-Medina et al., 2009; Radley et al., 2004; Shansky 
& Morrison, 2009; Sousa et al., 2000; Tata et al., 2006; Watanabe et al., 1992a; Watanabe et al., 
1992b; Wellman, 2001; Woolley et al., 1990), and suppress BDNF expression in these same 
regions (Aboul-Fotouh, 2015; Chen et al., 2008; Dwivedi et al., 2006; Filho et al., 2015; Fu et 
al., 2014; Gourley et al., 2008; Grønli et al., 2006; Guo et al., 2014; Hamani et al., 2012; 
Jacobsen & Mørk, 2006; Jin et al., 2015; Li et al., 2012; Liang et al., 2012a; Liang et al., 2012b; 
Liu et al., 2014; Liu et al., 2015; Luoni et al., 2014; Monsey et al., 2014; Nibuya et al., 1999; 
Nitta et al., 1997; Ray et al., 2011; Smith et al., 1995; Yan et al., 2015; Zhang et al., 2015a; Zhu 
et al., 2016). Chronically stressed animals also exhibit impairments in LTP within the 
hippocampal-PFC pathway that is essential to long-term fear extinction retention, a phenomenon 
which could explain the recovery and spontaneous reinstatement of conditioned fear observed in 
CORT-treated animal in Chapter 3 (Cerqueira et al., 2007; Deschaux et al., 2015; Foy et al., 
1987; Garcia et al., 1997; Herry & Garcia, 2008b; Kim et al., 1996;  Pavildes et al., 2002; Wilber 
et al., 2011; Shors et al., 1989; Xu et al., 1997; Zheng et al., 2013). Furthermore, chronic stress 
and glucocorticoid exposure induces dendritic hypertrophy, enhances neuronal excitability, and 
reduces GABAergic inhibition within the BLA, the primary gateway for conditioned fear 
responding (Duvarci & Paré, 2007; Kavushansky & Richter-Levin, 2006; Mitra & Sapolsky, 
2008). Collectively, these studies suggest that chronic stress impairs the function of neural 
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circuits that serve to inhibit amygdalar activity during extinction testing, while simultaneously 
strengthening the function of circuitry responsible for conditioned fear recall. 
 Although the balance between extinction expression and fear recall can easily be biased 
in the favor fear reemergence through a number of means, relapses of conditioned responding are 
preventable through interventions that enhance the efficacy of extinction circuits. Application of 
high-frequency stimulation, which is known to induce LTP in its targets, to the mPFC or 
hippocampus successfully prevents the sub-conditioning reinstatement of conditioned fear 
(Deschaux et al., 2011a; Zheng et al., 2013). Theoretically, if a drug were to similarly induce 
LTP in fear extinction pathways, it would stand to reason that this drug might also promote the 
long-term retention of fear extinction. In Chapter 3, I demonstrated that a single subanesthetic 
dose of ketamine prevents both the spontaneous recovery and sub-conditioning reinstatement of 
auditory fear in rats with chronic CORT exposure. Not only does ketamine potentiate the 
synaptic efficacy of the PFC and hippocampus (Autry et al., 2011; Li et al., 2011; Nosyreva et 
al., 2013), but it also stimulates excitatory neurotransmitter release (Chowdhury et al., 2012; 
Homayoun & Moghaddam, 2007; Moghaddam et al., 1997; Stone et al., 2012), increases 
neuronal activity (Imre et al., 2006), and reverses stress-induced deficits in BDNF (Zhang et al., 
2015a; Zhang et al., 2015b) and synaptic protein expression (Li et al., 2010; Li et al., 2011; 
Zhang et al., 2015a) within these same regions. It is evident that ketamine facilitates the 
inhibition of amygdalar fear output, as amygdalar expression of the neuronal activity marker c-
Fos is reduced in conjunction with the ketamine-induced impairment of conditioned fear recall 
(Pietersen et al., 2006). The findings of these past studies and those of Chapter 3 illustrate the 
ability for ketamine to overcome the stress-induced bias towards conditioned fear retrieval, 
instead promoting a robust maintenance of extinction expression. Figure 4-1 schematically 
summarizes the means by which chronic CORT exposure and ketamine might mediate the 
balance between conditioned fear and extinction expression. 
 
4. Depression-Like Behavior Induced by Chronic CORT Exposure 
 Chronic exogenous CORT administration has become an increasingly popular preclinical 
model of depression over the past 15 years. One of the CORT model’s virtues lies in its precise 
control over sustained glucocorticoid exposure, which limits individual variability in stressor  
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Figure 4-1. Schematic representation of a possible model by which CORT and ketamine 
modulate conditioned fear behavior. Chronic exposure to CORT impairs the integrity and 
function of the hippocampus and mPFC, which in turn compromises the ability for these 
structures to suppress amygdalar fear output. As a result, CORT-treated animals express recall of 
the associative fear memory through defensive freezing. Conversely, treatment with ketamine 
strengthens hippocampal and prefrontal function, facilitating successful inhibition of the 
amygdala and prevention of cue-elicited freezing. 
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response. Prolonged CORT exposure also induces pathological alterations in neuroplasticity that 
provide mechanistic similarity to the pathogenesis of depression in humans (Bremner et al., 
2000; Campbell et al., 2004; Cole et al., 2010; Colla et al., 2007; Frodl et al., 2002; Lange & Irle, 
2004; Liu & Aghajanian, 2008; Magariños et al., 1998; Magariños et al., 1999; Mitra & 
Sapolsky, 2008; Morales-Medina et al., 2009; Seib & Wellman, 2003; Sheline et al., 1999; 
Sheline et al., 2003; Sousa et al., 2000; Tata et al., 2006; Videbech & Ravnkilde, 2004; 
Watanabe et al., 1992a; Wellman, 2001; Woolley et al., 1990). Imperative to the face validity of 
the model, chronic CORT administration produces several depression-like behaviors in rodents, 
including various forms of anhedonia (David et al., 2009; Gorzalka et al., 1999; Gorzalka et al., 
2001; Gorzalka et al., 2003; Gorzalka & Hanson, 1998; Gourley et al., 2008a; Gourley et al., 
2008b; Gupta et al., 2015; Wu et al., 2013; Yau et al., 2014) in addition to learned helplessness 
(Brummelte et al., 2006; David et al., 2009; Fenton et al., 2015; Gourley et al., 2008a; Gregus et 
al., 2005; Hill et al., 2003; Johnson et al., 2006; Kalynchuk et al., 2004; Koike et al., 2013; 
Marks et al., 2009; Murray et al., 2008; Wu et al., 2013; Zhao et al., 2008a; Zhao et al., 2008b). 
However, it is also important for animal models to recapitulate the negative cognitive biases that 
are associated with depression, as these pathological alterations in cognition are believed to 
contribute to the development and maintenance of the disorder (Elliott et al., 2011; Harmer et al., 
2009a; Robinson & Sahakian, 2008). For example, individuals with depression exhibit a bias 
towards the recall of negative autobiographical events and negatively-valenced information 
(Balut et al., 2013; Gerritsen et al., 2012; Gupta & Kar, 2012; Harmer et al., 2009a; Hsu et al., 
2010; Liu et al., 2012; Mogg et al., 2014; Taylor & John, 2004). Thus far, attempts to model 
depression-associated negative cognitive biases in CORT-treated animals have mostly remained 
limited to measuring changes in contextual and auditory fear conditioning recall (Conrad et al., 
2004; Marks et al., 2015; Monsey et al., 2014, Skórzewska et al., 2006; Thompson et al., 2004). 
By demonstrating a persistent failure of extinction recall in CORT-treated animals, the results of 
Chapter 3 help further establish the ability for the chronic CORT animal model of depression to 
produce depression-like biases in memory, bolstering the model’s face validity. Furthermore, this 
study showed that the effects of CORT exposure on extinction recall last for at least 5 days 
following the cessation of CORT injections. Negative cognitive memory biases are also 
persistent in humans with depression, and can even endure beyond remission off the disorder 
(Gupta & Kar, 2012). 
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 The usefulness of an animal model also depends upon its predictive validity. Drugs that 
are effective at treating depression in humans should likewise be effective in reversing the 
symptoms of pathology produced in the animal model, and vice versa (Belzung & Lemoine, 
2011). Although the chronic CORT model of depression has demonstrated excellent predictive 
validity in measures of learned helplessness (Ago et al., 2013; Chen et al., 2014; Crupi et al., 
2010; Fenton et al., 2015; Gourley et al., 2008; Huang et al., 2011; Koike et al., 2013; 
O’Donovan et al., 2014; Mao et al., 2012; Mao et al., 2014; Ulloa et al., 2010; Wu et al., 2013), 
investigation into the effect of antidepressants on negative cognitive biases in CORT-exposed 
animals has previously been limited to fluoxetine (Anderson et al., 2013). The predictive validity 
of the CORT model is supported by the observation in Chapter 3 that acute treatment with 
ketamine, a powerful antidepressant in humans (Aan Het Rot et al., 2012; Berman et al., 2000; 
Cusin et al., 2012; Diazgranados et al., 2010; Ibrahim et al., 2011; Kranaster et al., 2011; 
Murrough et al., 2013; Okamoto et al., 2010; Phelps et al., 2009; Price et al., 2009; Rasmussen et 
al., 2013; Wang et al., 2012; Zarate et al., 2006), is also capable of preventing the development 
of depression-like behavior in an auditory fear extinction paradigm. Furthermore, ketamine in 
this study demonstrated a similar time course of therapeutic effect to that observed in humans 
(Diazgranados et al., 2010; Murrough et al., 2013; Zarate et al., 2006), producing rapid 
antidepressant-like effects within an hour following administration, which then lasted for several 
days following acute treatment. These findings suggest that repeated CORT injection is a viable 
model for studying the antidepressant-like effects of ketamine on glucocorticoid-induced 
negative cognitive biases in memory. 
 The results of Chapter 3 also help illustrate the importance of examining extinction 
retention and inducing chronic stress states when investigating antidepressant efficacy in 
attenuating pathological memory biases. Previous studies corroborate my observation that 
chronic CORT exposure does not always facilitate auditory fear recall (Conrad et al., 2004; 
Marks et al., 2015), so analyzing long-term extinction recall in addition to fear conditioning can 
reveal CORT-induced changes in memory that would otherwise go unnoticed. Extinction 
retention following sub-conditioning retraining is a particularly valuable measure in the 
evaluation of antidepressant-like effects on memory, as previous research has shown that 
fluoxetine’s facilitation of auditory fear extinction is not apparent until extinction is challenged 
through mild tone-shock pairings (Deschaux et al., 2013). Thus, by not examining long-term 
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extinction retention, a study might erroneously conclude that a drug of interest is ineffective in 
alleviating negative emotional memory bias. Studies on the effect of antidepressants on fear 
conditioning and extinction should also strive to utilize animal models of depression, as this can 
yield additional information compared to what could be achieved by examining healthy animals 
alone. In Chapter 3, although both repeated vehicle- and CORT-injected animals demonstrated a 
significant reduction of initial conditioned fear expression as a result of ketamine treatment, only 
CORT animals experienced a ketamine-induced facilitation of long-term extinction recall. Had 
this study been conducted using only nonstressed animals, the results would not have revealed 
ketamine’s enduring antidepressant-like facilitation of extinction retention. For these reasons, 
future preclinical studies on depression-like memory biases should include extinction retention 
measures and use chronically stressed animals in addition to nonstressed animals. 
 
5. Antidepressant-Like Effects of Ketamine 
 Subanesthetic ketamine has demonstrated efficacy in ameliorating several depression-like 
behavioral deficits induced by chronic stress in rodents, including immobility in the forced swim 
test (Autry et al., 2011; Gigliucci et al., 2013; Jett et al., 2015; Koike et al., 2013; Perrine et al., 
2014), anhedonia in the sucrose preference test (Autry et al., 2011; Garcia et al., 2009; Li et al., 
2011), impaired cognitive flexibility in the attentional set-shifting task (Jett et al., 2015), and 
passivity in the shock-probe defensive burying task (Jett et al., 2015). Although several previous 
studies have revealed antidepressant-like effects of ketamine on fear conditioning (Amann et al., 
2009; Calzavara et al., 2009; Pietersen et al., 2006; Pietersen et al., 2007; Zhang et al., 2008), 
none of these investigations evaluated the ability for ketamine to prevent depression-like 
alterations in memory during extinction, nor memory deficits caused by chronic stress. By 
addressing these gaps in the existing literature, the studies presented in Chapter 2 and Chapter 3 
advance our current understanding of ketamine’s antidepressant-like influence on negative 
emotional memory. These experiments not only confirmed that a single pre-conditioning 
subanesthetic dose of ketamine can impair next-day fear recall, but also demonstrated that 
ketamine can prevent long-term extinction retrieval failure (both in spontaneous fear recovery 
and sub-conditioning fear reinstatement) provoked by chronic CORT exposure. These 
antidepressant-like behavioral effects were observed within only one hour of ketamine 
administration and were maintained for at least 5 days, mirroring the rapid and long-lasting 
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therapeutic response that ketamine has previously demonstrated in several other models of 
depression-like behavior (Autry et al., 2011; Carrier & Kabbaj, 2013; Gigliucci et al., 2013; 
Maeng et al., 2008; Nosyreva et al., 2013). 
 Compared to typical antidepressants, ketamine in the present studies also demonstrated 
some clear advantages in its effects on negative emotional memory. For example, acute 
treatment with SSRIs such as paroxetine and tricyclic antidepressants such as tianeptine can fail 
to reduce conditioned fear recall in rodents, requiring weeks of continuous treatment in order to 
have a therapeutic effect (Burghardt et al., 2004; Takahashi et al., 2006). Furthermore, chronic 
treatment with the antidepressants citalopram or tianeptine can surprisingly impair the 
acquisition of fear extinction (Burghardt et al., 2013), while acute treatment with fluoxetine or 
tianeptine impairs both extinction acquisition and recall in rats (Godsil et al., 2015; Lebrón-
Milad et al., 2013). These findings raise concerns that treatment with these drugs might be 
counter-productive to challenging negative emotional memory biases, particularly during the 
early phases of antidepressant treatment. Conversely, ketamine induced a rapid and long-lasting 
facilitation of extinction behavior in the present investigations, demonstrating none of the 
limitations observed with typical antidepressant drugs. 
 Together, the findings from Chapter 2 and Chapter 3 help establish ketamine’s 
antidepressant-like modulation of fear conditioning and ability to prevent stress-induced biases 
towards negatively-valenced memory. If these therapeutic cognitive effects are preserved across 
species, ketamine could have additional value in the treatment of depression in humans, as the 
memory of depressed individuals is biased towards the recollection of and fixation upon negative 
events (Gupta & Kar, 2012; Nolen-Hoeksema, 2000). By shifting recollection away from 
emotionally aversive events, ketamine could possess utility in overcoming depression-associated 
memory biases. This would be an important therapeutic asset, as the degree to which memory is 
biased towards negative information is correlated with depression symptom severity (Liu et al., 
2012), and negative cognitive biases contribute to the maintenance of depression (Elliott et al., 
2011; Harmer et al., 2009a; Robinson & Sahakian, 2008). Furthermore, various forms of 
negative cognitive biases do not operate in isolation, but rather co-exist and influence the 
expression of one another (Balut et al., 2013; Gupta & Kar, 2012; Mogg et al., 2006). It is 
possible that a pathological fixation on negative memories (as seen in depression-associated 
rumination; Nolen-Hoeksema, 2000) could also contribute to the unrealistically pessimistic 
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outlook depressed individuals have of their future (Strunk & Adler, 2009; Strunk et al., 2006). If 
memory is constantly biased towards focus on negative emotional experiences, then one might 
have little reason to expect positive outcomes in the future, and instead develop a sense of 
hopelessness. Suicidality is a serious concern in depression, so it is important to address the 
contributing symptoms of depression as quickly as possible through treatment. Clinical trials 
have shown that ketamine rapidly reduces suicidal ideation in patients in addition to all other 
depressive symptoms (Berman et al., 2000; Diazgranados et al., 2010; Price et al., 2009; Zarate 
et al., 2006). Thus, the remarkable rapidity of ketamine’s antidepressant effects would make it 
particularly useful during the early stages of therapeutic intervention, when typical 
antidepressants would be ineffective at reducing symptoms (Judd et al., 2002; Thase et al., 2005; 
Trivedi et al., 2006). 
 
6. Limitations 
6.1. Pathogenic Validity of Repeated Exogenous CORT Administration in Modeling Depression 
 Any attempt to model a human psychiatric disorder in animals will be met with an 
inherent compromise between validity, consistency, and practicality. As previously discussed, 
there are a number of unique experimental paradigms that researchers use to induce depression-
like behavior in rodents, and each model possesses its own set of strengths and weaknesses. 
Although repeated restraint stress is procedurally simple, progressive habituation to this single 
stressor can cause excessive variability in results or fail to produce depression-like behaviors 
altogether (Dunn & Swiergiel, 2008; Gregus et al., 2005; Lussier et al., 2009; Perrot-Sinal et al., 
2004; Platt & Stone, 1982). By exposing animals to a variety of mild stressors over a prolonged 
period of time, the chronic unpredictable stress model offers excellent pathogenic validity, in that 
the processes leading to disease in animals are semantically similar to those believed to lead to 
depression in humans. However, the chronic unpredictable stress model is difficult to implement, 
and results are still liable to be affected by individual variation in stress susceptibility and HPA 
axis response. Repeated exogenous CORT injection avoids the problems of stressor habituation 
and stress response variability by administering glucocorticoids directly and circumventing 
behavioral stress induction entirely. Unfortunately, these advantages come at the cost of reduced 
pathogenic validity, since chronic high levels of circulating corticosterone in this model are 
artificially induced. In addition, a 40 mg/kg dose of CORT exceeds the level of glucocorticoid 
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release that is triggered by natural stressors. Although a lower 5 mg/kg dose would more 
accurately reproduce physiological CORT concentrations (Sandi, Venero, & Guaza, 1996), past 
research has found that this dose is insufficient to reliably produce depression-like behavior in 
the forced swim test (Johnson et al., 2006), defeating one of the primary advantages of this 
model. Despite these limitations, exogenous CORT exposure produces similar depression-like 
deficits in neurobiology and neuronal morphology those observed in humans (Bremner et al., 
2000; Campbell et al., 2004; Cole et al., 2010; Colla et al., 2007; Dwivedi et al., 2006; Föcking 
et al., 2003; Frodl et al., 2002; Gourley et al., 2008a; Jacobsen & Mørk, 2006; Lange & Irle, 
2004; Liu & Aghajanian, 2008; Magariños et al., 1998; Magariños et al., 1999; Mitra & 
Sapolsky, 2008; Monsey et al., 2014; Morales-Medina et al., 2009; Nitta et al., 1997; Seib & 
Wellman, 2003; Sheline et al., 1999; Sheline et al., 2003; Smith et al., 1995; Sousa et al., 2000; 
Stein-Behrens et al., 1992; Stein-Behrens et al., 1994; Tata et al., 2006; Venero & Borrell, 1999; 
Videbech & Ravnkilde, 2004; Virgin et al., 1991; Watanabe et al., 1992a; Wellman, 2001;  
Woolley et al., 1990), lending the model sound mechanistic validity. Furthermore, prolonged 
CORT administration produces several depression-like behaviors similar to those induced by 
behavioral stress models (Brummelte et al., 2006; David et al., 2009; Fenton et al., 2015; 
Gorzalka et al., 1999; Gorzalka et al., 2001; Gorzalka et al., 2003; Gorzalka & Hanson, 1998; 
Gourley et al., 2008a; Gourley et al., 2008b; Gregus et al., 2005; Gupta et al., 2015; Hill et al., 
2003; Johnson et al., 2006; Kalynchuk et al., 2004; Koike et al., 2013; Marks et al., 2009; 
Murray et al., 2008; Willner, 1997; Wu et al., 2013; Yau et al., 2014; Zhao et al., 2008a; Zhao et 
al., 2008b). Thus, while repeated CORT administration models might not be suitable for 
studying the naturalistic development of depression-like symptoms, there is ample evidence to 
support the utility of this model in preclinical studies so long as its limitations are kept in mind. 
 
6.2. Sex Differences in Depression-Like Behavior and Response to Ketamine 
 The animals used within the present studies were exclusively male, which has important 
implications for the generalizability of the experiments’ results. First, female rats exhibit higher 
basal and stress-induced circulating glucocorticoid levels compared to male rats, and 
glucocorticoid concentrations and stress responses are dependent upon an female’s present stage 
within the estrous cycle (Atkinson & Waddell, 1997; Carey, Deterd, de Koning, Helmerhorst, & 
de Kloet, 1995; Critchlow, Liebelt, Bar-Sela, Mountcastle, & Lipscomb, 1963; Dalla et al., 2005; 
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Figueiredo, Dolgas, & Herman, 2002; Handa, Burgess, Kerr, & O’Keefe, 1994; Kitay, 1961; 
Pollard, White, Bassett, & Cairncross, 1975; Seale et al., 2004a; Seale, Wood, Atkinson, Harbuz, 
& Lightman, 2004b; Viau & Meaney, 1991; Weinstock, Razin, Schorer-Apelbaum, Men, & 
McCarty, 1998). There are also sex differences in behavioral responses to exogenous CORT 
exposure, as female rats exhibit less depression-like behavior in the forced swim test than males 
(Hill et al., 2003; Kalynchuk et al., 2004). 
 Particularly relevant to fear extinction, IL dendritic morphology is enhanced in stressed 
female rats, while male rats experience dendritic retraction (Garrett & Wellman, 2009; Shansky 
et al., 2010). Furthermore, some of these IL neurons that undergo dendritic proliferation in 
response to stress project to the BLA, which could have significant implications for the 
suppression of conditioned fear (Shansky et al., 2010). Accordingly, one study has found that 
chronically stressed female rats exhibit enhanced extinction acquisition and recall compared to 
unstressed females, while chronic stress impairs extinction recall in male rats (Baran et al., 
2009). Interestingly, this same study revealed that nonstressed females display deficits in 
extinction acquisition and recall compared to nonstressed male rats (Baran et al., 2009). 
However, the behavior of female rats during fear extinction is greatly affected by relatively small 
changes in experimental protocol (Baran, Armstrong, Niren, & Conrad, 2010), and changes 
drastically with estrous cycle phase (Milad, Igoe, Lebron-Milad, & Novales, 2009a), causing 
conflicting results between studies. 
 Finally, female rodents appear to be more sensitive to the antidepressant-like effects of 
ketamine than male rats (Carrier & Kabbaj, 2013; Franceschelli, Sens, Herchick, Thelen, & 
Pitychoutis, 2015; Zanos et al., 2016). While male rats require at least a 5 mg/kg dose of 
ketamine to reduce swimming immobility in the forced swim test, this same effect can be 
achieved in females with only a 2.5 mg/kg dose (Carrier & Kabbaj, 2013). This enhanced 
sensitivity to ketamine is mediated by female sex hormones, as ovariectomy abolishes sex 
differences in forced swim test behavior (Carrier & Kabbaj, 2013). Interestingly, although 
chronically stressed female mice are more sensitive to the antidepressant-like effects of ketamine 
within the first 24 hours after administration, ketamine has longer-lasting effects in stressed male 
mice (Franceschelli et al., 2015). These sex-dependent behavioral effects might be explained by 
sex differences in (2S,6S;2R,6R)-hydroxynorketamine (HNK) metabolite levels (Franceschelli et 
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al., 2015). It is uncertain if ketamine also differentially affects fear conditioning in female rats, 
so future investigation into possible sex differences is warranted. 
 
7. Future Directions 
7.1. Retroactive Influence of Chronic CORT on Fear and Extinction Memory 
 Thus far, the vast majority of research on the effects of stress on negative emotional 
memory has been conducted by inducing chronic stress states prior to the acquisition and recall 
of conditioned fear and extinction (Baran et al., 2009; Bisaz & Sandi, 2010; Conrad et al., 1999; 
Conrad et al., 2004; Cordero et al., 2003a; Farrell et al., 2010; Gourley et al., 2009; Hoffman et 
al., 2014; Marks et al., 2015; Miracle et al., 2006; Monsey et al., 2014; Sandi et al., 2001; 
Skórzewska et al., 2006; Thompson et al., 2004; Wilber et al., 2011; Zhang & Rozencranz, 
2013). However, it is plausible that chronic stress might also be able influence the expression of 
fear-relevant memories that have previously been successfully consolidated in nonstressed states. 
For example, stress-induced amygdalar hypertrophy could potentially facilitate conditioned fear 
recall, while hippocampal and prefrontal atrophy could impair extinction recall (Rodgrigues et 
al., 2009). This matter is of potential clinical relevance, as it means that individuals with 
depression might be susceptible to pathological fixation upon all past negative experiences, not 
just ones acquired during a depressive episode. If this is true, it would likely contribute 
significantly to the burden of negative cognitive biases on the maintenance of depression. By 
training rats in a contextual fear conditioning paradigm, and then administering 40 mg/kg CORT 
daily over 21 days, fear recall could be assessed on the final day of CORT injections to 
determine the effect that prolonged glucocorticoid exposure has on the recall of negative 
emotional memory. In an additional experiment, pre-CORT fear extinction could be added to this 
same protocol in order to elucidate the influence chronic CORT exposure on the suppression of 
previously extinguished fear memories. 
  
7.2. Antidepressant-Like Effects of Ketamine Metabolites 
 Although ketamine’s rapid and long-lasting antidepressant characteristics are without a 
doubt impressive, concerns have been raised regarding the drug’s dissociative effects and 
potential for addiction and abuse (Morgan & Curran, 2012). These limitations present a 
significant barrier to the widespread clinical use of ketamine as an antidepressant, but derivative 
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pharmacotherapies might be able to offer more practical alternatives. For example, one group has  
recently found that the metabolism of ketamine to (2R,6R)-HNK plays an important role in the 
induction of antidepressant-like effects in the forced swim test and learned helplessness test 
(Zanos et al., 2016). Importantly, direct administration of (2R,6R)-HNK to mice produced rapid 
and enduring antidepressant-like effects in these same measures, and reversed CORT-induced 
anhedonia in the sucrose preference test (Zanos et al., 2016). Similar to ketamine, (2R,6R)-HNK 
appears to exert its antidepressant effects by enhancing AMPA-mediated neurotransmission, and 
it also induces an upregulation of hippocampal BDNF (Zanos et al., 2016). The advantage of 
using (2R,6R)-HNK over ketamine is that by circumventing NMDA receptor antagonism, this 
metabolite has fewer side effects and appears to possess no abuse potential. While mice will 
engage in progressive self-administration of ketamine, this effect does not occur with (2R,6R)-
HNK (Zanos et al., 2016). However, the effect that (2R,6R)-HNK has on fear conditioning, 
extinction, and stress-induced negative memory biases is uncertain. It is possible that ketamine’s 
antidepressant-like effects in fear conditioning and extinction measures are the result of 
downstream signaling cascades initiated by NMDA receptor antagonism, which might not be 
replicated with (2R,6R)-HNK administration. This uncertainty warrants further investigation into 
the antidepressant characteristics of this intriguing metabolite.  
 
8. Conclusions 
 Individuals with depression exhibit a pathological bias towards focus on negatively-
valenced memories, which contributes significantly to the development, severity, and chronicity 
of the disorder (Nolen-Hoeksema, 2000). As a result, antidepressants that can relieve patients of 
these negative cognitive biases are of great potential clinical value. The aim of this dissertation 
was to explore ketamine’s ability to modulate the expression of negative emotional memory and 
prevent stress-induced deficits in the regulation of emotionally-driven behavior in rats. The first 
experiment sought to dissociate the effects of acute subanesthetic ketamine on distinct stages of 
auditory fear conditioning, and provided evidence that ketamine impairs the consolidation and 
recall, but not acquisition, of conditioned fear. Ketamine had no effect on the extinction of 
nonstressed rats in this study, so a second experiment was conducted to examine the effect of 
pre-extinction ketamine on conditioned fear and extinction behavior in a repeated CORT animal 
model of depression. The results of this study revealed that chronic CORT exposure impairs the 
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long-term recall and retention of extinction memory, and that ketamine rapidly abolishes these 
CORT-induced cognitive and behavioral deficits. Collectively, the findings of this dissertation 
help establish ketamine as a powerful modulator of negatively-valenced memory and 
emotionally-driven behavior, and contribute to our understanding of its antidepressant-like 
characteristics. Having demonstrated ketamine’s ability to ameliorate negative memory biases in 
rodents, future research should determine if these therapeutic effects are preserved in human 
patients with depression. 
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